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This thesis focuses on the phenomenology of depression and anxiety disorders, 
and pleads for a transition from a categorical to a multidimensional approach in 
the description of these disorders.
 The relationship between depression and anxiety disorders has drawn much 
attention for several decades. This continuing interest is mainly due to the high 
comorbidity between the disorders, and the similarities between effective 
treatments. In line with that, there is an on-going discussion about whether 
depression and anxiety disorders should be considered as separate diagnostic 
entities with specific phenomenological and neurobiological characterizations, 
or should be considered as manifestations of the same disorder.
 The way the phenomenology of these disorders is described influences the 
design and the results of studies on the cause and treatment of the disorders. 
Although the development of clear categorical diagnostic criteria, as described 
in the widely used diagnostic system of the DSM-IV (Diagnostic and statistical 
manual of mental disorders (American Psychiatric Association, 1994, p. 111)), 
has advanced the field considerably, it has become more and more clear that 
a mere categorical approach hampers further progress. In this dissertation we 
set out to make a step forward from the use of categorical conceptualization to 
a dimensional approach of depression and anxiety.
 In this introduction we first present the advantages and disadvantages of 
categorical systems. Second, we describe the general benefits of a dimensional 
approach, and present several dimensional approaches that have been 
proposed in the literature. Third, we discuss the tripartite model (a well-known 
dimensional approach) at length, and present some of the criticism on this 
model. Fourth, we explain how the tripartite model can be improved. Finally, 
we describe the main purpose and outline of this thesis.
1.1 Categorical systems
Categorical systems: advantages
In psychiatry the DSM-IV and ICD-10 (International Statistical Classification of 
Diseases and Related Health Problems) are the commonly used categorical sets 
of criteria for psychiatric diagnoses. Each disorder is defined by its symptoms 
and criteria are given which have to be met, for a diagnosis to apply. As an 
example the DSM-IV criteria for a Major Depressive Episode are shown in 
textbox 1.1.
 The development of clear diagnostic criteria has advanced the field 
considerably. Since the introduction of the DSM and ICD, communication 
among professionals and among researchers about disorders and individual 
patients has become more straightforward. On top of that, comparing research 





As a basis for research into psychopathology (e.g. endophenotype, genotype, 
trauma’s, personality), a categorical approach has serious drawbacks. One 
problem with a categorical diagnostic system is the arbitrary nature of its 
diagnostic boundaries. For instance, the presence or absence of just one 
symptom can make the difference between meeting and not meeting the 
diagnostic criteria for a disorder. Indeed, research into etiological or risk factors 
for mental disorders shows that subsyndromal cases are very similar to cases 
fully meeting the diagnostic criteria for the disorder (McGorry, Hickie, Yung, 
Pantelis, & Jackson, 2006; De Beurs et al., 1999).
 Another problem with categorical diagnostic classification is that patients 
with different symptom profiles may nevertheless meet criteria for the same 
diagnosis, which results in heterogenic groups of patients within a diagnostic 
class. To illustrate the heterogeneity of patients with a depression, we describe 
and compare the psychopathology of two patients in textbox 1.2. Both patients 
meet diagnostic criteria for a Major Depressive Disorder (MDD) according to 
the DSM-IV.
 Although both patients fulfil the criteria of a MDD, they display a very different 
pattern of symptoms. This is possible because in the DSM-IV fulfilling five out 
of nine criteria described for MDD (see textbox 1.1), is enough to be eligible for 
a diagnosis. On top of that, several criteria contain both the increase and the 
DSM-IV criteria for Major Depressive Episode
Five (or more) of the following symptoms have been present during the 
same 2-week period and represent a change from previous functioning; 
at least one of the symptoms is either (1) depressed mood, or (2) loss of 
interest or pleasure.
1. Depressed mood (either subjective report or observation)
2. Markedly diminished interest or pleasure in activities
3. Significant weight loss when not dieting or weight gain
4. Insomnia or hypersomnia
5. Psychomotor agitation or retardation nearly every day
6. Fatigue or loss of energy
7. Feelings of worthlessness or excessive or inappropriate guilt.
8. Diminished ability to think or concentrate, or indecisiveness.
9. Recurrent thoughts of death, recurrent suicidal ideation   




decrease of certain behaviour (e.g. weight loss OR weight gain). This illustrates 
that a group of patients with MDD may indeed be very heterogeneous group.
 To complicate matters further, in the current diagnostic systems it is quite 
likely that a psychiatric patient meets criteria for two or even more, psychiatric 
disorders simultaneously. In fact, the majority of patients meet criteria of more 
than one psychiatric disorder concurrently (e.g., Brown, Campbell, Lehman, 
Grisham, & Mancill, 2001; De Graaf, Bijl, Smit, Vollebergh, & Spijker, 2002; 
Kessler et al., 1996). This is certainly true for mood and anxiety disorders (e.g., 
Belzer & Schneier, 2004). High rates of comorbidity between anxiety disorders 
and depression have been reported in the general population (Kessler et al., 
1996), in primary care (Roca et al., 2009) and in secondary care (Brown et al., 
2001).
 As a syndrome is defined as a permanent combination of symptoms, it can 
be concluded that DSM-IV diagnoses are not real syndromes. Rather, they 
are more or less arbitrarily constructed clusters of symptoms. The etiology 
and pathophysiology of depression and anxiety disorders are unknown, and 
illness-specific treatments are absent. For instance, a wide range of emotional 
disorders respond similarly to the same psychosocial and psychotropic 
drug treatment (Brown & Leyfer, 2009). In this respect, the growing number 
of disorders in each new version of the DSM has led to questions about the 
discriminant validity of the categories. For example, the DSM-II had only three 
anxiety disorders (American Psychiatric Association, 1968) and the more recent 
DSM-IV includes twelve anxiety disorders (American Psychiatric Association, 
1994). The distinction between these various anxiety disorders is predominantly 
based on their symptomatic phenomenology and not on established knowledge 
Two patients with Major Depressive Disorder (MDD)
Patient A (female, 36 years of age) is feeling sad and worthless, has pro-
blems with falling asleep, and has lost weight. She is quite agitated, is fee-
ling very guilty towards her family (husband and two young children), and 
often wished she would not wake up the next morning (“that would be 
better for everyone”). 
Patient B (female, 29 years of age) does not enjoy her life as much as she 
used to do. She feels bogged down and sluggish. She sleeps a lot and has 
energy loss, gained 5 kilograms in the past 3 months and does not get any-




regarding their etiology or treatment response to different (pharmacological or 
psychotherapeutical) agents.
1.2 Multidimensional models
General benefits of a dimensional approach
Many researchers and clinicians agree that the fields of psychiatry and clinical 
psychology could benefit from a dimensional model of the psychopathology 
of common mental disorders (Clark, 2005; Cuthbert, 2005; Krueger, Watson, 
& Barlow, 2005). A multidimensional model provides each patient with a 
symptom profile on a number of dimensions of psychopathology, rather than 
a dichotomous presence or absence of one or more disorders. It offers a more 
specific and accurate description of individuals, covers the full range of severity 
from healthy to severe psychopathology and may help to avoid stereotyping. 
Moreover, a multidimensional approach has the potential to associate 
psychopathology more accurately to etiological factors and biological markers 
and may predict more accurately which patients will benefit from a specific 
treatment (Kupfer, 2005; Widiger & Samuel, 2005).
 The idea that a dimensional model has great benefits over a categorical 
system has gained much support in the last decades. Several dimensional 
models of depression and anxiety have been proposed. However, there is yet 
no clarity about which model is to be preferred. Among the models proposed so 
far, a distinction can be made between ‘disorder-based models’ and ‘symptom-
based models’. 
Disorder-based models
There are several disorder-based approaches. The first line of research 
focuses on finding dimensions with optimal ability to discriminate between 
DSM patient groups, for example between generalized anxiety disorder and 
depression (Kessler et al., 2002; Wittchen et al., 2002). In this approach, the goal 
is to determine the symptom group(s) that represent(s) the most characteristic 
features of a DSM diagnosis.
 A second disorder-based approach that is often referred to as a dimensional 
approach is the clustering of DSM-categories in a hierarchical way, with the aim 
to find common and distinctive features among various disorders based on their 
co-occurrence. In two large studies in respectively the United States (National 
Comorbidity Survey) and The Netherlands (NEMESIS study) the latent structure 
of common mental disorders was studied in the general population (Krueger, 
1999; Vollebergh et al., 2001). In both studies the results of confirmatory factor 
analysis show an optimal fit for a hierarchical three-factor model, in which 
the internalizing problems are represented by two latent factors: 1) anxious 
misery (major depression, dysthymia and generalized anxiety disorders), 
and 2) fear (the other anxiety disorders). The third factor in these two studies 
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represents respectively the external disorders (Krueger, 1999), and alcohol/
drug dependence (Vollebergh et al., 2001). For future research on common 
mental disorders both studies suggest to focus on core processes and core 
psychological features of the disorders, rather than on their manifestations as 
distinguished disorders, and on further differentiating between subtypes of 
disorders.
 Referring to the studies of Krueger and Vollebergh, Watson states that 
“there are now sufficient data to eliminate this rational system and replace it 
with an empirically based structure that reflects the actual similarities among 
disorders” (2005). With ‘this rational system’ Watson means the DSM-IV, and 
he subsequently makes a suggestion for the structure of emotional disorders 
in the next version of the DSM, the DSM-5. He suggests to use a quantitative 
hierarchical model in which the mood and anxiety disorders are taken together 
to form an overarching class of emotional disorders with 3 subclasses (distress 
disorders, fear disorders and bipolar disorders) (Watson, 2005).
 Although practical and intuitive, a disadvantage of this disorder-based 
approach is that the ‘dimensions’ are broad latent variables of existing DSM-IV 
categories, which are arbitrary and heterogeneous as discussed above. This 
means that the problems with a categorical system (arbitrary boundaries, 
comorbidity and heterogeneity of patient groups) are not fully resolved and 
seep into the new system.
Symptom-based models
A symptom-based dimensional approach is characterized by exploring large 
symptom-pools for underlying constructs, without requiring that the studied 
subjects meet particular DSM-IV diagnoses. This line of research focuses on 
the constructs of anxiety and depression and their overlap (e.g. Nitschke, 
Heller, Imig J.C., McDonald P., & Miller, 2001). The goal of these studies is to 
find dimensions that assess the relevant and distinguishable aspects of the 
psychopathology of mental disorders, commonly seen in outpatient care. In 
this line of research the DSM categories do not play a role in validating the 
constructs, and therefore the main advantage of this approach is that it can 
circumvent or bypass the problems inherent to the DSM-IV.
 With psychometric techniques such as exploratory and confirmatory factor 
analysis, the structure of latent factors that underlie the symptoms can be 
explored. The discovered factors could be regarded as symptom dimensions. 
With respect to depression and anxiety disorders (the focus of this thesis), 
several dimensional models have been developed. An important contribution 
was made by Clark and Watson with the introduction of the tripartite model 




1.3 The tripartite model
Description of the tripartite model
Clark and Watson introduced the tripartite model to assess and model distinct 
and overlapping features of mood and anxiety disorders (Clark & Watson, 
1991). This symptom-based model was initially proposed to explain the high 
comorbidity rates of depressive and anxious disorders. The first dimension is 
negative affect (NA). NA is characterized by aversive emotional states, such 
as being distressed, fearful and nervous, and is regarded as common to both 
mood- and anxiety disorders. The second is positive affect (PA) and contains 
‘enthusiasm, excitement and energy’. A low score on this dimension is typical 
for depression. The third dimension is ‘somatic arousal’ (SA) and is specific for 
anxiety. 
The Mood and Anxiety Symptom Questionnaire MASQ
Clark and Watson designed a 90-item instrument to measure the three dimensions 
of the tripartite model, the Mood and Anxiety Symptom Questionnaire MASQ 
(Watson & Clark, 1991). Although the model consists of three dimensions (PA, 
NA and SA), the items of the MASQ are allocated on five subscales; in the 
proposed structure of the MASQ, Watson and Clark divided the dimension NA 
of the tripartite model into three subcategories: General Distress Depression, 
General Distress Anxiety and General Distress Mixed (see Figure 1.1). The 
items were assigned in line with their similarity with DSM-IIIR criteria for mood 
or anxiety disorders (American Psychiatric Association, 1987). All 90 items are 
presented with a five-point Likert scale ranging from 1 (not at all) to 5 (very much).













General Distress Depression (GDD)
General Distress Anxiety (GDA)
General Distress Mixed (GDM)
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Critique on the tripartite model
The tripartite model has inspired a large body of research, but has met some 
criticism as well. We will review the major points of critique on each of the three 
factors of the tripartite model and the MASQ.
 First, there is criticism on the general distress factor NA. According to the 
theory of the tripartite model one would expect comparable relationships 
between NA and each of the different mood and anxiety disorders. However, 
large differences are found (Brown, Chorpita, & Barlow, 1998). This may 
be explained by the heterogeneous nature of NA. In the tripartite model, 
NA is characterized by aversive emotional states, such as feeling upset, 
angry, guilty, afraid, sad, scornful, and disgusted. Because the factor NA 
contains all these different constructs, it may be too heterogeneous to be 
regarded as a unidimensional construct (Shankman & Klein, 2003). With the 
proposed structure of the MASQ, Watson and Clark already acknowledged 
the heterogeneity of NA, as they divided the general distress items into three 
subcategories (See Figure 1.1). These three subscales of NA, however, were 
not confirmed with factor analysis of the MASQ-data (Boschen & Oei, 2006; 
Buckby, Cotton, Cosgrave, Killackey, & Yung, 2008; Burns & Eidelson, 1998).
 Second, the PA scale is presented as a dimension with two endpoints: a low 
positive affect endpoint (lack of interest) and a high positive affect endpoint 
(feeling good). This assumption of the tripartite model that PA comprises of 
a single dimension with two extremes (lack of interest and feeling good) has 
however not been confirmed in analyses. Several studies showed that these two 
elements appear as separate factors in factor-analysis, suggesting that the two 
constructs do not belong to a single dimension (Keogh & Reidy, 2000; Nitschke 
et al., 2001;   et al., 1995). Other evidence that lack of interest and feeling good 
are separate constructs is found in the research of Tomarken (2004). He reported 
medication to have a differential effect on lack of interest and on feeling good. 
Items assessing the low positive affect pole of the anhedonia dimension were 
more sensitive to earlier/lower dose bupropion SR treatment, whereas items 
assessing the high positive affect pole were more sensitive to later/higher dose 
bupropion SR treatment.
 Finally, there is criticism on the third scale: somatic arousal. Although the 
model suggests a high score on SA is characteristic for all anxiety disorders, 
this is not the case, since it predominantly entails the symptoms of a panic 
disorder, such as increased heartbeat, transpiration, respiratory en gastro-
intestinal symptoms (Chorpita & Daleiden, 2002; Joiner et al., 1999; Mineka, 
Watson, & Clark, 1998). Other types of anxiety symptoms like fear and worrying 
are therewith not well represented in the tripartite model.
 The critics described above are largely focussing on the conceptualization 
of the tripartite model by means of the MASQ, and not on the model itself. 
The tripartite structure of the model is confirmed in many studies in different 
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populations (Bedford, 1997; Reidy & Keogh, 1997; Watson et al., 1995), and PA 
and NA are broadly accepted as a useful representation of affect, and being the 
dominant dimensions of self-reported mood (e.g., Watson, Wiese, Vaidya, & 
Tellegen, 1999; Remmington, Fabrigar, & Visser, 2000; Russell & Carroll, 1999). 
Therefore, despite the critics, the tripartite model is a strong basis for future 
research.
1.4 Extending the tripartite model
The current challenge is to develop a more refined model of phenotypes of 
psychopathology of depression and anxiety disorders, than the tripartite model. 
Although the tripartite model has met much support, we mentioned that it does 
not cover all relevant anxiety symptoms and that its negative affect dimension 
is rather unspecific. It is worthwhile trying to extend the tripartite model and 
move away from the DSM-IV. This is in concordance with the suggestions made 
by the original developers of the tripartite model. They proposed to specify the 
nature of unique components of mood- and anxiety disorders more precisely 
in a future model. In addition, they suggest to “view individual disorders as 
representing unique combinations of different types of symptoms, with each 
type showing varying degrees of nonspecificity and with no type being entirely 
unique to any single disorder” (Mineka et al., 1998).
 Subsequently, we believe that in an ideal integrative approach, each 
dimension should cover a separate construct, and together the dimensions 
should assess the main aspects of the psychopathology of both depression 
and the specific anxiety disorders. The constructs should be unidimensional, 
have low intercorrelations, and together provide each patient with an accurate 
symptom profile. For instance, the two patients introduced in Textbox 1.2 
would each have a different profile, despite the fact that both meet the criteria 
of the same DSM-diagnosis. With a specific symptom profile for each patient, 
more justice would be done to the idiosyncrasies of individual patients and 
their symptoms. Moreover, a dimensional model has the potential to associate 
psychopathology more accurately to etiological factors and biological 
markers. The ultimate goal is to improve our understanding of common mental 
disorders. A better understanding consequently may enable us to devise better 
treatments and ultimately may make it possible to predict which patients will 
benefit from a specific treatment for their complaints. 
 In this dissertation we take a step forward from the use of categorical 
diagnostic systems towards a dimensional approach of the psychopathology of 
depression and anxiety disorders. Towards this goal, several steps have to be 
taken. A first condition was the availability of large data sets from representative 
clinical samples to perform the analyses on. Until now, much of the research 
on dimensions of psychopathology has been undertaken with inappropriate 
samples such as college students or homogeneous patient groups, selected 
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to partake in clinical trials. Data on real life patients groups are much needed. 
In the spring of 2002, the Department of Psychiatry of the Leiden University 
Medical Center (LUMC) and the mental health institute ‘Rivierduinen’ (together 
serving a region of more than 1 million people), started collaboration for 
routinely assessing diagnosis and complaints at intake, and at 3-4 months 
intervals during treatment. The method is called Routine Outcome Monitoring 
(ROM). The data collected through ROM were available for this project. 
 The second step was to construct a Dutch translation of the MASQ, and to 
investigate its psychometric qualities and the fit of the tripartite model in our 
Dutch patient samples.
 The third step was to expand the tripartite model in order to overcome some 
of the disadvantages of the tripartite model. Specifically, to cover anxiety more 
adequately additional anxiety-like constructs (e.g. phobic fear and anxious 
apprehension) had to be incorporated in the symptom-based dimensional 
model. On top of that, the statistical unidimensionality of factors had to be 
determined to guarantee that there were no heterogeneous dimensions in 
the model. We tested the applicability of various extended multidimensional 
models in a large set of data of psychiatric patients.
1.5 Outline of the studies
The data used for the analyses in this thesis, are collected in daily clinical 
practice by Routine Outcome Monitoring (ROM). Chapter 2 describes ROM as 
it was implemented in Rivierduinen and the LUMC in Leiden and presents data 
of the patient group included.
 Chapter 3 describes a study into the relationship between comorbidity and 
severity. The aim of the study was to determine in a large outpatient sample 
whether patients with comorbidity have increased symptom severity and 
greater functional impairment as compared to patients with only a depressive 
or an anxiety disorder.
 Chapter 4 reports on the psychometric properties of the Dutch adaptation 
of the Mood and Anxiety Symptom Questionnaire (MASQ). The Dutch version 
was constructed, its reliability and validity were tested, as was the fit of the 
tripartite model in our Dutch patient sample.
 In Chapter 5 a proposal for an extension of the tripartite model is presented. 
The aim of this study was to develop scales that assess symptoms of depression 
and anxiety, that can adequately differentiate between depression and anxiety 
disorders, and that also better account for the diverse phenomenology of the 
various anxiety disorders.
 With the study described in Chapter 6, we aimed to integrate aspects of 
several models into one broad dimensional model, that does not take DSM-IV 
diagnoses as a point of departure. The intended result was a multidimensional 
model to characterize patients in terms of their specific symptom profile, which 
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has potential for both clinical diagnosis and for use as a clinical phenotype.
 Chapter 7 summarizes the main findings, provides a general discussion 
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Routine Outcome Monitoring (ROM) is a method devised to systematically 
collect data on the effectiveness of treatments in everyday clinical practice. 
ROM involves documenting the outcome of treatments through repeated 
assessments. Assistants are employed who perform a baseline assessment 
comprising a standardized diagnostic interview, administration of rating 
scales, and completion of several self-report measures by the patient. At fixed 
time intervals assessments are repeated. Dedicated web-based software has 
been developed to assist in this task. ROM informs therapists and patients 
on the severity of the complaints at intake, and the waxing and waning 
of symptoms over the course of treatment. Researchers can use ROM for 
effectiveness research and managers can use it for benchmarking. The use 
of ROM for research is illustrated by presenting data on the diagnostic status 
of patients participating in ROM and data on treatment outcome data of a 
subgroup of patients (with panic disorder) in our database. The results show 
that implementation of ROM is feasible and, after some initial reservations, 
most therapists now consider ROM to be a necessary and important adjunct 
to the clinical treatment. In addition, ROM furthers research as the data can be 
used to study the phenomenology of psychiatric disorders and the outcome of 
treatments delivered in everyday practice.
Key Practioner Message:
- A form of tracking the progress of treatment through Routine Outcome Moni-
toring (ROM) is described.
- Implementation of ROM appears feasible and can be carried out in large 
institutions as well as smaller practices.
- Providing feedback about outcome in an appealing format is highly valued by 
both therapists and patients.
- ROM data enable investigation of the effectiveness of treatments in everyday 
clinical practice.
Chapter 2: Routine Outcome Monitoring in the Netherlands
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2.1 Introduction
Routine Outcome Monitoring (ROM) is the assessment of treatment outcome 
at regular intervals in order to monitor patients’ progress during treatment. It 
involves the application in everyday clinical practice of assessment technology 
that was originally developed for randomized clinical trials. Several objectives 
may be achieved with ROM. It provides information on type and severity of 
psychopathology before treatment commences, which can be used to optimize 
allocation of patients to treatment forms. Further, ROM provides feedback to 
therapist and patients on progress made in treatment. Finally, ROM data can be 
used for research into the effectiveness of treatments in care as usual. 
 Already in 1988, Ellwood proposed routine and frequent assessment of 
patients’ health and suggested to build large databases from these data 
(Ellwood, 1988). Although this idea was well-received in editorials (see, for 
recent examples, Holloway, 2002; Slade, 2002), in clinical practice routine 
assessment is seldom realized. In a survey among 396 psychiatrists in England, 
only 19.4% “routinely or occasionally” measured the outcome of the treatment 
provided (Gilbody, House, & Sheldon, 2002). Since then, some projects have 
been initiated in which treatment outcome is routinely assessed using different 
outcome measures.
 In the UK two developments are worth mentioning, the Mental Health 
Minimum Data Set (MHMDS) of the National Health Service (http://www.
ic.nhs.uk/services/mental-health/mental-health-minimum-dataset-mhmds) 
and the Clinical Outcomes in Routine Evaluation (CORE) system. Since 2003, 
mental health institutes are required by the Department of Health to provide 
anonymized outcome data on treatments to the MHMDS. The HoNOS is the 
central part of the MHMDS. The HoNOS was developed as a clinician-rated 
instrument for routine outcome assessment and appeared a reliable, valid and 
sensitive outcome measure, especially suitable for the more severe mental 
disorders (Wing et al., 1998). Until now, the NHS has reported only results on 
data quality and no outcomes on “spells of care” have been reported yet. The 
CORE system was designed as a quality evaluation system to evaluate therapy 
service delivery. Its central measure, the CORE-OM, was developed as a “user-
friendly, pantheoretical and free measure to monitor the outcome of counseling 
and psychotherapy” (Barkham, Culverwell, Spindler, & Twigg, 2005). It is best 
suited for the less severe, more common mental disorders, such as mood and 
anxiety disorders. Stiles et al. (2006) report on its application in evaluating the 
outcome of various treatments of patients that were mostly seen in primary 
care. Interestingly, they found a large treatment effect (average effect size 
[ES]=1.36 for the pre-post difference), but little difference in outcome was 
found between theoretically different approaches to treatment.
 In Australia a nationwide program of routine outcome measurement 
was implemented in 2000 (Burgess et al., 2009). Mental health services are 
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required to provide outcome data for a national database. In this program both 
clinician-rated (HoNOS) and self-report instruments (e.g., K-10+,Kessler et al., 
2003) are used. To analyse the data, the Australian Mental Health Outcomes 
and Classification Network (AMHOCN) was established in 2003. They not only 
analyse and report individual and aggregated results (benchmarking) but also 
take steps to organize the data properly, and give trainings on how to collect 
and use data. 
 In the USA, Lambert, Hansen and Finch (2001) coined the term “patient-
focused” research for routine assessment of the course of symptoms over time. 
They promote session-by-session assessments and developed a relatively short 
questionnaire for this purpose: the Outcome Questionnaire (OQ-45, Lambert et 
al., 1996). The results of the OQ-45 are discussed with the patient, allowing 
ample time for this in the session. The high frequency of assessments makes 
short-term changes in psychopathology and functioning visible, but limits the 
number of items that can be administered and thus the comprehensiveness of 
the assessment. Apart from reporting on the changes per session, the expected 
trajectory of scores at future assessments is estimated using the pretreatment 
score. If a patient’s score falls outside a specified range around the projected 
score the therapist receives a warning of potential premature dropout and/or 
negative outcome should therapy continue unchanged. A similar approach is 
advocated by Miller and colleagues (Miller, Duncan, Sorrell, & Brown, 2005). 
They use an even shorter scale, the Outcome Rating Scale (ORS), comprising 
only four visual analog scale items to be completed every session. These four 
items mirror the four subscales of the OQ-45. In addition, at the end of the 
session the patient also rates the therapeutic alliance and the usefulness of the 
session (agreement on goal, methods, and overall approach of therapy) on a 
Session Rating Scale comprising also four visual analog scales. This score is 
used to assess whether discrepancies exist between what a patient wants from 
therapy and is receiving (Miller et al., 2005).
 This paper presents a method for monitoring treatment outcome in clinical 
practice which has been implemented in the Netherlands. In contrast to 
projects described above, we employ a less frequent but more comprehensive 
assessment battery including both generic and disorder-specific measures, 
and evaluate treatment outcome from the viewpoint of the patient and an 
independent rater. The method of ROM is described, as are the experiences with 
ROM and the use of ROM data by managers and researchers. To illustrate the 
potential of ROM for research purposes we present the baseline characteristics 
(diagnoses and comorbidity) of the first cohort of patients, and present outcome 
data of a subgroup of patients with panic disorder.




In spring 2002, the mental health clinics of ‘Rivierduinen’ (an institute serving 
a region of more than 1 million people) and the Department of Psychiatry of 
the Leiden University Medical Center (LUMC) started collaboration for routine 
assessment of the diagnosis at intake, and the severity of complaints at intake. 
Reassessments take place every 3-4 months during treatment. ROM is restricted 
to patients referred for treatment of mood, anxiety, and somatoform (MAS) 
disorders. These patients form a relatively homogenous group with substantial 
mutual comorbidity (Kessler et al., 1996) and mainly receive outpatient care. 
So far, patients referred for treatment of other disorders, such as addiction or 
substance abuse or Axis II disorders, do not participate in ROM. Finally, to be 
included patients must be literate and have sufficient command of the Dutch 
language to complete the self-report instruments. For the present report, a 
group of patients with complete data was selected (N=3,798) and their data 
were analysed to illustrate the research potential of ROM- data.
Ethical considerations and privacy issues
At intake, patients are informed that ROM is part of the general policy of 
Rivierduinen to monitor treatment outcome, that outcomes are made available 
only to their therapist, and that the data will be used for research purposes, but 
only in anonymized form. If patients object to such use, their data are removed. 
A comprehensive protocol safeguards anonymity of the patients and ensures 
proper handling of the data. This protocol is available for patients on request. 
The Medical Ethical committee of the LUMC approved the regulations and 
agreed with this policy.
Instruments
At intake the Axis-I diagnosis according to the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV) is established using the Mini-
International Neuropsychiatric Interview-plus (MINI-plus, Sheehan et al., 
1998). The Dimensional Assessment of Personality Pathology (DAPP-SF) is 
administered to assess maladaptive personality traits (Livesley & Jackson, 
2006; Van Kampen D., De Beurs E., & Andrea, 2008). Subsequently, a number 
of instruments are administered at intake, which are also completed at each re-
assessment to allow for the evaluation of treatment outcome. Together, these 
instruments cover change in three areas of functioning: symptom reduction, 
increased wellbeing, and improvement in general life functioning (Sperry, Brill, 
Howard, & Grissom, 1996). They are commonly used in treatment outcome 
research and have good psychometric properties as evidenced by national 
and international publications (an overview of instruments used is available 
at http://www.lumc.nl/psychiatry/ROM-instruments). Outcome is assessed 
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by patients’ self-report and by an independent assessor, and includes both 
generic and disorder-specific measures. Generic instruments are completed 
by all patients, e.g., the Brief Symptom Inventory (BSI, Derogatis, 1975) and 
allow the comparison of treatment outcome among all patients irrespective 
of their disorder. Disorder-specific measures are administered only to those 
patients meeting criteria for the disorder at hand, e.g., the Beck Depression 
Inventory Revised (BDI-II, Beck & Steer, 1987) in case of a mood disorder. The 
latter instruments are more sensitive to change as they assess the intensity 
of the symptoms which the treatment targets; they provide a more accurate 
picture of the clinically important improvements or progress of the individual 
patient (Lee, Jones, Goodman, & Heyman, 2005). The assessment outcomes 
are made available to the therapist, discussed with the patient, and used to 
support decision-making for the future course of the treatment.
Specialized staff for ROM
The LUMC and Rivierduinen employ and train psychiatric nurses and 
psychologists (Master’s level) to carry out ROM. They are less costly than 
therapists, and ratings from a small specialized staff tend to be more reliable 
than ratings from therapists. ROM assistants administer the MINI-Plus 
interview, rating scales such as the Clinical Global Impression (CGI, Guy, 1976) 
and the Global Assessment of Functioning (GAF, Endicott, Spitzer, Fleiss, & 
Cohen, 1976), and write a brief report (1-2 pages) on the main findings for the 
therapist.
To date, 20 ROM assistants have been trained in the administration of the MINI-
Plus interview and the rating scales. Initially, weekly training sessions were 
organized. From 2006 on, assistants who had started in 2002 and had at that 
time ≥ 4 years experience with the ROM instruments, assisted in training new 
staff. To further sharpen their diagnostic skills, ROM assistants currently still 
meet every month (for half a day) for instruction (by invited speakers) on the 
phenomenology of various disorders. In addition, they practice with rating 
scales to improve interrater reliability. Videotaped interviews with patients 
are rated and the ratings are afterwards compared and discussed to reach 
consensus.
Treatments
The diagnostic information from the first ROM assessment is used in conjunction 
with the standard clinical intake interview to select the optimal treatment 
for the patient. Psychiatrists and clinical psychologists provide treatment in 
accordance with the national multidisciplinary guidelines of the National 
Steering Committee describing evidenced-based treatments for mood and 
anxiety disorders. Treatment usually consists of medication, mainly selective 
serotonin reuptake inhibitors (SSRIs), cognitive behaviour therapy (CBT), or 
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a combination of both. Simultaneous with the start of ROM, a new stepped-
care approach to treatment delivery was introduced in which the first treatment 
of choice is the least invasive/least intensive treatment for which efficacy has 
been established (e.g., a protocolled CBT or short course of pharmacotherapy). 
Only when this treatment does not result in sufficient symptom reduction, a 
more invasive or intensive treatment is offered (e.g., a combination of CBT and 
pharmacological treatment or, eventually, electroconvulsive therapy).
Clinically significant change 
To designate a change from pretest to retest as clinically meaningful we 
follow the proposal of Jacobson and colleagues (Jacobson, Roberts, Berns, 
& McGlinchey, 1999) to combine two statistical criteria for clinical significant 
change. First, the change from baseline to posttest should fall outside the 
range of the measurement error of the instrument, i.e., a statistically reliable 
change should be attained (Reliable Change Index). Secondly, the posttest 
score should be beyond a cut-off point signifying the transgression from 
dysfunctional to functional, i.e., a clinically significant change. Combining these 
two criteria provides five possible outcomes: recovery (both criteria are met), 
mere improvement (only statistically reliable change), no change, deterioration 
(reliable change in the ‘wrong’ direction), and relapse (reliable change and a 
posttest score which falls within the dysfunctional range). In ROM the results 
of all instruments and subscales are provided in terms of these five possible 
outcomes.
Feedback to the therapist and patient
ROM provides the therapist with detailed information on the state and progress 
of their patients. The therapist shares and discusses these results with the 
patient. The report on the baseline assessment consists of a summary of the 
results of the diagnostic interview and a selection of the most relevant results of 
the instruments (Figure 2.1). The re-assessment report describes the progress 
made since the previous assessment, or presents a review of the course of 
complaints over successive assessments (Figure 2.2). To accommodate 
therapists and patients, care is taken to present results in a visually attractive 
way and to provide feedback without delay. Reports follow within one day of 
the (re)assessment.
Therapists use the reports to inform their patients about the results. Patients 
are not granted direct access to their data; it was considered important to 
assist and inform patients on how to interpret the results in an appropriate 
way. The results (such as depicted in Figs. 2.1 and 2.2) can be printed and given 
to the patient to take home. Apart from being used to inform patients, the ROM 
results are also used in staff meetings were the course of treatment of patients 
is discussed periodically.
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Figure 2.1 An example of the output from a single assessment with the Brief Symptom 
Inventory (T-scores).
Brief Symptom Inventory (BSI), Assessment 1, (12-12-2008)
Personal data:
Name:   J. Doe
Birth year:  1969
Reg. number:  0321431
Therapist:  E. de Beurs
Results:
               compared to:
subscale  score  miss  patients  gen. population
SOM   61 #  0%  high   very high
OC   50 #  0%  average   high
I S   46 #  0%  below av.  above av.
DEP   38  0%  low   average
ANX   60 #  0%  above av.  very high
HOS   49 #  0%  average   high
PHO   65 #  0%  high   very high
PAR   48 #  0%  below av.  above av.
PSY   57 #  0%  above av.  very high
TOT   52#  0%  above av.  very high
# the score is higher than the cut-off between functional/dysfunctional
In a graph:
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Brief Symptom Inventory (BSI) - course
Personal data:
Name:   J. Doe
Birth year:  1969
Reg. number:  0321431
Therapist:  E. de Beurs
Results:
   Assessment:
subscale  1 (12-12)  2 (4-9) 3 (8-20) 4(11-22)
SOM  61  >>  42 -  42  -  46 (below av.)*
OC  50  -  39  -  38  -  39 (low)
I S  46  -  44  -  37  -  37 (very low)
DEP  38  -  35  -  35  -  35 (very low)
ANX  60  >  44  -  41  -  39 (low)
HOS  49 -  42  -  42  -  42 (low)
PHO  65  >  48  -  50  -  42 (low)
PAR  48  -  43  -  41  -  39 (very low)
PSY  57  >>  37  -  40  -  40 (low)
TOT  52  >>  39  -  37  -  37 (low)
* normative level of the last score
- no significant change
> improved (sign. change in comparison to the previous assessment)
>> recovered (significant progress and transgression of the cut-off)
In a graph:
       SOM  OC      I S         DEP            ANX
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Software support
Dedicated web-based computer software has been developed for the 
administration of the MINI-Plus diagnostic interview, completion of rating 
scales, administration of self-report measures, and ascertainment of treatment 
outcome. The software presents each question of the MINI-Plus on the screen 
of the interviewer together with the response options. The computer software 
is able to deal with the sometimes complicated scoring rules in this interview 
and is ‘intelligent’: if sufficient symptoms are answered as absent to preclude 
a diagnosis, or sufficient symptoms are rated present to establish a positive 
diagnosis, no additional questions are asked, after which the module is closed 
and the next module is started.
 The software is also used for completion of self-report questionnaires. For 
this purpose it has been designed as an open system: any questionnaire can be 
defined and administered with the software. The assessment can take place at 
the clinic where touchscreens can be used to accommodate computer-illiterate 
patients or, if they wish, patients can complete questionnaires at home via the 
internet.
 The software computes (sub)scale scores and compares them with 
normative values for male/female patients and male/female respondents 
from the general population (Figure 2.1) and depicts the course of symptoms 
over time (Figure 2.2). Furthermore, the software helps in the management 
of data collection, e.g. allowing to list all patients who need to be invited for 
an upcoming ‘outcome assessment’ session. Finally, the software allows for 
the export of aggregated and anonymized data for analysis with statistical 




Multiple assessments of the same case were available from the training 
sessions of the ROM staff, but these cannot be used to formally establish 
interrater reliability, as this would lead to underestimation of the reliability of 
experienced ROM assistants. Interrater reliability has, however, been formerly 
assessed with a small subset of patients (n=44) revealing sufficient interrater 
reliability for the Comprehensive Psychiatric Rating Scale (Goekoop, De Beurs, 
& Zitman, 2007); average Cohen’s Ƙ=0.60), the GAF (average Cohen’s Ƙ=0.73) 
and the CGI (average Cohen’s Ƙ=0.55). These indices denote acceptable 
interrator reliability.
Time investment
The time needed for the first assessment is about 2 hours; 35 minutes for 
the MINI-Plus, 40 minutes for the rating scales and 45 minutes for the self-
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report measures. A ROM re-assessment session takes (on average) 1 hour to 
complete. Research assistants, however, reported that for some patients there 
was insufficient time to include all the disorder-specific instruments which 
should be administered according to the MINI-Plus diagnoses.
Acceptability of the ROM procedure to patients
Patients showed good compliance with the ROM procedure. The percentage of 
patients with a mood, anxiety, and/or somatoform disorder that participated 
in ROM increased to 80% by 2009. Reasons for not participating were: the 
patient’s command of the Dutch language was deemed insufficient to complete 
the questionnaires, or the assessment procedure was considered too invasive 
for the patient. No patients refused to partake in the ROM procedure, but 
approximately 5% failed repeatedly to show up at their first assessment. 
Comparison of the demographic data of patients who did and did not participate 
in ROM revealed no significant difference for gender, age, or educational level 
(all p > 0.20); however, more patients with a non-Dutch ethnic origin did not 
participate in ROM.
 Patients were satisfied with ROM; they did not feel excessively burdened and 
the comprehensive assessment made them feel that their problem or disorder 
was taken seriously by the staff.
Attrition 
Even though patients were willing to participate in ROM at intake, in our study 
sample, on each successive assessment the cohort was reduced in size by 
about 50%. Half of the patients without a re-assessment had discontinued 
their treatment and their last assessment can be considered a proper endpoint. 
However, the other half was still undergoing treatment, should have been 
assessed, and is considered as real loss to follow-up. Thus, no formal endpoint 
assessment was available for about 25% of the patients of the baseline sample 
due to repeated no-show. The assessment session had been rescheduled twice 
for these latter patients before we gave up on their outcome data. No-show for 
re-assessment ranges from 10 to 30% of the appointments, making it a costly 
problem.
Therapists’ impressions of ROM
In an early phase of the implementation of ROM we conducted a survey 
among therapists and managers, investigating their views on the accuracy and 
usefulness of the data in their day to day clinical work. Therapists reported 
that they utilized the outcome data to motivate patients by showing them the 
progress made thus far, and the symptoms that still need attention in treatment. 
Initially, some resistance from therapists toward standardized assessment had 
to be overcome. Some felt that ROM was intrusive, violating the privacy of the 
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therapy dyad. Others felt they were better able to judge the clinical progress 
than could be done with standardized instruments. In practice, however, it 
appeared that ROM data supported or supplemented their clinical impression 
on how the patient fared in treatment; the data sometimes even corrected a false 
impression. As a result, therapeutic staff became more sensitive to treatment 
outcome data and eventually the majority enthusiastically accepted ROM.
 During staff meetings the ROM results are presented and when they 
demonstrate lack of progress different courses of action are discussed. 
Likewise, when the ROM results indicate recovery, i.e., reliable and clinical 
relevant decreases in scores measuring the intensity of the main complaints, 
this signals that therapy might be ended, preventing the unnecessarily lingering 
on of treatment. Thus, ROM more than likely improved the efficiency of the 
treatments provided in the clinic.
Other use of ROM data
Apart from therapists and patients, researchers and managers may also 
use ROM data. Managers have just started to use ROM data for internal 
benchmarking purposes. As yet, only results on the proportion of successfully 
monitored treatments have been compared among the seven outpatient 
clinics. Outcomes on differential effectiveness of various treatment programs, 
locations, departments, or even therapists, have so far not been supplied. For 
these outcomes more complete data are needed, i.e. less loss of re-assessments.
 ROM data have been used for psychometric research (Wardenaar et al., 2010; 
De Beurs E., Rinne, van, Verheul, & Andrea, 2009; De Beurs, Den Hollander-
Gijsman, Helmich, & Zitman, 2007; Den Hollander-Gijsman, De Beurs, Van 
der Wee, Van Rood, & Zitman, 2010; Van Kampen D. et al., 2008), treatment 
outcome research, and for basic research (Van Noorden et al., 2010; Veen et al., 
2009).
Examples of findings with ROM data
The results described in this paper are based on ROM data collected from 
January 2004 to December 2006. This dataset consists of 3,798 patients. The 
average age of the group was 39.6 (SD=13.3) years and 63% were women.
Diagnostic status at intake
According to the MINI-Plus, 1,618 patients (42.6%) met criteria for one MAS 
disorder, and 1,556 patients (41.0%) had more than one concurrent disorder (967 
patients (25.5%) with two comorbid disorders, 403 patients (10.6%) with three, 
and 186 patients (4.9%) with four or more). Figure 2.3 presents an overview of 
the various (combinations of) diagnoses found in this sample when grouped in 
higher-order categories of MAS disorders: 1,788 patients (47.0%) met criteria 
for one or more mood disorders, 1,653 patients (43.5%) for one or more anxiety 
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disorders, 653 patients (17.2%) for one or more somatoform disorders, and 851 
patients (22.4%) had other disorders (e.g., adjustment disorder, mixed anxiety-
depression), or did not meet criteria for a DSM-IV Axis-I diagnosis (16.4%).
Outcome for panic disorder patients
To further illustrate the potential of ROM, we investigated the treatment 
outcome of patients with panic disorder using the Panic Disorder Severity Scale 
(PDSS) as an observer rater instrument for the assessment of the intensity of 
panic disorder symptoms (Shear et al., 1997). A total of 415 patients had a MINI-
Plus diagnosis of panic disorder (with current panic attacks) and filled in the 
PDSS. Their average age was 35.9 (SD=10.7) years; 64% were women and 62% 
suffered from panic disorder with agoraphobia. On the PDSS the average score 
at pretest was 12.34 (SD=5.03). A second assessment after (on average) 25.8 
(SD=18.7) weeks was available for 238 patients. In this subsample, the PDSS 
total score dropped from 12.56 (SD=5.01) to 7.04 (SD=5.84), a difference of 
almost 1 SD. At posttest 68% scored below the cutoff score of 7 on the PDSS 
indicating clinically significant change (at the pretest 18% of the patients 
scored below 7). Finally, 58 patients completed four assessments spanning (on 
average) 62 weeks of treatment. Multivariate analysis of variance for repeated 
measures was used to test whether the drop in score over time followed a 
linear pattern: F linear contrast (1, 57)=52.11, p < .000, partial Ƞ2=.48, which denotes 
a large effect.
Figure 2.3 Number of patients with mood (MOOD), anxiety (ANX), somatoform (SOM) 
disorders (or MAS disorders), and those not meeting criteria for mood, anxiety, or soma-







The value of ROM
Our experiences with ROM suggest that ROM offers several benefits; however, 
these need to be investigated in more detail (preferably in a controlled study) 
as the present study provides no empirical proof of the positive value of 
ROM. In the literature different approaches to ROM have been developed and 
described. Some use a single instrument (e.g., the HoNOS, CORE-OM, or the 
OQ-45), others use multiple measures from different perspectives (e.g. clients, 
therapist or clinical raters). Some administer these instruments at pretest and 
posttest only, others assess periodically, and still others (Lambert, Harmon, 
Slade, Whipple, & Hawkins, 2005) organize assessments on a session-by-
session basis.
 The benefits from monitoring and providing feedback to patients have been 
studied in a few studies using a controlled design. Lambert and colleagues 
(2005) compared three conditions: informing both the therapist and the patient 
of the results, informing only the therapist, and informing neither the therapist 
nor the patient. They report positive effects on treatment outcome of providing 
feedback. The greatest reduction of symptoms was seen in the condition where 
both parties were provided with feedback. In this condition the rate of patients 
demonstrating clinically significant improvement was doubled. Slade et al. 
(2006) evaluated in their controlled study the effects of 3-monthly feedback to 
patients treated in a community mental health centre. These patients regularly 
completed (postal) questionnaires on their mental health. On the primary 
outcome measures the intervention group did not fare better than the ‘treatment 
as usual’ control group. However, informed patients spent significantly less 
days in in-patient care which made the intervention cost effective. A recent 
meta-analysis on the effects of providing feedback on therapist and patients 
concluded that the benefits are present but rather limited in effect size (Knaup, 
Koesters, Schoefer, Becker, & Pushner, 2009). The research of Lambert and 
colleagues (Lambert et al., 2005) and Miller and colleagues (Miller et al., 2005) 
suggests the best results are attained with patients that otherwise would 
have stopped the treatment prematurely. Thus, additional controlled studies 
are needed, in view of the substantial efforts and costs involved in obtaining 
outcome data in a routine manner. In addition, further research is required to 
determine the minimal assessment battery necessary to serve all stake holders; 
i.e. therapists and patients, researchers and managers.
Attrition 
In our study sample, on each successive assessment the cohort was reduced 
in size by about 50%. High attrition rates with ROM are frequently reported. 
For example, in the study of Stiles et al. (2006) posttest data were available for 
only 33% of the patients that had provided pretest data. The high number of 
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patients that is lost for follow up precludes conclusions on the effectiveness 
of the treatments evaluated (Clark, Fairburn, & Wessely, 2008). To increase the 
number of patients with complete ROM data we have improved communication 
between ROM assistants and therapist. Now, therapists are required to inform 
the ROM assistant if treatment is about to conclude. The assessment session 
can then be scheduled prior to the final treatment session. Until more complete 
data are available, an intention-to-treat analysis of aggregated data might yield 
a more valid reflection of results obtained in everyday clinical practice than is 
provided by a completer analysis (Wood, White, & Thompson, 2004).
Ratings versus self-report data
ROM data are (in part) based on ratings by the ROM staff. Reliability of 
these ratings ranged from 0.60 to 0.74 (Cohen’s Ƙ). This denotes moderate to 
substantial agreement between the raters. However, these interrater reliability 
estimates may be somewhat inflated as they are based on the re-rating of a 
videotaped interview. Subjecting patients twice to two separate interviews was 
deemed too demanding for patients, but would have yielded more valid (and 
likely lower) interrater reliability estimates.
 Traditionally, outcome research with mood disorders relies predominantly 
on rating scales whereas with anxiety disorders it is more common to use self-
report scales. Using the same instruments in ROM allows for direct comparison 
between the treatment results attained in clinical practice (efficacy) and in 
randomized controlled studies. However, there are considerable additional 
efforts and costs involved in utilizing ratings made by independent observers. 
The incremental value of using raters and rating scales, compared to assessing 
outcome by patients’ self-report with questionnaires needs to be further 
investigated.
Computerised assessment
We decided to use computerized administration of questionnaires for ROM 
as this implies that there are no missing data, instruments are scored straight 
away, and normed results are immediately available. A disadvantage is that 
some experience with computers is required, which older people in particular 
might not have. To solve this problem the assessment sessions are scheduled 
at the treatment centres were touchscreens are available and ROM staff can 
help the patient when this is necessary. 
 The software allows for completion of the self-report questionnaires at 
home. Although this is patient-friendly, the drawback is that we cannot be 
100% certain that the patient completed the measures without the help of 
family members or others. The option of completing self-report questionnaires 
at home is, however, still open and we are currently exploring options for this 
more patient-friendly version of ROM.
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Scientific research implications
To illustrate the research potential of ROM data, we investigated the diagnostic 
data of all the patients participating in ROM between January 2004 and 
December 2006, and the treatment outcome of panic disorder patients. The 
diagnostic data of the MINI-Plus reveal that in clinical practice comorbidity 
abounds: a large proportion of patients meet criteria for two or more diagnoses. 
This may in part be due to the use of a structured diagnostic interview in which 
the criteria of a large number of DSM disorders are methodically checked 
and diagnoses are not easily overlooked. In a clinical interview, the intaker 
might be more focused on establishing the disorder to treat, disregarding 
comorbid psychopathology, and may see symptoms which could qualify for 
a comorbid diagnosis as belonging to the primary diagnosis (See also Rettew, 
Lynch, Achenbach, Dumenci, & Ivanova, 2009). The importance of diagnostic 
accuracy was underlined by Jensen-Doss and Weisz (2008) who showed in a 
meta-analysis that less drop-outs occurred and a better outcome was attained 
in cases where clinicians and researchers (using a structured diagnostic 
instrument) agreed about the diagnosis.
 The patients monitored in this study form a representative sample of the 
patients typically seen in clinical practice. The ROM data from this sample can 
be used to investigate whether these patients differ substantially from patients 
that participate in clinical trials. Treatment outcome of panic disorder patients 
was assessed with a widely-used disorder-specific outcome measure, the 
PDSS. After (on average) 6 months of treatment scores on this rating scale had 
dropped by almost 1 SD. Barlow, Gorman, Shear, and Woods (2000) in their 
landmark randomised controlled trial, report a response rate of 60%, defined 
as a score below the threshold of 7 for clinically relevant complaints. In our 
sample, 68% of the patients scored below 7 at post-test, comparing favourably 
with the results of Barlow and colleagues.
 The findings on comorbidity and panic disorder treatment illustrate that 
data collected through ROM can be used for research. Researchers normally 
do not have easy access to the treatment results attained in mental health 
institutes. With ROM the interests of both therapists and researchers are 
served. The ROM structure allows for the collection of additional data, such 
as information on biological, social, psychological, or cognitive functioning of 
patients. With these data fundamental research questions can be addressed 
regarding differences between diagnostic subgroups, associations between 
the phenomenology of disorders and biological or psychological parameters, 
and the prognostic value of these variables for treatment outcome. The latter 
can be advantageous for clinical practice, potentially allowing for a better 
match between patient needs and treatment. For instance, the choice of 
medication in the treatment of anxiety or depression is largely a process of 
‘trial and error’ to find an acceptable balance between side-effects and optimal 
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therapeutic effect. In the future, it might be possible to select medication based 
on the patient’s genetic information. Currently, a biological database is being 
built with genetic information of the patients who participate in ROM. This will 
enable future research into the genetic background of the phenomenology of 
common mental disorders and may yield preliminary data on the interaction of 
genes, pharmacological agents and treatment response.
2.5 Conclusions
In summary, ROM is a method for the routine assessment of treatment outcomes 
in clinical practice, which simultaneously serves the interests of patients, 
therapists, mental healthcare managers, and researchers. Implementation 
of ROM has been shown to be feasible and created an efficient ‘assessment 
culture’ in a mental health institute with little academic tradition.




COmOrBId depressIOn and anxIety: 
symptOm and funCtIOnal severIty In the ClInICal settIng
Submitted for publication
Margien E. den Hollander-Gijsman
Nic J.A. van der Wee
Edwin de Beurs
Klaas J. Wardenaar
Yanda R. van Rood






Comorbidity between depression and anxiety disorders is widely understood 
to be associated with poorer outcome, increased symptom severity and more 
functional impairment. However, symptom severity and functional impairment 
in comorbidity have not been compared directly to those in pure depression 
and pure anxiety disorder in general psychiatric patient samples. The aim 
of this study is to determine in a large outpatient sample whether patients 
with comorbidity have increased symptom severity and greater functional 
impairment as compared to patients with only a depressive or an anxiety 
disorder.
Method
Analyses were performed on a large sample consisting of 2278 outpatients 
with a depression and/or an anxiety disorder from a general psychiatric setting. 
We studied the relation of diagnostic status with global severity, functional 
severity, depression severity and anxiety severity.
Results
Symptom severity (global severity, depression severity and anxiety severity) 
and functional impairment were increased in the comorbid group as compared 
to the pure groups. Depression severity in the comorbid group was higher 
than in the pure depression group and anxiety severity in the comorbid group 
was higher than in the pure anxiety group. The latter was also the case when 
analyses were repeated for specific DSM-IV anxiety disorders.
Conclusions
In a large general psychiatric outpatient sample comorbidity is associated 
with increased depressive and anxiety severity, and increased functional 
impairment.
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3.1 Introduction
High rates of comorbidity between anxiety disorders and depression have been 
reported in the general population (Kessler et al., 1996), in primary care (Roca 
et al., 2009) and in secondary care (Brown et al., 2001). Comorbidity between 
depression and anxiety disorders is widely understood to be associated 
with increased severity, poorer outcome and more functional impairment. 
Researchers have argued that comorbidity of depression and anxiety disorders 
even warrants a separate diagnosis (e.g. Tyrer, 2001; Silverstone & Von Studnitz 
E., 2003). The appreciation of the importance of comorbidity is also reflected 
in the goals set for the next version of the Diagnostic and Statistical Manual 
(DSM)-5, as this version should enable clinicians and researchers to take the 
presence and effects of comorbidity into account (www.dsm5.org).
 However, contrary to many studies on the prevalence of comorbidity or its 
effects on disease outcome (Emmanuel, Simmonds, & Tyrer, 1998), studies 
reporting on the severity of depressive and anxiety symptoms in comorbidity 
usually did not include the full spectrum of symptomatology. In these studies, 
only depression with and without comorbid anxiety disorders (e.g. Dalrymple 
& Zimmerman, 2007; Fava et al., 2004), or only anxiety disorders with and 
without comorbid depression (Kaufman & Charney, 2000), but never the three 
groups together, were examined. Furthermore, these studies have only been 
performed in the general population or in samples from specialized psychiatric 
care settings, or did assess only the severity of one type of symptoms 
(depressive or anxiety) or the impact of comorbidity of depression and anxiety 
on general distress and daily functioning (Pirkola et al., 2003; Wittchen, Carter, 
Pfister, Montgomery, & Kessler, 2000).
 It is of relevance for routine clinical practice and for the ongoing research 
into the nature and consequences of comorbidity, to obtain more insight in the 
severity of depressive and anxiety symptoms and their effects on functioning 
in patients with comorbidity in routine general psychiatric practice settings. In 
this study, we examined the severity of depressive and anxiety symptoms and 
the related functional impairment of patients with comorbid and pure mood 
and anxiety disorders in a large naturalistic routine psychiatric outpatient 
sample. We hypothesized that patients with comorbidity of depression and 
anxiety disorders would have 1) a higher global symptom severity than patients 
with only one disorder, 2) more severe depressive symptoms than patients 
with a pure depression, 3) more severe anxiety symptoms than patients with 
a pure anxiety disorder and 4) a higher severity of functional impairment than 
patients with a pure depression or a pure anxiety disorder. Because one can 
expect different effects for different anxiety disorders, we also tested the third 
hypothesis for specific anxiety disorders.




This study was conducted on data collected through Routine Outcome 
Monitoring (ROM, (De Beurs et al., 2011)). ROM is an ongoing monitoring 
system for patient care, implemented in the outpatient clinics of Rivierduinen 
(a large organization for the provision of mental health care in the province 
of Zuid-Holland, the Netherlands) and the Department of Psychiatry of the 
Leiden University Medical Center (LUMC). All patients referred to these clinics 
for treatment of a mood-, anxiety- or somatoform disorder, have assessment 
sessions with a psychiatric research nurse at the start, during, and at the end 
of the treatment (De Beurs et al., 2011). For this study, the baseline ROM-
assessments were used. During these baseline assessments, a standardized 
diagnostic interview is administered and interviewer and self-reported ratings 
are completed. ROM data are primarily used for diagnosis and to inform 
clinicians and patients about treatment progress. The use of anonymous data 
of these patients for research purposes has been approved by the Medical 
Ethical Committee of the Leiden University Medical Center.
Sample
The initial group consisted of 3798 outpatients admitted consecutively between 
January 2004 and December 2006. For the present study, three diagnostic 
groups of patients were selected (total n=2278): (1) patients with one or more 
anxiety disorders and no depression (n=729), (2) patients with a depression 
and no anxiety disorders (n=860) and (3) patients with comorbid an anxiety 
disorder and a depression (n=689). The diagnosis ‘depression’ includes both 
Major Depressive Disorder (MDD) and dysthymia (respectively 62,6% and 
5.4% of the total sample (n=2278)), but not bipolar disorder. The majority 
of the patients that were not included in this study had a single or comorbid 
somatoform disorder.
Instruments
Mini International Neuropsychiatric Interview (M.I.N.I.) - Plus 5.0.0.-R 
To establish the presence of current and life-time Axis-I disorders according 
to the DSM-IV diagnostic criteria, The Dutch translation of the M.I.N.I.-Plus 
5.0.0-R (Van Vliet, Leroy, & van Megen, 2000) was used (Sheehan et al., 1998). 
The M.I.N.I.-Plus is an extended version of the original M.I.N.I. Lecrubier and 
colleagues (Lecrubier et al., 1997) report sufficient reliability of the M.I.N.I 
(k=0.88-1.00; test-retest reliability= 0.76-0.93). Validity was demonstrated by 
sufficient concordance with the Composite International Diagnostic Interview 
(CIDI, WHO). Interviews were performed by extensively trained and supervised 
psychiatric research nurses. All diagnoses reported in this study were current 
at the time of assessment. In the M.I.N.I.-Plus some hierarchical exclusion rules 
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apply: in case of a current depression diagnosis, concurrent dysthymia is ruled 
out. Depression, and generalized anxiety disorder (GAD) can only be diagnosed 
concurrently if both disorders have a different time of onset.
Brief Symptom Inventory
The Brief Symptom Inventory (BSI) (Derogatis & Melisaratos, 1983; De Beurs, 
2005) is a shortened version of the Symptom Checklist (SCL-90) (Derogatis, 
Lipman, & Covi, 1973) , and is used to measure psychological complaints or 
symptoms. The BSI consists of 53 items, rated on a five-point Likert scale, 
ranging from 0 (not at all) to 4 (very much). The items are subdivided into nine 
subdimensions: 1) somatic complaints; 2) cognitive problems; 3) interpersonal 
sensitivity; 4) depression; 5) anxiety; 6) hostility; 7) phobic fear; 8) paranoid 
ideation, and 9) psychoticism. The average score of all 53 items is the BSI-Global 
Severity Index (BSI-GSI), which is an overall measure of psychopathology 
severity. In the current study the BSI-GSI and the anxiety and depression 
subscale (BSI-ANX and BSI-DEP) were used.
Rating scales for symptom severity of depression and anxiety
Research nurses rated the symptom severity of depression on the 10-item 
Montgomery Åsberg Depression Rating Scale (MADRS; (Montgomery & 
Åsberg, 1979)) and anxiety on the 10-item Brief Anxiety Scale (BAS; (Tyrer, 
Owen, & Cicchetti, 1984)). Items on both scales (e.g., “pessimistic thoughts”, 
“worries about minor issues”) are rated on a 7-point scale anchored at 4 points 
(1, 3, 5, and 7).
SF-36 Health Survey
Functional status was measured with the SF-36 Health Survey (Aaronson et al., 
1998; Ware, Jr. & Sherbourne, 1992). The SF-36 is composed of 36 questions 
and standardized response choices, organized into eight multi-item scales: 
physical functioning (PF), role limitations due to physical health problems 
(RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social 
functioning (SF), role limitations due to emotional problems (RE), and general 
mental health (MH). All raw scale scores are linearly converted to a 0 to 100 
scale, with higher scores indicating higher levels of functioning or well-being.
Demographic characteristics
Ethnic background, education, housing situation and employment status were 
assessed with a self-report questionnaire. A Dutch ethnic background was 
assumed when the patient and both parents were born in The Netherlands.
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Statistical analyses
To investigate differences between the three diagnostic groups on socio-
demographic variables, chi-square tests were used on categorical variables and 
analyses of variance (ANOVA) on continuous variables. To test our hypotheses, 
we performed several ANOVAs with the severity measures as dependent 
variables and with diagnostic group as independent variable with 3 levels (1: 
pure anxiety, 2: pure depression, 3: comorbid depression and anxiety).
 Subsequently, we performed separate analyses for several specific anxiety 
disorders: obsessive compulsive disorder (OCD), posttraumatic stress disorder 
(PTSD), generalized anxiety disorder (GAD), agoraphobia (AGO), panic disorder 
(PD) and panic disorder combined with agoraphobia (PD-AGO). For these 
analyses, we selected patients with singular anxiety disorders. To investigate 
differences between patients with- and without a comorbid depression in each 
of these anxiety disorders, we used t-tests with BSI-ANX as dependent variable 
and the presence of comorbidity as independent variable with two levels (1: 
only anxiety 2: anxiety and depression).
 To investigate the role of age as a possible confounder, all analyses were 
rerun with Age as covariate. All analyses were conducted using SPSS 17. 
Casewise deletion was used, which resulted in different numbers for the 
analyses on different outcome measures.
3.3 Results
Sample characteristics
The demographic characteristics of the subjects arranged by diagnostic 
group are shown in Table 3.1. In the total sample (n=2278) mean age was 
38.4 (SD=13.0) and 64.4% were women. A complete survey of demographic 
variables was available for 1919 (84%) patients in our sample. The percentage 
of patients with a completed survey did not differ significantly between the 
three diagnostic groups (resp. 85%, 85% and 83%).
 No differences between the three diagnostic groups were found for gender 
and housing situation. The mean age did differ significantly between the three 
groups; the highest mean age was found in patients with a pure depression 
(mean age=41.0; SD=13.8). Other significant differences were found for ethnic 
background, educational status and employment status. Within the group ‘pure 
anxiety’ the number of patients with a Dutch ethnic background was higher 
than in the other two groups. Patients with comorbidity revealed a slightly 
lower percentage of patients with college education and a higher percentage 
of patients unable to work due to their sickness of disability.
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Table 3.1 Characteristics by diagnostic groups: gender and age and demographic 
variables.
  Total Pure Pure Anxiety p-value
   Anxiety  Depression and depression
n  2278 729 860 689
Gender (% female)  64.4 63.1 64.1 66.2 .47
       Mean age (sd) 38.8 (13.0) 35.8 (12.4)a 41.0 (13.8)b 38.0 (12.0)c <0.001
n  1919 617 733 569
Ethnic background (%)     .03
- Dutch 80.6 84.1 79.1 78.6
- Other ethnicity 19.4 15.9 20.9 21.4
Housing situation (%)     .53
- Living alone 25.7 24.5 27.6 24.6
- Living with partner 49.9 51.1 49.4 49.2
- Living with family 24.4 24.5 23.1 26.2
Educational status (%)     <.001
- Lower education 10.4 7.0 11.1 13.4
- High school (lower) 33.8 32.1 34.2 35.0
- High school (higher) 38.4 41.8 35.5 38.3
- College/university 17.5 19.1 19.2 13.4
Employment status (%)     <.001
- Employed - part time 21.6 26.3 21.8 16.2
- Employed - full time 22.0 29.3 20.3 16.2
- Unemployed/retired 28.9 25.6 30.6 30.2
- Unable to work due 27.6 18.8 27.3 37.4
  to sickness or 
  disability 
Note. Means having a different subscript are significantly different at p < .05 in the 
Tukey difference comparison.
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Table 3.2 Global symptom severity and symptoms of depression and anxiety by 
diagnostic group in 2201 outpatients.
Subscale Pure Pure  Anxiety F (df: 2, p-value
mean (sd) Anxiety Depression and depression 2198)
  (n=705) (n=833) (n=663)
BSI-GSI 1.06 (0.61)a 1.35 (0.66)b 1.74 (0.73)c 180.00 <.001
 
Symptoms of depression
- BSI-DEP 1.12 (0.85)a 2.00 (0.92)b 2.23 (0.96)c 291.32 <.001
- MADRS 13.77 (8.02)a 23.30 (7.91)b 25.49 (8.16)c 429.39 <.001
Symptoms of anxiety
- BSI-ANX 1.45 (0.91)a  1.34 (0.87)a 1.96 (0.97)b 92.86 <.001
- BAS 14.32 (6.47)a 14.71 (5.70)a 19.05 (6.66)b 123.81 <.001
Note. MADRS = Montgomery - Åsberg Depression Rating Scale; BAS = Brief Anxiety 
Scale; BSI = Brief Symptom Inventory. BSI-GSI = global severity index. BSI-DEP = 
depression subscale. BSI-ANX = anxiety subscale. 




The ANOVA with the BSI-GSI as dependent variable showed a significant 
overall-effect of diagnostic group (p<0.001). The pure anxiety group had a 
lower mean BSI-GSI than the pure depression group; the comorbid group had 
a higher mean BSI-GSI than both pure disorder groups (See Table 3.2).
Depression severity
The ANOVAs with measures of depression severity (BSI-DEP and MADRS) as 
dependent variable showed a significant overall-effect of diagnosis (p<0.001). 
The pure anxiety group had lower mean BSI-DEP and MADRS scores than the 
pure depression; the comorbid group had higher mean scores than both pure 
disorder groups (See Table 3.2).
Anxiety severity
The ANOVAs with the two measures of anxiety severity (BSI-ANX and BAS) 
as dependent variable showed a significant overall-effect of diagnostic group 
(p<0.001). The comorbid group had higher mean BSI-ANX and BAS scores than 
47
both pure disorder groups; the scores did not differ between the pure groups 
(See Table 3.2).
Functional severity
The ANOVAs with each of the subscales of the SF-36 as dependent variable 
showed an overall effect of diagnostic group on all scales (p<0.001). The pure 
anxiety group had a higher mean score than the pure depression group on all 
subscales (i.e. a less severe functional impairment). The comorbid group had 
lower mean scores (i.e. higher functional impairment) than each of the pure 
groups (See Table 3.3). Only on the subscale ‘Role limitations due to emotional 
problems (RE)’, the comorbid group did not have a significant lower score than 
the pure depression group.
 Because four of the eight subscales of the SF-36 had a skewed distribution, 
these variables were log-transformed (PF, BP) or dichotomized (RP, RE). 
Subsequently, to evaluate the impact of the skewness on the results, we repeated 
the analyses with the transformed variables: ANOVAs with the continuous 
outcome variables (PF, BP) and chi-square tests in with the dichotomous 
outcome variables (RP, RE). The results for the transformed SF-36 scales were 
highly similar to the results for the untransformed scales (See Table 3.3): all 
group differences were significant for all subscales except for RE, and in the 
same direction.
Specific anxiety disorders
The mean scores on BSI-ANX were compared between specific anxiety 
disorders with and without comorbid depression; mean BSI-ANX scores for the 
different groups are shown in Figure 3.1. T-tests revealed that in all but one of 
the specific anxiety disorder groups, the score on the BSI-ANX was significantly 
higher in patients with a comorbid depression compared to patients with only 
an anxiety disorder. Only for patients with GAD, mean scores on the BSI-
ANX did not differ between the pure GAD group and the group with GAD and 
depression.
Adjustment for age
When the analyses were adjusted for age, only the difference in BSI-ANX 
between patients with a panic disorder and agoraphobia with and without a 
comorbid depression was no longer significant. All other effects remained 
unchanged.
3.4 Discussion
We examined the severity of depressive and anxiety symptoms as well as 
functional impairment in patients with comorbid depression and anxiety 
disorders compared to those in pure disorders in a large general psychiatric 
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Table 3.3 Functional severity (SF-36 subscales) by diagnostic group in 2153 outpatients.
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SF-36 subscale  Pure Pure  Anxiety F (df: 2, p-value
mean (sd) Anxiety Depression and depression 2150)
  (n=696) (n=815) (n=641)
Physical  82.9 (20.5)a 73.6 (24.0)b 70.5 (24.4)c 54.06 <.001
functioning (PF)    
Social functioning  55.8 (25.7)a 41.4 (25.3)b 34.8 (22.7)c 128.7 <.001
(SF)    
Role limitations  54.5 (41.9)a 36.4 (38.7)b 30.4 (37.5)c 69.8 <.001
due to physical    
health problems 
(RP)        
Role limitations 41.5 (40.3)a 22.6 (32.0)b 19.3 (29.7)b 84.66 <.001
due to emotional
problems (RE)
General mental  50.3 (16.5)a 35.8 (16.0)b 31.9 (14.2)c 264.3 <.001
health (MH)    
Vitality (VT) 45.2 (17.4)a 29.9 (15.6)b 27.5 (14.9)c 250.3 <.001
Bodily pain (BP) 75.8 (24.2)a 66.2 (27.1)b 61.5 (28.6)c 50.8 <.001
General health  58.9 (20.8)a 51.6 (21.1)b 47.5 (19.8)c 53.23 <.001
perception (GH)
Note. SF-36 denotes Short Form 36 (RAND 36). Scores are on a 100 point-scale. 
A higher score corresponds to better functioning / health status. Means having a 
different subscript are significantly different at p < .05 in the Tukey difference com-
parison.
outpatient sample. The results confirmed our hypotheses and showed that in 
routine clinical practice, patients with comorbidity have a higher global and 
specific symptom severity and suffer more from severe functional impairment 
than patients with a pure depressive or anxiety disorder. Our main finding is 
that depression severity in the comorbid group was higher than that in the 
pure depression group, and anxiety severity in the comorbid group was higher 
than that of the pure anxiety group. Apparently, having an anxiety disorder 
in addition to a depression does not only increase the severity of anxiety 
symptoms, but also the severity of depressive symptoms. Similarly, having 
a depression in addition to an anxiety disorder does not only increase the 
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Figure 3.1 Mean (std error) scores on BSI anxiety scale for specific anxiety disorders 




























BSI ANX = anxiety subscale. NO DEP = no concurrent depression, DEP = concurrent de-
pression. OCD = obsessive compulsive disorder, PTSD = posttraumatic stress disorder, 
GAD = generalized anxiety disorder, SAD = social anxiety disorder, PD = panic disorder, 
AGO = agoraphobia, PD+AGO = Panic disorder combined with agoraphobia.
*= p-value < 0.05 (t-test).
severity of depressive symptoms, but also the severity of anxiety symptoms. 
The latter was also the case when analyses were repeated for specific DSM-IV 
anxiety disorders.
 Our findings are in line with the extended literature on comorbidity. Several 
studies found within a group of patients with MDD, that those with many 
anxiety symptoms were more severely depressed (e.g. Fava et al., 2004; Joffe, 
Bagby, & Levitt, 1993). Other studies focused on a specific anxiety disorder and 
reported higher anxiety severity or functional impairment (e.g. Wittchen et al., 
2000; Cassin, Richter, Zhang, & Rector, 2009) in patients with comorbidity. We 
replicated these findings in a sample of patients with pure depression, pure 
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anxiety disorders and patients with comorbidity of depression and anxiety. 
With this study design, the symptom severity of the pure disorders could also 
be taken into account. Our data show that many patients with a ‘pure’ DSM 
IV depression also have anxiety symptoms, and patients with a ‘pure’ DSM 
IV anxiety disorder also have depressive symptoms. Moreover, we found 
that the mean scores on the anxiety measures (BSI-anx & BAS) did not differ 
significantly between patients with a pure depression and patients with a pure 
anxiety disorder.
 Our findings are limited by the fact that we had no control group of subjects 
derived from the general population. This would have enabled us to determine 
whether the effect of diagnostic group on severity is cumulative or interactive, 
i.e. whether the increased symptom severity in comorbid patients equals the 
sum of the severity scores of the separate diagnoses or whether severity is 
exponentially increased when more than one diagnosis is present.
 The finding that patients with comorbidity have increased anxiety 
severity compared to patients with a pure anxiety disorder was replicated for 
subgroups of patients with OCD, PTSS, PD, SAD, and Agoraphobia in our study. 
However, there was no difference in severity of anxiety symptoms for patients 
with comorbid depression in the subgroup of patients with GAD. Also, GAD 
revealed the highest score on depressive symptoms compared to the other 
anxiety disorders. This finding is in line with previous studies on the structure 
of DSM-IV anxiety and depression diagnoses that have shown that GAD is best 
grouped together with depression in a cluster of distress disorders, whereas all 
other anxiety disorders are grouped together in another class of fear disorders 
(Krueger, 1999; Watson, 2005). Our results provide further evidence that GAD 
might be more closely linked to depression than to other anxiety disorders.
 An important strength of the current study is the large size and 
representativeness of the used sample. Also, the included patients were 
all well characterized and the sample comprised both a broad range of pure 
disorders and different forms of comorbidity, which enabled us to investigate 
the influence of comorbid depression in patients with different specific anxiety 
disorders. Moreover, we examined functional impairment in addition to 
symptom severity.
 We believe that our findings give further support to the claims that 
depression and anxiety disorders should not be investigated in isolation (e.g. 
Beuke, Fischer, & McDowall, 2003). Moreover, the findings are in line with 
the idea that ‘the use of categorical diagnostic approaches and dimensional 
rating scale in tandem will facilitate identification of meaningful phenotypes 
for future genetic, biochemical, neuroimaging, and treatment studies’ (pag.73, 
Kaufman & Charney, 2000). This is not only relevant for research, but also for 
clinical practice. When using both a diagnostic interview and several severity 
measures at intake, a large amount of additional relevant information becomes 
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available to the clinician. This information can help to decide which treatment is 
most suitable for the patient at hand, and at follow-up, what effect the treatment 
has on different sorts of symptoms. Ultimately, large sets of these naturalistic 
data could be used to find an optimal treatment approach for patients with 
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The tripartite model conceptualizes symptoms of depression and anxiety in 
three groups: low positive affect and anhedonia, which is specific to depression, 
somatic arousal, which is unique to anxiety, and nonspecific general distress. 
The Mood and Anxiety Symptom Questionnaire (MASQ) was developed to 
measure these symptom domains. This study reports on the psychometric 
properties of the Dutch translation of the MASQ.
Method
The questionnaire was completed by a population-based sample and by patients 
with anxiety and/or mood disorders. Scores of these respondent groups were 
compared to assess the discriminant validity of the MASQ and evaluate the 
appropriateness of the tripartite model.
Results
The psychometric properties of the translated MASQ were highly satisfactory. 
In accordance with the model, we found the MASQ to comprise three main 
scales, which discriminate well between subgroups of patients with mood and 
anxiety disorders.
Discussion
Overall, like the English version the Dutch translation of the instrument appears 
to be a reliable and valid measure of symptoms of depression and anxiety, 
conceptualized as comprising three groups of symptoms. The Dutch MASQ is 
better able to distinguish unique aspects of mood and anxiety disorders than 
other self-report instruments.
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4.1 Introduction
Whether a valid distinction can be made between anxiety and depression 
is subject to much debate. Both disorders show considerable overlap in 
symptomatology, making it sometimes hard to decide which diagnosis best 
fits the clinical picture (e.g. generalized anxiety disorder vs. major depression). 
Consequently, instruments assessing the key symptoms of mood and anxiety 
disorders show high convergence, partly due to the similarity in item content 
of such measures. This is unfortunate and hinders progress in research into 
the shared and distinct features of both disorders. For instance, investigating 
whether mood and anxiety disorders have a different etiology or a different 
biological background is hampered when the difficulty in psychometrically 
distinguishing both disorders is not resolved. After a comprehensive review 
of the existing literature on the relation between anxiety and depression, 
Clark and Watson proposed the tripartite model for depression and anxiety 
(Clark & Watson, 1991). The model proposes one general distress factor 
and two additional factors specific to anxiety and depression. The model is 
based on Clark and Watson’s and Tellegen’s earlier work (Tellegen, Watson, 
& Clark, 1999) on dissecting mood into two independent components: 
negative affect (NA) and positive affect (PA). NA is characterized by aversive 
emotional states, such as feeling upset, angry, guilty, afraid, sad, scornful, 
and disgusted. PA represents positive emotional states such as feeling active, 
delighted, interested, and enthusiastic. Lack of PA is best described by terms 
such as feeling tired, sluggish, feeling that nothing is enjoyable, and not 
having fun in life (Clark & Watson, 1991). Not only are both mood dimensions 
fairly independent as evidenced by moderate to low intercorrelations, their 
separateness is also supported by distinctive correlational patterns with other 
variables, such as social activity (only with PA) and health complaints (only 
with NA). Furthermore, personality trait characteristics such as neuroticism 
are more strongly associated with NA, whereas extraversion has a stronger 
association with PA. In addition to PA and NA, Clark and Watson proposed a 
third dimension, physiological hyperarousal, which encompasses symptoms 
such as tenseness, shortness of breath, feeling dizzy or lightheaded, trembling 
and shaking. This dimension has also been labeled in the literature as somatic 
arousal (SA). These symptoms appear to be better in differentiating between 
anxious and depressed patients than symptoms reflecting anxious mood 
per se (Clark & Watson, 1991). The model explains the high concurrence of 
anxiety and depression by proposing that both disorders share the dimension 
of NA. Unique to mood disorders is a lack of PA; unique to anxiety disorders 
(especially panic disorder) is physiological hyperarousal. The tripartite model 
for depression and anxiety has found broad acceptance, not only with adult 
patients (Marshall, Sherbourne, Meredith, Camp, & Hays, 2003; Joiner et al., 
1999; Keogh & Reidy, 2000) but also in child psychiatry populations (Chorpita 
Chapter 4: The tripartite model for assessing symptoms of anxiety and depression
56
& Daleiden, 2002).
 Watson and Clark (1991) developed a 90-item self-report questionnaire to 
measure the three dimensions of the tripartite model, the Mood and Anxiety 
Symptom Questionnaire (MASQ). The MASQ contains two scales with 
symptoms specific to depression and anxiety. The first scale, Anhedonic 
Depression (AD) is meant to measure (lack of) PA. The second scale, Anxious 
Arousal (AA) measures symptoms of SA. The remaining items are all relatively 
non-specific and measure NA or general distress (GD). However, based on their 
content, these items are further subdivided into a third, forth and fifth scale 
containing depression General Distress Depression (GDD), General Distress 
Anxiety (GDA) and General Distress Mixed (GDM) symptoms. Research 
findings regarding the validity of these scales are favorable for the MASQ 
(Reidy & Keogh, 1997; Watson et al., 1995), but the dimensional structure of 
the MASQ as comprising five scales is not clearly supported. Investigations 
into the factors of the MASQ with clinical and normal samples have generally 
found the MASQ to comprise three scales (Bedford, 1997; Reidy & Keogh, 1997; 
Watson et al., 1995), which is actually more in accordance with the tripartite 
model. 
 The present study set out to translate the MASQ in Dutch and evaluate 
the psychometric characteristics of the Dutch translation in a large sample of 
psychiatric outpatients with mood and anxiety disorders and a representative 
sample of the general population. The MASQ was translated according to the 
guidelines of Widenfelt and colleagues (Van Widenfelt, Treffers, De Beurs, 
Siebelink, & Koudijs, 2005). First, we investigated whether the dimensional 
structure of the MASQ was preserved in the Dutch translation with exploratory 
factor-analysis. We compared the factor structure for the translated MASQ 
with published results from US (Watson et al., 1995) and British (Keogh & 
Reidy, 2000) samples. Next, we evaluated the psychometric characteristics 
of the translation by assessing indices of reliability (internal consistency). 
Concurrent and divergent validity was assessed by comparing the MASQ with 
other self-report questionnaires or rating scales (Campbell & Fiske, 1959). 
The discriminant validity of the MASQ scales was evaluated by comparing 
scores of psychiatric outpatients with the population-based sample. Also we 
compared scores of subgroups of patients with specific diagnoses. With these 
latter analyses, we could investigate the uniqueness of the PA and somatic 
anxiety subscales of the MASQ for depression and anxiety, respectively. We 
hypothesize lower PA scores for patients with depressive disorders and higher 
somatic anxiety scores for patients with anxiety disorders, especially patients 
with panic disorder.




A patient sample was composed of 950 patients from three outpatient clinics 
of the Rivierduinen Psychiatric Hospital (675 consecutive admissions from 
Leiden; 158 from Alphen a/d Rijn, and 117 from Voorhout). All patients were 
referred to these clinics by their General Practitioner for a mood, anxiety or 
somatoform disorder. The sample contained 625 (65.8%) females; the average 
age was 36.2 years, sd=11.6, range 17–68). The diagnosis was assessed with 
a standardized diagnostic interview, the Mini International Neuropsychiatric 
Interview (MINI-plus; (Sheehan et al., 1998), which was carried out by a research 
nurse (a psychiatric nurse or a psychologist). In the assessment session with 
the research nurse self-report questionnaires were administered through a 
computer program and the research nurse completed several rating scales. The 
entire assessment session took about 120 min. Total of 894 patients met criteria 
for one or more DSM-IV diagnosis (94.9% of the sample); 261 (27.5%) had one 
diagnosis, 286 (30.1%) had two, 189 (19.9%) had three, 80 (8.4%) had four, and 
78 (8.2%) had more than four diagnoses. In the sample, 498 anxiety disorders 
were diagnosed and 490 mood disorders, 270 of these were comorbid cases.
 A sample of 200 respondents from the general population was obtained by 
randomly picking names from a listing in the phonebook of Leiden and vicinity. 
Special care was taken to ensure that the sample was similar to the general 
population on relevant variables such as size of the place of residence and 
gender (two-staged proportioned stratified sampling (Moser & Kalton, 1979). 
Various techniques were employed to optimize the response rate (Dillmann, 
1978), such as telephoning potential respondents for consent before sending 
them questionnaires, inclusion of a cover letter in which the importance and 
the scientific purpose of the study was underlined, and sending a follow-up 
letter to those, who had not returned the questionnaire within 3 weeks. Thus, 
363 persons were approached and invited to partake in a study “investigating 
questionnaires for the assessment of emotional functioning” of which 255 
(70%) agreed to participate. A total of 204 questionnaires were returned, of 
which 200 contained usable data (78% of the questionnaires that had been 
sent out and 55% of all contacted potential respondents). A response rate of 
55% is substantial for a mail survey, boosting our confidence in the sample as 
being representative. We compared demographic characteristics of the sample 
(gender, age, marital status, education level, and religiosity) with the general 
population. This indicated that there was no sample bias, except for a slight 
under representation of the age group 18–25 and an overrepresentation of 
respondents aged 65 and older. This was probably due to the fact that younger 
people are less likely to be listed in the telephone book (our first source of 
respondents) because they use nowadays predominantly mobile phones in 
the Netherlands. Fifty-five percent of the respondents were female; the mean 
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age was 47.5 years (sd=15.0, range=18–88); 69.0% was married; 52.0% held a 
fulltime or part-time job; 25.5% were stay at home wives or mothers.
Measures
MASQ
The MASQ (Watson & Clark, 1991) contains “a list of feelings, sensations, 
problems and experiences that people sometime have” (instructions to the 
respondent). The respondent is asked to indicate on a Likert–scale (0=not 
at all, 4=extremely) how much they have felt or experienced these feelings 
or thoughts in the past week including today. Watson and Clark grouped 77 
of the 90 items of the MASQ in 5 subscales based on their content. Three 
subscales measure relatively nonspecific symptoms of general distress. Due 
to their similarity with DSM-III-R criteria for mood or anxiety disorders, items 
were assigned to either the GDM, GDA, or GDD subscale. Furthermore, two 
subscales comprise symptoms specific to anxiety and depression. Seventeen 
items reflecting symptoms of somatic tension and hyperarousal were grouped 
in the AA scale. Eight loss of interest items and 14 PA items composed the AD 
scale.
 Three independent translations of the MASQ were made by native Dutch 
researchers with ample experience in translation of measurement instruments 
(A.M. van Hemert, M.D., Ph.D., J. Goekoop, M.D., Ph.D., and E. de Beurs, Ph.D.). 
The three translations were compared and discrepancies in the translations 
were discussed until consensus on a final translation was reached. Next, a 
native speaker (B.M. van Widenfelt, Ph.D.) translated this version back into 
English. The original questionnaire and the back translation were compared 
and where discrepancies were found minor revisions were applied to the 
translation. For 12 of the 90 items, minor revisions in phrasing were deemed 
necessary. These revised items were discussed among the original translators 
and again a back translation was performed with a satisfactory outcome.
Other instruments
All patients and the respondents from the population sample completed the Brief 
Symptom Inventory (BSI, (Derogatis, 1975). On this checklist of 53 symptoms, 
the respondent indicates to what extend they have been bothered by each 
symptom in the last week, including today (0=“not at all”, 4=“extremely”). The 
BSI comprises among others subscales for somatic complaints, depression, 
anxiety, phobic avoidance and interpersonal sensitivity. The total score on the 
BSI is generally perceived as a highly reliable index of general psychopathology. 
Patients with a current major depression or dysthymia completed the Beck 
Depression Inventory II (BDI; (Beck & Steer, 1987).
 Diagnostic status was assessed with the MINI-plus (Sheehan et al., 1998). 
The MINI-plus is a standardized diagnostic interview comprising 23 modules 
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in which the presence or absence of DSM criteria for the main psychiatric 
disorders (mood, anxiety, psychotic, somatoform, and eating disorders) is 
investigated. Each module starts with one or two screening questions. If these 
are answered affirmatively, additional questions from the module are asked. 
Lecrubier and colleagues (1997) report sufficient reliability for most modules. 
Inter-rater reliability ranged from k=0:88 to 1.00, test-retest reliability ranged 
from 0.76 to 0.93, validity was demonstrated by sufficient concordance with 
the CIDI (k ranged from 0.36 for generalized anxiety disorder to 0.82 for alcohol 
dependence.
 In addition, the psychopathology of the patients was rated by the research 
nurse on a shortened version of the Comprehensive Psychiatric Rating Scale 
(CPRS) comprising 25 items in three subscales, the Montgomery Asberg 
Depression Rating scale (MADRS (10 items), the Brief Anxiety Scale (10 items) 
and the Retardation Scale (5 items) (Goekoop et al., 1991). Items on the CPRS 
(e.g., “pessimistic thoughts”, “worries about minor issues”) are rated on 
a 7-point scale anchored at 4 points (1, 3, 5, and 7) with different response 
options for each item. The research nurse completed the Global Assessment of 
Functioning scale of the DSM, a scale for impairment in functioning due to the 
psychiatric complaints ranging from 0 to 100 (American Psychiatric Association, 
1994), and the Clinical Global Impression (CGI; (Guy, 1976) (severity of 
illness scored on a 7 point scale ranging from 1=“normal, no complaints” to 
7=“extremely ill”). Research nurses were extensively trained in administration 
of the rating scales and in the diagnostic interview. Each new research nurse 
followed an intensive 2-week training with an experienced nurse in performing 
the assessments, before being allowed to do ratings on her own. In addition, 
biweekly training sessions of 2 h were organized continuously in which invited 
speakers taught about psychiatric disorders and videotaped patients were 
conjointly rated by the group of research nurses to improve interrater reliability. 
For a small subset of patients (n=44) the assessment session was audio taped. 
After listening to these tapes another research nurse rated patients again and 
this revealed sufficient interrater reliability (average concordance between 
raters was sufficient. Average Cohen’s k=0:60 for the CPRS (average k=0:59 for 
19 interview items and average k=0:63 for 6 observational items), k=0:73 for 
the GAF-score (recoded into 5 categories), and k=0:55 for the CGI-score).
Statistical analysis
First, the frequency distributions of scores on the translated items were 
investigated (mean, sd, skewedness, and kurtosis). Next, the factor structure 
of the instrument was investigated with exploratory factor analysis, utilizing 
parallel analysis to decide on the number of factors to retain (O’Connor, 
2000). The rotated factor solution was compared with published results of 
US and British samples. Reliability was investigated by assessing the internal 
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consistency of scales. Validity was evaluated by assessing the convergence 
with parallel tests (bivariate correlations). Finally, we assessed the ability of the 
MASQ scales to differentiate between the patient sample and the population 
sample, as well as between diagnostic subgroups within the patient sample 
with t-test.
4.3 Results
Basic psychometrics and construct validity (factor structure)
Inspection of the frequency distributions of the individual items of the 
translated questionnaire did not reveal substantial deviation from normality, 
implying no need to alter phrasing of any items. For some items, scores from 
the population-based sample were skewed, but this is understandable given 
the low prevalence of certain feelings in the general population (e.g. “thought 
about death or suicide”).
 To investigate the factor structure the 90 items of the MASQ were subjected 
to an exploratory factor analysis. Parallel analysis suggested retaining three 
factors and the screening occurred after the third or fourth factor. Thus, a 
three-factor solution was chosen. Next, factor loadings were inspected to 
allocate items to subscales. Utilizing two criteria of a primary loading >0.30 
and sufficient purity (a cross-loading <0.20), the first factor (NA) comprised 20 
items; items 4, 6, 8, 13, 16, 17, 20, 22, 24, 26, 28, 29, 42, 47, 53, 64, 74, 77, 84, 89), 
the second factor (PA) comprised 22 items (1, 11, 14, 18, 23, 27, 30, 35, 36, 38, 
40, 41, 43, 46, 49, 54, 58, 62, 68, 72, 78, 86), and the third factor (somatic anxiety 
or SA) 18 items (9, 25, 45, 48, 52, 55, 57, 61, 63, 65, 67, 69, 73, 75, 79, 81, 87, 88). 
The factor loading were quite similar to the results of Watson, Clark, et al. (1995) 
and the factor solution was in almost perfect agreement with the results of 
Keogh and Reidy (2000). As can be seen in Table 4.1, the best correspondence 
is found for the PA scale. Our items match almost perfectly with the Keogh and 
Reidy (2000) solution and the Watson, Clark, et al. (1995) solution. Regarding 
the SA dimension, the match in items is still substantial: 16 of 18 items of the 
present solution match up with Watson et al., 15 with Keogh and Reidy. Finally, 
comparison of the item composition of the NA scale in the three samples again 
reveals substantial overlap: 17 of 20 items match with the Watson et al. solution, 
14 of 20 match with the Keogh and Reidy solution. 
Reliability of the scales
The reliability indices of the scales (internal consistency) and intercorrelations 
among the scales are presented in Table 4.2. Reliability of the three scales was 
excellent: all a≥0.88. The correlation between the NA and the PA scale was 
substantial (r=0.62), but the SA scale correlated only moderately with the NA 
scale (r=0.53) and low with the PA scale (r=0.35), indicating a shared variance 
of 28% and 12%, respectively. Correlations among the scales were generally 
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Table 4.1 Number of corresponding items in various factor solutions.
Table 4.2 Reliability and correlation coefficients between MASQ scales and reliabilities 
(Cronbachs a).
  Watson et al. (1995)a Keogh & Reidy (2000) 
  GD A-PA SA Not assig. NA PA SA Not assig. Total
Present NA 17   3 14   6 20
sample PA  21  1  22   22
 SA   16 2   15 3 18
 Not 5 1 2 22 7 1 1 21 30
 assigned
 Total 22 22 18 28 21 23 16 30 90
NA = negative affect, PA = positive affect, SA = somatic anxiety.
a In Watson et al. (1995) Table 6 the three factors found are named General Distress 
– GD, Anhedonia/Positive Affect – A-PA, and Somatic Anxiety-SA)
 NA PA SA
No. of items: 20 22 18
NA (0.96)  
PA 0.62 (0.96) 
SA 0.53 0.35 (0.91)
Note: Scale reliabilities are shown between parentheses. All correlations are signifi-
cant at the 0.001 level (2-tailed).
NA = Negative Affect, PA = Positive Affect, SA = Somatic Anxiety
62
lower than the correlation between scales composed according to the allocation 
of Watson, Clark, et al. (1995) would be. With calculations based on our data the 
correlation between the AD and AA scales would amount to r=0.49; between 
the PA–SA scales the association is r=0.35, a decrease from 24% to 12% shared 
variance. The current two scales are clearly more distinct. 
 Table 4.3 presents the correlation coefficients between the three MASQ 
scales and other measures of psychopathology. Both the GAF and the CGI scores 
show modest and roughly equal correlations with the MASQ scales. In contrast 
the MADRS, a rating scale for depression shows the highest convergence with 
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Table 4.3 Correlation of the MASQ scales with rating scales and self-report measures.
 N NA PA SA
Rating scales:    
GAF 596* -0.32 -0.33 -0.34
CGI 599* 0.30 0.31 0.28
MADRS  935 0.69 0.64 0.50
BAS 848 0.50 0.42 0.57
INH 515 0.44 0.46 0.27
Self-report:    
BDI-II 583** 0.80 0.61 0.47
BSI -dep 929 0.86 0.63 0.43
BSI -anx 929 0.62 0.37 0.62
BSI -pho 929 0.53 0.34 0.47
BSI-som 927 0.45 0.32 0.84
BSI -int 929 0.69 0.41 0.33
BSI -tot 929 0.82 0.52 0.64
NA = Negative Affect, PA = Positive Affect, SA = Somatic Anxiety; GAF = Global As-
sessment of Functioning; CGI = Clinical Global Impression, MADRS = Montgomery 
Asberg Depression Rating Scale, BAS = Brief Anxiety Scale, INH = Inhibition; BDI = 
Beck Depression Inventory Revised; BSI = Brief Symptom scale; dep = depression, 
anx = anxiety, pho = phobic anxiety, som = somatic complaints, int = interpersonal 
sensitivity, tot = Total score (all correlations p < .001)
* Data are available for less patients since these measures were later introduced in 
the assessment battery.
** The BDI-II was administered only if patients met criteria for a mood disorder.
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the NA and the PA scale (r=0.69 and 0.64, respectively), whereas the BAS (rating 
of anxiety) has stronger correlations with the SA scale than with the PA and NA 
scales. A similar pattern of correlation emerges with the self-report measures: 
The BDI-II and the BSI-dep scale correlate most strongly with the NA and PA 
scales. The high correlation between the SA and the BSI Somatic complaints 
subscale (r=0.83) reflect the predominance of somatic markers of anxiety in the 
SA scale (Table 4.3).
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Table 4.4 Comparison of mean scores on five MASQ scales of the patient and population 
sample.
Table 4.5 Mean scores (and sd’s), results of t-tests and effectsize of the difference when 
analysing two contrast: patient with and without a mood disorder and patients with and 
without an anxiety disorder.
 Patients (950) Population (200) T (1148) Cohen’s d
 mean sd mean sd  
NA 2.57 0.97 1.44 0.50 16.20* 1.46
PA 4.00 0.77 3.25 0.77 12.55* 0.97
SA 1.88 0.74 1.25 0.36 11.80* 1.08
NA = negative affect, PA = positive affect, SA = somatic anxiety.
* p < 0.001
 No depression Depression t(948)   d No anxiety Anxiety t(948)    d
 (N = 460) (N = 490)   (N = 452) (N = 498)  
 mean sd mean sd   mean sd mean sd 
NA 2.09 0.79 3.03 0.90 16.98* 1.11 2.34 0.92 2.79 0.96 7.27* 0.48
PA 3.61 0.75 4.37 0.58 17.53* 1.13 3.91 0.81 4.09 0.72 3.57* 0.23
SA 1.67 0.64 2.09 0.77   6.25* 0.59 1.71 0.62 2.04 0.80  7.14* 0.46
NA = negative affect, PA = positive affect, SA = somatic anxiety.
* p < .001.
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Discriminant validity
A first test for the criterion related validity of the instrument is its ability to 
discriminate between patients and the normal population. We compared both 
groups with t-tests. The means, sd’s, results of the t-tests, and the effect size 
of the difference (Cohen’s d) are listed in Table 4.4. All scales discriminate well 
between patients and normal controls and statistical significance is upheld 
after Bonferonni correction for multiple testing. Differences among the various 
subscales in discriminant validity are small. 
 Demonstrating that the MASQ scales are able to discriminate between 
patients and respondent from the general population may be useful for certain 
research goals (e.g. screening in epidemiological research), but a test of the 
validity of the MASQ should also encompass assessment of the ability of the 
instrument to discriminate between groups of patients, especially patients who 
suffer predominantly from anxiety vs depressed patients. The ability of the 
PA scale to discriminate between patients with and without a mood disorder 
(as PA is supposedly unique to depression) and the ability of the SA scale 
to discriminate between patients with and without an anxiety disorder are 
especially relevant for the MASQ. Therefore, we compared MASQ scale scores 
for different subgroups of patients in our patient sample.
 Based on the DSM diagnosis according to the MINI we selected from 
the patient sample several subgroups: patients with and without a current 
diagnosis of mood and patients with and without an anxiety disorder. Table 
4.5 presents mean scores of the subgroups of patients and results of the 
comparison with t-tests. The largest difference between depressed and non-
depressed patients is on the PA scale, closely followed by the NA scale. The SA 
scale is less suited to distinguish depressed from non-depressed cases. This 
finding supports the validity of the PA scale. Regarding the anxiety contrast, 
the results are somewhat less favorable for the measure. The NA and SA scales 
appear to be the best in differentiating between patient with and without an 
anxiety disorder. However, the difference between both groups is not larger on 
the SA scale as compared to the NA scale. This finding does not support the 
presumed uniqueness of the SA scale for anxiety.
4.4 Discussion
Until now, most of the psychometric research with the MASQ has been 
done with non-clinical samples (usually undergraduate students) or with 
relatively small patient samples. We administered the questionnaire to a large 
patient group with the relevant disorders: mood and anxiety. Furthermore, 
the diagnostic status of these patients was comprehensively assessed in a 
diagnostic interview by well-trained research nurses. Data on the diagnostic 
status of the respondents enabled us to investigate the discriminant validity of 
the MASQ by comparing scores on subscales from distinct clinical subgroups. 
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Administration of other, well established selfreport measures enabled us to 
investigate convergent and divergent validity.
 First of all, the present findings suggest that the MASQ has been adequately 
translated for use in the Netherlands: The items show satisfactory psychometric 
properties and, although the factor solution differs considerably from the five 
subscales originally proposed by Watson, Clark, et al. (1995), the solution is in 
accordance with the results of factor analyses from US and English datasets. 
The three scales of the instrument are reliable considering their high internal 
consistency coefficients. The validity of the scales of the instrument is also 
supported by substantial correlations with other instruments. The MASQ-
scales have sufficient discriminant power. In sum, the validity coefficients favor 
three subscales for the MASQ, rather than the original conceptualization of the 
instrument in five subscales.
 The factor structure of the translated MASQ was concordant with results 
obtained by Keogh and Reidy (2000), but less so with results of Watson, 
Clark, et al. (1995). Discongruity can stem from two sources: crosscultural 
differences or problems with the translation of the MASQ into Dutch. Both 
effects are difficult to disentangle, but a first attempt could be to compare all 
three-factor solutions amongst each other. This comparison revealed the best 
concordance between the Dutch results and the results based on the British 
sample, suggesting a cross-cultural difference rather than a difference due to a 
problematic translation of the instrument.
 The findings of the factor analyses support the tripartite structure of 
depression and anxiety with three distinct factors. Moreover, a three-factor 
solution has been repeatedly suggested in the literature as best fitting the 
data (Bedford, 1997; Reidy & Keogh, 1997) and is in accordance with the 
formulation of the tripartite model. However, two findings deserve more critical 
consideration than they have been given in the previous studies. The PA factor 
comprises 22 of the 24 reversed keyed items of the MASQ. This result is not 
due to the translation into Dutch, but replicates the results of Watson, Clark, 
et al. (1995) and Keogh and Reidy (2000). Previous studies fail to comment 
on this potential flaw of the instrument. The grouping of all reversed keyed 
items in one factor is an unfortunate outcome as it suggests the possibility of 
a method effect underlying this factor, rather than a true distinct construct. For 
the factor structure of the MASQ Watson, Clark, et al. (1995) predicted three 
broad factors with one factor being a “specific depression factor that is on 
one end defined by items reflecting energy, enthusiasm and high PA and on 
the other by items reflecting anhedonia, loss of interest, and low PA”(p. 16). 
Consequently, they grouped the “lack of interest” items under the AD scale. 
The results of exploratory factor analysis of the present study, as well as results 
from the study by Keogh and Reidy (2000) and Watson, Clark, et al. (1995) 
themselves do not support such an item allocation. Nitschke and colleagues 
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tested the homogeneity of the AD scale with confirmatory factor analysis and 
also concluded that this scale comprised two separate constructs: the eight 
“lack of interest” items and the 14 reversed scored items describing positive 
feelings. According to the present findings, the lack of interest items belong to 
the NA dimension and are thus no longer specific for mood disorders (Nitschke 
et al., 2001). The PA dimension now only comprises items describing positive 
feelings. Future revisions of the MASQ should encompass items belonging to 
lack of PA that describe negative feelings.
 Further research is needed to investigate the validity of the dimensions of 
the tripartite model and the ability of the MASQ to adequately assess these. 
Strengths of the present study are the use of a representative population sample 
and the large dataset of patients. A limitation of the study is that investigation of 
concurrent and divergent validity was restricted to comparison with other self-
report scales and ratings by an observer. Furthermore, discriminant validity 
was assessed by comparison of diagnostic subgroups. Both approaches have 
their drawbacks. First, the other scales used to validate the MASQ have their 
own flaws and weaknesses. Secondly, forming diagnostic subgroups based on 
a diagnostic interview such as the MINI will never be perfect and some patients 
will have been misclassified. Therefore, additional validation by other means is 
called for. For instance, comparison of MASQ-scores with neuroendocrinological 
or neuro-imaging data or outcomes of neuro-psychological testing will yield 
valuable data regarding the validity of the tripartite model (Shankman & Klein, 
2003). Presently we are evaluating a shortened scale comprising 10 items 
for each of the three concepts of the tripartite model. The scale is included 
in a large longitudinal study (Netherlands Study on Depression and Anxiety, 
NESDA). The predictive validity of these shortened scales on the long-term 
course of mood and anxiety disorders will be investigated. Thus, the ability of 
the MASQ to assess changes in symptomatology and to predict the course of 
anxiety and depression symptoms over time will be investigated. Until now, 
research on the MASQ has been limited to cross-sectional data. Its sensitivity 
to change over time or to treatment effect has not been established. Testing of 
etiological models for depression and anxiety with the MASQ as dependent 
variable may shed more light on the validity of the measure and the value of the 
tripartite model (De Beurs et al., 2005).
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The aim of the current study was to develop scales that assess symptoms of 
depression and anxiety and can adequately differentiate between depression 
and anxiety disorders, and also can distinguish within anxiety disorders. As 
point of departure, we used the tripartite model of Clark and Watson which 
discerns three dimensions: negative affect, positive affect and physiological 
hyperarousal.
Methods
Analyses were performed on the data of 1449 patients, who completed the 
Mood and Anxiety Symptom Questionnaire (MASQ) and the Brief Symptom 
Inventory (BSI). From this, 1434 patients were assessed with a standardized 
diagnostic interview.
Results
A model with five dimensions was found: depressed mood, lack of positive 
affect, somatic arousal, phobic fear and hostility. The scales appear capable 
to differentiate between patients with a mood and with an anxiety disorder. 
Within the anxiety disorders, somatic arousal was specific for patients with 
panic disorder. Phobic fear was associated with panic disorder, simple phobia 
and social anxiety disorder, but not with generalized anxiety disorder.
Conclusions
We present a five factor model as an extension of the tripartite model. Through 
the addition of phobic fear, anxiety is better represented than in the tripartite 
model. The new scales are capable to accurately differentiate between 
depression and anxiety disorders, as well as between several anxiety disorders.
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5.1 Introduction
Anxiety and depression are highly associated. High comorbidity is repeatedly 
found between mood disorders and anxiety disorders (e.g. De Graaf et al., 
2002; Kessler, Chiu, Demler, & Walters, 2005; Mineka et al., 1998). Some argue 
that both disorders are best understood as subtypes of a general neurotic 
syndrome (e.g. Andrews, 1996). In the most widely used diagnostic system, 
the DSM-IV (American Psychiatric Association, 1994), however, anxiety and 
depression are conceptualized as diagnostically distinct disorders. Either way, 
methods are needed that can adequately differentiate between depression and 
anxiety, in order to effectively study their relation and their (shared or distinct) 
etiological factors.
 An important contribution to the field was made by Clark and Watson who 
introduced the tripartite model to assess distinctive and overlapping features of 
mood disorders and anxiety (1991). To make a model that is able to differentiate 
between patients with a depression and patients with an anxiety disorder, they 
took the basic dimensions of affect, negative affect and positive affect, and 
added a third factor physiological hyperarousal. Thus, their model comprises 
three dimensions to describe the symptomatology of depression and anxiety. 
Negative affect consists of symptoms of general distress and is common to both 
depression and anxiety disorders. Positive affect is referring to enthusiasm, 
excitement and energy. A low score on this dimension is typical for depression. 
The third dimension physiological hyperarousal, consist of somatic tension 
and arousal and was presented as specific for anxiety. To operationalize and 
measure the dimensions of the tripartite model, Watson and Clark developed 
the Mood & Anxiety Symptom Questionnaire (MASQ, Watson & Clark, 1991).
 The tripartite model has inspired a large body of research, but has met some 
criticism as well. We will review the major points of critique on each of the 
three factors of the tripartite model and the MASQ. First, there is criticism on 
the general distress factor: negative affect (NA) comprises a heterogeneous 
group of symptoms such as anger, fear, and tension. Although it is supposed 
to be non-specific for depression as well as for anxiety, some symptoms are 
in fact quite specific for either depression or anxiety disorders. Anger attacks, 
for instance, are twice as prevalent in depressed patients as in patients with 
anxiety disorders ((Pasquini, Picardi, Biondi, Gaetano, & Morosini, 2004; 
Picardi, Morosini, Gaetano, Pasquini, & Biondi, 2004), Gould et al. 1996 in 
(Shankman & Klein, 2003)). Symptoms like ‘felt afraid’ and ‘felt nervous’ on 
the other hand, seem more specific for anxiety disorders than for depression. 
Clark and Watson acknowledged the heterogeneity of NA by subdividing the 
general distress items of the MASQ in three subcategories: General Distress 
Depression (GDD), General Distress Anxiety (GDA) and General Distress 
Mixed (GDM). The items were assigned to these subcategories on face value, 
i.e. on their similarity with DSM-IIIR criteria for either depression or anxiety 
Chapter 5: Distinguishing between depression and anxiety
72
disorders. The separateness of these three subscales of NA, however, could 
not be confirmed with factor analyses: Several studies on the MASQ concluded 
that a two or three factor model had the best fit (Boschen & Oei, 2006; Buckby 
et al., 2008; Burns & Eidelson, 1998; De Beurs et al., 2007; Keogh & Reidy, 2000; 
Watson et al., 1995).
 Second, there are criticisms on the scale positive affect (PA), called 
anhedonic depression (AD) in the MASQ. Although the scale is presented as 
a single dimension with two endpoints, (a low positive affect endpoint, loss of 
interest and a high positive affect endpoint, feeling good), the two endpoints 
appear as separate factors in factor-analysis (Keogh & Reidy, 2000; Watson 
et al., 1995; Nitschke et al., 2001; De Beurs et al., 2007) suggesting these two 
endpoints represent different dimensions. Other evidence that ‘lack of interest’ 
and ‘feeling good’ are separate constructs can be found in the research of 
Tomarken and Dichter (Tomarken, Dichter, Freid, Addington, & Shelton, 2004). 
They reported medication to have a differential effect on ‘lack of interest’ and 
‘feeling good’ as measured with the MASQ. Items assessing the low positive 
affect pole of the anhedonia dimension were more sensitive to earlier/lower 
dose bupropion SR (sustained-release) treatment, whereas items assessing the 
high positive affect pole were more sensitive to later/higher dose bupropion SR 
treatment.
 The third factor, physiological hyperarousal, has been criticised as well. 
Firstly, a high score on the MASQ scale ‘anxious arousal’ (AA) seems to 
be characteristic for panic disorder only and not for all anxiety disorders 
(e.g.(Mineka et al., 1998; Chorpita, 2002; Joiner et al., 1999)). Somatic signs 
of anxiety dominate this scale, while other anxiety symptoms are not well 
represented. In addition, the scale does not distinguish between patients 
with and without an anxiety disorder (Buckby, Yung, Cosgrave, & Cotton, 
2007). It also does not distinguish between patients with anxiety disorder and 
depression (Boschen & Oei, 2007; De Beurs et al., 2007). Buckby (Buckby et al., 
2007) even found significant higher scores for depressed patients over anxious 
patients on AA.
 The possible limitations of the tripartite model have been acknowledged by 
the original authors. They recommend to view in future research „individual 
disorders as representing unique combinations of different types of symptoms, 
with each type showing varying degrees of nonspecificity and with no type 
being entirely unique to any single disorder” (Mineka et al., 1998, p.398). To 
operationalize this idea, adequate symptom scales must be developed to 
include the more unique symptoms of specific mood- and anxiety disorders 
in addition to common symptom scales. In such a dimensional approach to 
psychopathology, every disorder (and every patient) will have a more or less 
unique profile. This is a valuable recommendation and underlines the need for 
scales that can represent more adequately relevant aspects of anxiety.
Chapter 5: Distinguishing between depression and anxiety
73
 The aim of the current study was to develop scales that assess symptoms of 
depression and anxiety and can adequately differentiate between depression 
and anxiety disorders, and also can distinguish within anxiety disorders. First, 
we explored the factor structure of the items of the MASQ extended with 
items of a questionnaire containing many anxiety items. We choose the Brief 
Symptom Inventory (BSI), because this questionnaire has many anxiety-related 
items and resembles the MASQ in the construction of the items and time span. 
We expected to find in addition to the two specific scales of the MASQ (AA and 
AD) at least one extra scale, based to a large extent on BSI-items, tapping other 
aspects of anxiety than the AA scale. We expected the set of new scales to 
cover anxiety more adequately than the tripartite model and to provide profiles 
specific for depression and each of the anxiety disorders.
 To examine the psychometric properties of the scales found with factor-
analysis, we addressed the following questions: (a) What is the reliability of 
the scales based on the found factor structure? (b) Do these scales measure 
more distinct concepts as compared to the original scales of the MASQ? 
(c) Do the new scales have good discriminatory validity for depression and 
anxiety? (d) Are the new scales able to differentiate between specific anxiety 
disorders? We expected the set of new scales to have a good reliability and 
better discriminatory validity than the original MASQ scales.
5.2 Materials and methods
Study sample
This study was conducted on data collected through Routine Outcome 
Monitoring (ROM, (De Beurs et al., 2011)). ROM is a monitoring system for 
patient care, implemented in the outpatient clinics of Rivierduinen (a large 
organization for the provision of mental health care in the province of Zuid-
Holland, the Netherlands) and the department of psychiatry of the Leiden 
University Medical Center (LUMC). All patients referred to these clinics for 
treatment of a mood-, anxiety- or somatoform disorder, have an assessment 
session with a psychiatric research nurse at the start, during, and at the end 
of the treatment. During the first session, a standardized diagnostic interview 
is administered and interviewer and self-reported ratings are determined. The 
sample consisted of 1479 patients admitted consecutively between January 
2002 and March 2005 to the outpatient clinics of the Rivierduinen Psychiatric 
Hospital (754 in Leiden; 198 in Alphen a/d Rijn, 163 in Leidschendam and 163 
in Voorhout) and the psychiatric outpatient department of Leiden University 
Medical Center (LUMC, n=201).
Measures
Mini International Neuropsychiatric Interview (M.I.N.I.) Plus 5.0.0.-R.
The M.I.N.I. is a short clinical diagnostic interview developed to explore the 
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presence of current and life-time Axis-I disorders according to the DSM-IV 
diagnostic criteria (Sheehan et al., 1998). The Dutch translation of the M.I.N.I. 
Plus 5.0.0-R was used in the present study (Van Vliet et al., 2000). The M.I.N.I.-
Plus is an extended version of the original M.I.N.I.. Lecrubier and colleagues 
(Lecrubier et al., 1997) report sufficient reliability of the M.I.N.I; Inter-rater 
reliability ranged from k=.88 to 1.00, test-retest reliability ranged from 0.76 to 
0.93, validity was demonstrated by sufficient concordance with the Composite 
International Diagnostic Interview (CIDI, WHO). Psychiatric research nurses 
who were extensively trained and supervised performed the interviews. All 
diagnoses reported in this paper were current at the time of investigation.
Mood and Anxiety Symptom Questionnaire (MASQ, (Watson & Clark, 1991)). 
The MASQ consists of 90 items, allocated to five subscales: 1) anhedonic 
depression; 2) anxious arousal; 3) general distress depression; 4) general 
distress anxiety, and 5) general distress mixed. All items are presented with a 
five-point rating scale ranging from 1 (not at all) to 5 (very much). We used a 
Dutch adaptation of the MASQ (De Beurs et al., 2007).
Brief Symptom Inventory (BSI)
The Brief Symptom Inventory (Derogatis & Melisaratos, 1983; De Beurs, 2005) 
is a shortened version of the Symptom Checklist (SCL-90) (Arrindel & Ettema, 
1986; Derogatis et al., 1973), and is used to measure psychological complaints 
or symptoms. The BSI consists of 53 items that are rated on a five-point 
Likert type scale, ranging from 0 (not at all) to 4 (very much). The items are 
assigned to nine dimensions: 1) somatic complaints; 2) cognitive problems; 3) 
interpersonal sensitivity; 4) depression; 5) anxiety; 6) hostility; 7) phobic fear; 
8) paranoid ideation, and 9) psychoticism.
Pool of items.
For this study a selection of items was made from the BSI and the MASQ. From 
the MASQ the 77 of 90 items which were assigned to a subscale by the authors 
of the MASQ (Watson & Clark, 1991) were used. The BSI subscales paranoid 
ideation and psychoticism were not used, because we are predominantly 
interested in mood and anxiety disorders and expected a high positive 
skewness on these items in the population we studied. Twelve items of the BSI 
closely resembling MASQ items were omitted, as highly collinear items should 
not be subjected to factor-analysis. The end result was a pool of 104 items.
Statistical analyses
All positively formulated items of the MASQ were reversed keyed before 
analysis. Exploratory factor analyses with oblique rotation were performed 
using SPSS procedure ‘Factor, rotations Oblimin’. We preferred factor analysis 
Chapter 5: Distinguishing between depression and anxiety
75
(FA) over principal component analysis (PCA), because we were looking for 
factors, uncorrelated or correlated, which explain the interrelationships 
between the observed variables. This approach is different from the idea of 
PCA in which uncorrelated components are sought which explain the most 
variation of the variables. Oblique rotation rather than orthogonal rotation was 
chosen, because substantial correlation between the factors was expected. 
Before factor extraction, the correlations between the items were inspected to 
check for items which failed to correlate 0.20 or more with any other item (Floyd 
& Widaman, 1995). None were found.
 The number of factors to extract was determined using eigenvalues above 
one, a parallel analysis (Monte Carlo PCA), the screeplot, the number of unique 
loading items per factor, and most importantly, the interpretability of the 
factors. New subscales (mean score) were formed with items loading at least 
.40 on the factors (loadings in the pattern matrix). Before calculating the scores 
on the new subscales all items of the BSI were recoded from 0-4 to 1-5 to match 
the scores of the MASQ.
 After new subscales were composed, the reliability and validity of these 
scales were determined. Coefficient α was used to assess the internal 
consistency of the scales (question a). To examine the level of distinctiveness 
of the new scales (question b), correlation coefficients (Pearson’s R) between 
all scales were calculated. To determine the discriminant validity of the newly 
found scales, we investigated whether subscale scores could discriminate 
between subgroups of patients based on diagnostic information obtained with 
the M.I.N.I.-Plus. A stepwise discriminant function analysis was performed 
to investigate the ability of the new scales to discriminate between the two 
diagnostically purest groups: 1) patients with one or more anxiety disorder(s) 
but without a depression and 2) patients with a depression but without an 
anxiety disorder (question c).
To determine whether different anxiety disorders reveal a different symptom 
profile (question d), we compared the mean scores of groups of patients with 
different anxiety disorders (and no comorbid depression) with a multivariate 
analysis of variance (MANOVA). All analyses were conducted using SPSS-16.
5.3 Results
Sample description 
The mean age was 39 years, (sd=13, range 18 – 82) and 936 patients (63.3%) 
were female. All patients (n=1479) completed the MASQ and 1449 (98%) also 
the BSI. The M.I.N.I.-PLUS was administered in 1434 (97%) patients. Criteria for 
at least one current Axis-I DSM-IV disorder were met by 1347 patients (94%) 
and for at least two current disorders by 947 (64%) patients: mood-, anxiety- 
and somatoform disorders were diagnosed in 52%, 57% and 21% of the patients 
respectively. Depression includes both depression (89%) and dysthymia (11%), 
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item questionnaire nr original scale DM LPA SA PF HOS
Felt like a failure masq 47 GDD 0.84    
Felt worthless masq 13 GDD 0.82    
Felt inferior to others masq 64 GDD 0.79    
Was disappointed in myself masq 74 GDD 0.77    
Blamed myself for a lot of things masq 24 GDD 0.67    
Felt hopeless masq 22 GDD 0.66    
Felt withdrawn from other people masq 26 AD (interest) 0.63    
Felt unattractive. masq 53 AD (interest) 0.61    
Feeling hopeless about the future BSI 35 DEP 0.60    
Felt discouraged masq 8 GDD 0.60    
Felt pessimistic about the future masq 42 GDD 0.60    
Feeling very self-conscious with others BSI 42 I-S 0.55    
Felt dissatisfied with everything masq 29 GDM 0.54    
Felt depressed masq 16 GDD 0.51    
Felt uneasy masq 20 GDA 0.51    
Feeling lonely BSI 16 DEP 0.51    
Felt like nothing was very enjoyable masq 33 AD (interest) 0.49 -0.31   
Had trouble making decisions masq 70 GDM 0.49    
Feeling blue BSI 17 DEP 0.47 -0.31   
Felt sad masq 6 GDD 0.44    
Felt like there wasn’t anything interesting or fun to do masq 44 AD (interest) 0.44    
Feeling that people are unfriendly or dislike you BSI 21 I-S 0.43    0.32
Thought about death or suicide masq 89 AD (interest) 0.42    
Feeling blocked in getting things done BSI 15 O-C 0.41    
Worried a lot about things masq 84 GDM 0.40    
Felt like I was having a lot of fun masq 23 AD (PA)  -0.86   
Felt optimistic masq 18 AD (PA)  -0.84   
Felt like I had a lot to look forward to masq 40 AD (PA)  -0.82   
Looked forward to things with enjoyment masq 30 AD (PA)  -0.78   
Felt really “up” or lively masq 58 AD (PA)  -0.77   
Felt like I had accomplished a lot masq 35 AD (PA)  -0.77   
Felt like I had a lot of interesting things to do masq 36 AD (PA)  -0.75   
Felt really good about myself masq 86 AD (PA)  -0.73   
Felt really happy masq 14 AD (PA)  -0.72   
Felt cheerful masq 1 AD (PA)  -0.70   
Was proud of myself masq 49 AD (PA)  -0.68   
Felt hopeful about the future masq 78 AD (PA)  -0.67   
Table 5.1 Factor structure after OBLIMIN rotation.
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item questionnaire nr original scale DM LPA SA PF HOS
Felt like a failure masq 47 GDD 0.84    
Felt worthless masq 13 GDD 0.82    
Felt inferior to others masq 64 GDD 0.79    
Was disappointed in myself masq 74 GDD 0.77    
Blamed myself for a lot of things masq 24 GDD 0.67    
Felt hopeless masq 22 GDD 0.66    
Felt withdrawn from other people masq 26 AD (interest) 0.63    
Felt unattractive. masq 53 AD (interest) 0.61    
Feeling hopeless about the future BSI 35 DEP 0.60    
Felt discouraged masq 8 GDD 0.60    
Felt pessimistic about the future masq 42 GDD 0.60    
Feeling very self-conscious with others BSI 42 I-S 0.55    
Felt dissatisfied with everything masq 29 GDM 0.54    
Felt depressed masq 16 GDD 0.51    
Felt uneasy masq 20 GDA 0.51    
Feeling lonely BSI 16 DEP 0.51    
Felt like nothing was very enjoyable masq 33 AD (interest) 0.49 -0.31   
Had trouble making decisions masq 70 GDM 0.49    
Feeling blue BSI 17 DEP 0.47 -0.31   
Felt sad masq 6 GDD 0.44    
Felt like there wasn’t anything interesting or fun to do masq 44 AD (interest) 0.44    
Feeling that people are unfriendly or dislike you BSI 21 I-S 0.43    0.32
Thought about death or suicide masq 89 AD (interest) 0.42    
Feeling blocked in getting things done BSI 15 O-C 0.41    
Worried a lot about things masq 84 GDM 0.40    
Felt like I was having a lot of fun masq 23 AD (PA)  -0.86   
Felt optimistic masq 18 AD (PA)  -0.84   
Felt like I had a lot to look forward to masq 40 AD (PA)  -0.82   
Looked forward to things with enjoyment masq 30 AD (PA)  -0.78   
Felt really “up” or lively masq 58 AD (PA)  -0.77   
Felt like I had accomplished a lot masq 35 AD (PA)  -0.77   
Felt like I had a lot of interesting things to do masq 36 AD (PA)  -0.75   
Felt really good about myself masq 86 AD (PA)  -0.73   
Felt really happy masq 14 AD (PA)  -0.72   
Felt cheerful masq 1 AD (PA)  -0.70   
Was proud of myself masq 49 AD (PA)  -0.68   
Felt hopeful about the future masq 78 AD (PA)  -0.67   
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item questionnaire nr original scale DM LPA SA PF HOS
Felt like I had a lot of energy masq 72 AD (PA)  -0.64   
Seemed to move quickly and easily masq 27 AD (PA)  -0.51   
Felt really slowed down masq 66 AD (interest) 0.35  0.48  
Felt faint masq 19 AA 0.30  0.45 -0.32 
Was trembling or shaking masq 79 AA   0.72  
Muscles twitched or trembled masq 69 AA   0.71  
Felt dizzy or light-headed masq 52 AA   0.67  
Hands were shaky masq 57 AA   0.63  
Heart was racing or pounding masq 75 AA   0.61  
Muscles were tense or sore masq 81 GDA   0.60  
Trouble getting your breath BSI 29 SOM   0.60  
Felt numbness or tingling in my body masq 25 AA   0.60  
Was short of breath masq 55 AA   0.58  
Had pain in my chest masq 45 AA   0.56  
Had hot or cold spells masq 48 AA   0.56  
Had trouble swallowing masq 87 AA   0.55  
Hands were cold or sweaty masq 88 AA   0.53  
Felt nauseous masq 9 GDA   0.51  
Feeling weak in parts of your body BSI 37 SOM   0.50  
Felt like I was choking masq 61 AA   0.50  
Had a lump in my throat masq 65 GDA   0.48  
Had a very dry mouth masq 67 AA   0.47  
Had an upset stomach masq 63 GDA   0.46  
Got tired or fatigued easily masq 90 GDM   0.44 -0.37 
Having to avoid certain things, places, or activities because they frighten you BSI 31 PHOB 0.31   0.45 
Suddenly scared for no reason BSI 12 ANX   0.37 0.48 
Spells of terror of panic BSI 45 ANX   0.35 0.50 
Feeling afraid to travel on buses, subways, or trains BSI 28 PHOB   0.30 0.44 
Feeling afraid in open spaces or on the streets BSI 8 PHOB    0.44 
Your feelings being easily hurt BSI 20 I-S 0.32    0.49
Temper outburst that you could not control BSI 13 HOS     0.79
Feeling easily annoyed or irritated BSI 6 HOS     0.76
Getting into frequent arguments BSI 46 HOS     0.75
Having urges to break or smash things BSI 41 HOS     0.72
Felt irritable masq 17 GDM     0.66
Having urges to beat, injure, or harm someone BSI 40 HOS     0.60
Feeling tense or keyed up BSI 38 ANX     0.54
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item questionnaire nr original scale DM LPA SA PF HOS
Felt like I had a lot of energy masq 72 AD (PA)  -0.64   
Seemed to move quickly and easily masq 27 AD (PA)  -0.51   
Felt really slowed down masq 66 AD (interest) 0.35  0.48  
Felt faint masq 19 AA 0.30  0.45 -0.32 
Was trembling or shaking masq 79 AA   0.72  
Muscles twitched or trembled masq 69 AA   0.71  
Felt dizzy or light-headed masq 52 AA   0.67  
Hands were shaky masq 57 AA   0.63  
Heart was racing or pounding masq 75 AA   0.61  
Muscles were tense or sore masq 81 GDA   0.60  
Trouble getting your breath BSI 29 SOM   0.60  
Felt numbness or tingling in my body masq 25 AA   0.60  
Was short of breath masq 55 AA   0.58  
Had pain in my chest masq 45 AA   0.56  
Had hot or cold spells masq 48 AA   0.56  
Had trouble swallowing masq 87 AA   0.55  
Hands were cold or sweaty masq 88 AA   0.53  
Felt nauseous masq 9 GDA   0.51  
Feeling weak in parts of your body BSI 37 SOM   0.50  
Felt like I was choking masq 61 AA   0.50  
Had a lump in my throat masq 65 GDA   0.48  
Had a very dry mouth masq 67 AA   0.47  
Had an upset stomach masq 63 GDA   0.46  
Got tired or fatigued easily masq 90 GDM   0.44 -0.37 
Having to avoid certain things, places, or activities because they frighten you BSI 31 PHOB 0.31   0.45 
Suddenly scared for no reason BSI 12 ANX   0.37 0.48 
Spells of terror of panic BSI 45 ANX   0.35 0.50 
Feeling afraid to travel on buses, subways, or trains BSI 28 PHOB   0.30 0.44 
Feeling afraid in open spaces or on the streets BSI 8 PHOB    0.44 
Your feelings being easily hurt BSI 20 I-S 0.32    0.49
Temper outburst that you could not control BSI 13 HOS     0.79
Feeling easily annoyed or irritated BSI 6 HOS     0.76
Getting into frequent arguments BSI 46 HOS     0.75
Having urges to break or smash things BSI 41 HOS     0.72
Felt irritable masq 17 GDM     0.66
Having urges to beat, injure, or harm someone BSI 40 HOS     0.60
Feeling tense or keyed up BSI 38 ANX     0.54
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item questionnaire nr original scale DM LPA SA PF HOS
Felt keyed up, “on edge” masq 82 GDA     0.51
Felt confused masq 4 GDM 0.39    
Felt sluggish or tired masq 56 GDD 0.38  0.36 -0.36 
Feeling uneasy in crowds, such as shopping or at a movie BSI 43 PHOB 0.38   0.35 
Feeling no interest in things BSI 18 DEP 0.37 -0.30   
Felt really bored masq 21 AD (interest) 0.37    
Had trouble paying attention masq 80 GDM 0.33   -0.31 
Felt like something awful was going to happen masq 34 GDM 0.31  0.32  
Felt like it took extra effort to get started masq 39 AD (interest) 0.30  0.36 -0.35 
Felt afraid masq 2 GDA 0.30   0.39 
Slept very well masq 5 GDM  -0.35   
Was afraid I was going to die masq 73 AA   0.39  
Startled easily masq 3 AA   0.38  
Nervousness or shakiness inside BSI 1 ANX   0.37  
Felt nervous masq 15 GDA   0.31  
Felt very restless masq 50 GDM   0.31  
Had to urinate frequently masq 85 AA   0.30  
Feeling nervous when you are left alone BSI 47 PHOB    0.32 
Had trouble concentrating masq 76 GDM    -0.31 
Feeling so restless you couldn’t sit still BSI 49 ANX     0.36
Having to check and double-check what you do BSI 26 O-C     0.35
Had diarrhea masq 12 GDA     
Had trouble remembering things masq 31 GDM     
Your mind going blank BSI 32 O-C     
Did not have much of an appetite masq 37 GDM     
Was unable to relax masq 59 GDA     
Had trouble falling asleep masq 51 GDM     
Had trouble staying asleep masq 83 GDM     
Felt like crying masq 10 GDD     
Felt tense or “high-strung” masq 77 GDA     
Table 5.1 Factor structure after OBLIMIN rotation (Continued).
Note: 
Original scales: MASQ: AA = anxious arousal, AD = anhedonic depression, GDD = 
general distress depression, GDA = general distress anxiety, GDM = general distress 
mixed. BSI: SOM = Somatization, O-C = Obsessive-Compulsive, I-S = Interpersonal 
Sensitivity, DEP = Depression, ANX = Anxiety, HOS = Hostility, PHOB = Phobic Anxiety.
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item questionnaire nr original scale DM LPA SA PF HOS
Felt keyed up, “on edge” masq 82 GDA     0.51
Felt confused masq 4 GDM 0.39    
Felt sluggish or tired masq 56 GDD 0.38  0.36 -0.36 
Feeling uneasy in crowds, such as shopping or at a movie BSI 43 PHOB 0.38   0.35 
Feeling no interest in things BSI 18 DEP 0.37 -0.30   
Felt really bored masq 21 AD (interest) 0.37    
Had trouble paying attention masq 80 GDM 0.33   -0.31 
Felt like something awful was going to happen masq 34 GDM 0.31  0.32  
Felt like it took extra effort to get started masq 39 AD (interest) 0.30  0.36 -0.35 
Felt afraid masq 2 GDA 0.30   0.39 
Slept very well masq 5 GDM  -0.35   
Was afraid I was going to die masq 73 AA   0.39  
Startled easily masq 3 AA   0.38  
Nervousness or shakiness inside BSI 1 ANX   0.37  
Felt nervous masq 15 GDA   0.31  
Felt very restless masq 50 GDM   0.31  
Had to urinate frequently masq 85 AA   0.30  
Feeling nervous when you are left alone BSI 47 PHOB    0.32 
Had trouble concentrating masq 76 GDM    -0.31 
Feeling so restless you couldn’t sit still BSI 49 ANX     0.36
Having to check and double-check what you do BSI 26 O-C     0.35
Had diarrhea masq 12 GDA     
Had trouble remembering things masq 31 GDM     
Your mind going blank BSI 32 O-C     
Did not have much of an appetite masq 37 GDM     
Was unable to relax masq 59 GDA     
Had trouble falling asleep masq 51 GDM     
Had trouble staying asleep masq 83 GDM     
Felt like crying masq 10 GDD     
Felt tense or “high-strung” masq 77 GDA     
New scales: DM = depressed mood, LPA = low positive affect, SA = somatic arousal, 
PF = phobic fear, HOS = hostility.
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but not bipolar disorder. The comorbidity between anxiety and depression was 
high: 30.1% of the patients had a depression as well as an anxiety disorder. The 
percentage of patients with one or more anxiety disorder(s) and no depression 
was 26.8 and the percentage of patients with a depression and no anxiety 
disorder was 21.5. The remaining group of patients (21.5%) had no anxiety or 
depression diagnoses and consisted of patients with a somatoform disorder or 
an adjustment disorder or no current disorder (6%) according to M.I.N.I.-Plus.
Factor Analysis
The 104 items were subjected to an exploratory factor analysis using the data 
of patients who completed the MASQ and BSI (n=1449). Parallel analysis 
suggested retaining 10 factors. Sixteen factors had an eigenvalue > 1 and 
the eigenvalues of the first 6 factors were: 33.8, 6.6, 4.4, 3.0, 2.5 and 2.0. The 
screeplot of the factor solution flattened out starting from the fifth or sixth 
component, suggesting that a four or five-factor solution would best fit the data 
(Catell, 1966). Rotated factor solutions (oblimin rotation) were calculated for 
three, four-, and five-factor solutions. The three factor solution resembled the 
tripartite model and explained 43% of the variance. Most items with uniquely 
loadings, loaded on the first factor (e.g. sad, angry, low self-esteem, guilty, 
unattractive, and worrying). The second factor contained all the positively 
skewed items (PA), and only items with explicit physical symptoms loaded 
uniquely on the third factor. The four factor solution (explaining 46% of the 
variance) resembled the three factor solution supplemented with a factor with 
only one item with a unique loading (“Having to avoid certain things, places, or 
activities because they frighten you” (BSI item 31)). In the five-factor solution 
no items had a loading higher than .399 on more than one factor (see Table 5.1) 
making this solution easier to interpret. Thus, a five-factor solution was chosen. 
The five-factor solution accounted for 48% of the total variance in the scores. 
The first factor loads mainly on items originally belonging to two subscales of 
the MASQ: general distress depression and the negative endpoint of anhedonic 
depression: loss of interest. The second factor represents the positive endpoint 
of the MASQ subscale anhedonic depression: positive affect. The items loading 
high on the third factor are mainly items about somatic symptoms of anxiety. 
The fourth factor is a combination of items of the BSI subscales anxiety and 
phobic anxiety. The fifth factor comprises predominantly items from the BSI 
subscale hostility. When comparing our five factors with the five scales of the 
MASQ, the scales anhedonic depression (low positive affect) and anxious 
arousal are retained. Three new scales emerged: depressed mood, phobic fear 
and hostility.
Subsequently, five scales were composed by calculating the mean of the items 
with loadings of at least .40 (the items in bold typeface in Table 5.1): depressed 
mood (DM; factor I), low positive affect (LPA, factor II), somatic arousal (SA; 
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factor III), phobic fear (PF; factor IV) and hostility (HOS; factor V). Although one 
of the scales (PF) consists of only five items, the internal consistency (reliability) 
of all the scales is high, ranging between α=.85 and α=.96 (depicted on the 
diagonal in Table 5.2). Furthermore, the new scales appear sufficiently distinct: 
The correlations among the new scales (Table 5.2) range from .26 to .68, while 
those among the original scales of the MASQ (Table 5.3) range from .50 to .79. 
Especially low is the correlation between low positive affect and phobic fear: 
r=.26, suggesting that these scales may differentiate well between depression 
and anxiety disorders.
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Table 5.2 Correlation & Cronbach’s alpha among newfound scales.
 DM LPA SA PF HOS
DM (26 items) (α= .96) .64 .57 .48 .68
LPA (14 items)   (α= .94) .41 .26 .39
SA (23 items)   (α= .93) .54 .54
PF (5 items)    (α= .85) .45
HOS (9 items)     (α=.89)
Note: 
New scales: DM=depressed mood, LPA=low positive affect, SA=somatic arousal, 
PF=phobic fear, HOS=hostility. All correlations are significant at the 0.01 level.
Table 5.3 Correlation & Cronbach’s alpha among original MASQ scales.
 AD AA GDD GDA GDM
AD (α= .94) .50 .79 .61 .76
AA  (α= .90) .54 .76 .66
GDD   (α= .92) .71 .79
GDA    (α= .85) .77
GDM     (α= .89)
Note: 
Original scales: MASQ: AD=anhedonic depression, AA=anxious arousal, 
GDD=general distress depression, GDA=general distress anxiety, GDM=general 
distress mixed. All correlations are significant at the 0.01 level.
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Note: 
New scales: LPA=low positive affect, DM=depressed mood, HOS=hostility SA=somatic 
arousal, PF=phobic fear, ANX= patients with one or more anxiety disorder(s) and no 
mood disorder, DEP= patients with a mood disorder and no anxiety disorder.
Discriminant analysis
To determine the discriminant validity of the new scales, we made two groups 
of patients: 1) patients with one or more anxiety disorder(s) without a comorbid 
depression (ANX) and 2) patients with a depression without a comorbid anxiety 
disorder (DEP). Because the discriminant validity of the scales is best tested in 
a comparison of pure anxiety with pure depression, we did not include patients 
with comorbid anxiety disorder and depression in this analysis. With excluding 
this group, we also limited the influence of the severity of psychopathology. A 
stepwise discriminant function analysis was performed to investigate the ability 
of the five new scales to discriminate between these two diagnostically purest 
groups. The analysis resulted in a model (χ2(3)=215, p≤.001) based on three 
of the five scales: low positive affect, depressed mood and phobic fear. Low 
positive affect and phobic fear are the best discriminators between depressed 
patients and patients with an anxiety disorder. Patients with a high score on 
Chapter 5: Distinguishing between depression and anxiety
Figure 5.1 Symptom profiles (mean z-scores) for patients with a singular depression 
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low positive affect are more likely to belong to the group with depression (mean 
score DEP=4.36, SD=.64 versus mean score ANX=3.70, SD=.82) and patients 
with a high score on phobic fear are more likely to belong to the group with an 
anxiety disorder (mean score DEP=0.60, SD=.73 versus mean score ANX=1.00, 
SD=.92). With this model 75% of the patients with an anxiety disorder and 71% 
of the patients with a depression were classified correctly. When analysed with 
the original MASQ these percentages are 77% and 69%, respectively. However, 
with the original MASQ none of the scales in the discriminant function reveal a 
high score specific for anxious patients: depressed patients score higher on all 
original MASQ-scales in the discriminant function than anxious patients. 
 To illustrate the discriminant value of each new scale, the results of the two 
groups in the discriminant analysis (patient with a depression and no anxiety 
disorder, and patients with an anxiety disorder and no depression) on the five 
scales are shown on Fig. 5.1. To make comparisons between the scales easier, 
we standardized scores for the five new subscales (z-scores). The figure shows 
that both groups have a specific profile.
 If scales are specific for either depression or anxiety, one also expects that 
patients with the specific disorder score higher on the scale than patients 
without any mood or anxiety disorder (NO ANX/DEP). We tested this with two 
t-tests on the new scales specific for anxiety (PF) and specific for depression 
(LPA). As expected, patients with a depression had a higher score on LPA than 
patients without a mood or anxiety disorder (mean score DEP=4.36, SD=.64 
versus mean score NO ANX/DEP=3.60, SD=.79, p=.000) and patients with an 
anxiety disorder had a higher score on PF than patients without a mood or 
anxiety disorder (mean score ANX=1.00, SD=.92 versus mean score NO ANX/
DEP=0.37, SD=.55, p=.000).
Multivariate analysis of variance
To further examine the discriminant validity of the new found scales, we 
compared the scores of four groups of patients with a specific anxiety disorder. 
For this analysis, we only selected patients with a singular anxiety disorder 
(no comorbid depression and no more than one anxiety disorder). Because 
of the high comorbidity in our sample, this resulted in relatively small groups 
of patients with singular anxiety disorders: general anxiety disorder (GAD; 
n=32), panic disorder (PDA; n=28), simple phobia (SP; n=20) or generalized 
social anxiety disorder (gSAD; n=47). The mean z-scores of these four groups 
of patients are shown on Fig. 5.2. The figure clearly shows that patients with 
panic disorder have a higher score on somatic arousal than patients with any 
of the other anxiety disorders. Differences between the groups were tested 
with a multivariate analysis of variance (MANOVA). Main effects were found 
on somatic arousal, phobic fear and depressed mood (SA (F(3)=4.4, p≤.006), 
PF (F(3)=3.5, p≤.019) and DM (F(3)=3.1 p≤.029)). Post-hoc analyses (Tukey) 
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showed that the panic disorder group had higher scores than the GAD and 
the gSAD patients on somatic anxiety (SA; PDA>GAD/gSAD). Patients with a 
panic disorder revealed a higher score on phobic fear than GAD patients (PF; 
PDA>GAD). On the scale depressed mood patients with gSAD had a higher 
score than patients with a simple phobia (DM; gSAD>SP).
5.4 Discussion
The aim of the present study was to develop scales that can adequately 
differentiate between depression and anxiety disorders, and also can distinguish 
within the anxiety disorders. The scales are based on a pool of items from the 
MASQ supplemented with BSI items. Factor-analysis resulted in a solution with 
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Note: 
New scales: LPA=low positive affect, DM=depressed mood, HOS=hostility SA=somatic 
arousal, PF=phobic fear, PDA=panic disorder, GAD=generalized anxiety disorder, 
gSAD=generalized social anxiety disorder, SP=simple phobia. Corresponding letters (a, 
b, c, d) refer to significant difference according to the post-hoc analyses (Tukey).
Figure 5.2 Symptom profiles (mean z-scores) for four specific anxiety disorders without a 
mood disorder: Panic disorder (n=28), generalized anxiety disorder (n=32), simple pho-



























five factors. The requirement of distinctness of the new scales was largely met: 
the correlations between the scales based on this factor solution were relatively 
low and the internal consistency of the scales was good. The intercorrelation 
of two scales, phobic fear and low positive affect, was even very modest 
(r=.26). In addition, the scales were able to differentiate rather well between 
patients with a mood and patients with an anxiety disorder. As compared to the 
original MASQ, the percentages correctly classified patients are highly similar. 
However, similar to a previous study in a clinical sample (Buckby et al., 2007), 
we found that depressed patients score higher on all original MASQ-scales in 
the discriminant function than anxious patients. The discriminant validity of the 
new scales was considerably better, as patients with an anxiety disorder scored 
significantly higher on one of the scales (PF) than patients with a depression.
 Mineka, Watson and Clark (Mineka et al., 1998) suggested the use of a 
model in which each individual syndrome contains both a common and a 
unique component: the integrative hierarchical model. The scales we found 
fit well in this model. Patients with only an anxiety disorder (except patients 
with GAD) are predominantly characterized by a heightened score on phobic 
fear whereas depressed patients show high scores on the low positive affect 
and depressed mood scales. Furthermore, each of the four included anxiety 
disorders had a different profile on the five new scales. Comparing the mean 
scores on the new scales between patients with one of four anxiety disorders 
(gSAD, GAD, SP and PDA), the scale somatic arousal appeared to be specific 
for patients with panic disorder. This is consistent with the findings of several 
previous studies (Chorpita, 2002; De Beurs et al., 2007; Keogh & Reidy, 2000). 
The phenomenology of anxiety disorders is better represented with phobic 
fear next to somatic arousal. 
 The scale hostility did not contribute to the discriminant function. A 
possible explanation can lie in the recent discovery that irritability within a 
depression, is associated with greater overall severity, anxiety comorbidity 
and suicidality (Perlis et al., 2009) and therefore not specific for depression 
nor anxiety. However, hostility is clinical relevant and underestimated in our 
current classification systems (Pasquini et al., 2004; Picardi et al., 2004) and can 
therefore be a valuable feature to assess.
 Our findings are in line with the structure underlying mood and anxiety 
disorders that was recently presented by Watson (Watson, 2005). For the DSM-5, 
Watson has suggested to use a quantitative hierarchical model in which the 
mood and anxiety disorders are taken together to form an overarching class of 
emotional disorders with 3 subclasses (distress disorders, fear disorders and 
bipolar disorders). Our finding that patients with GAD, just like patients with a 
depression do not have a high score on the two ‘anxiety-like dimensions’ PF 
and SA, is in line with the suggestion of Watson to classify GAD as a distress 
disorder rather than as a fear disorder. 
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 In the present study, the content validity of the new scales was investigated 
by comparing scores of patients with singular disorders. Of course, such 
an approach is not a definite test of the validity of the proposed scales for 
psychopathology of depression and anxiety disorders, given the inherent 
limitations of diagnostic categorization by itself and the resulting overlap in 
the phenomenology of depression and anxiety disorders. In future research 
the content validity should also be evaluated in other ways as well, for instance 
by demonstrating a distinct predictive value of dimensions for the course of 
complaints over time or a prognostic value for treatment effect. 
 Strength of the study is the large patient sample, mainly consisting of patients 
with the relevant disorders: depression and anxiety disorders. We choose to 
limit the analyses of the discriminant validity to only those patients with a pure 
depressive or anxiety disorder. This was feasible given the large number of 
patients included in the study. An important advantage of this approach is the 
diminished role of severity in the analysis.
 A limitation of the findings regarding the factor structure is that the subscale 
low positive affect is only composed of positively formulated items (e.g. “I felt 
cheerful”). The assumption of the tripartite model that the dimension positive 
affect comprises two extremes (lack of interest and feeling good) is thus not 
confirmed by our results. This finding is consistent with earlier studies that 
showed lack of interest as belonging to negative affect (De Beurs et al., 2007; 
Keogh & Reidy, 2000; Watson et al., 1995). However, the fact that all positively 
formulated items load predominantly on a single factor suggests a method 
effect, rather than the presence of a conceptually distinct construct.
 In sum, we present a five factor model as an extension of the tripartite 
model. Through the addition of phobic fear, anxiety is better represented than 
in the tripartite model. The new scales are capable to accurately differentiate 
between depression and anxiety disorders, as well as between several anxiety 
disorders.
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Clark and Watson developed the tripartite model in which a symptom dimension 
of ‘negative affect’ covers common psychological distress that is typically 
seen in anxious and depressed patients. The ‘positive affect’ and ‘somatic 
arousal’ dimensions cover more specific symptoms. Although the model has 
met much support, it does not cover all relevant anxiety symptoms and its 
negative affect dimension is rather unspecific. Therefore, we aimed to extend 
the tripartite model in order to describe more specific symptom patterns with 
unidimensional measurement scales.
Method
1333 outpatients provided self report data. To develop an extended factor 
model, exploratory factor analysis (EFA) was conducted in one part of the 
data (n=578). Confirmatory factor analysis (CFA) was conducted in the second 
part (n=755), to assess model-fit and comparison with other models. Rasch 
analyses were done to investigate the unidimensionality of the factors.
Results
EFA resulted in a 6-factor model: feelings of worthlessness, fatigue, somatic 
arousal, anxious apprehension, phobic fear and tension. CFA in the second 
sample showed that a 6-factor model with a hierarchical common severity 
factor fits the data better than alternative 1- and 3-factor models. Rasch analyses 
showed that each of the factors and the total of factors can be regarded as 
unidimensional measurement scales.
Limitations
The model is based on a restricted symptom-pool: more dimensions are likely 
to exist.
Conclusion
The extended tripartite model describes the clinical state of patients more 
specifically. This is relevant for both clinical practice and research.
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6.1 Introduction
The traditional distinction between depressive and anxiety disorders has 
often been challenged for several reasons. First, high rates of comorbidity 
between depression and anxiety disorders are suspected to be an artifact of 
this distinction (Brown et al., 2001; De Graaf et al., 2002; Kessler et al., 1996).
Second, depression and anxiety have overlapping key-symptoms, rendering 
depression- and anxiety measures highly correlated and only modestly 
discriminative (Clark & Watson, 1991). Third, the diagnoses encompass 
heterogeneous disorders. For instance, two patients with a similar diagnosis of 
Major Depressive Disorder (MDD) only have to share one out of nine criterion-
symptoms, making the label MDD very unspecific (Widiger & Samuel, 2005). 
As a consequence, specific etiological effects are hard to detect in research 
because of the large variability (noise) within diagnosis groups. Fourth, the 
use of dichotomous criteria with arbitrary boundaries leaves us with a many 
subsyndromal subjects, whose etiology and risk profile are often highly similar 
to patients with full-fledged disorders  (De Beurs et al., 1999). Fifth, using 
dichotomous diagnoses in research reduces statistical power, increasing the 
need for larger sample sizes (MacCallum, Zhang, Preacher, & Rucker, 2002).
 One often proposed way to overcome these problems is the use of a 
dimensional approach (Clark, 2005; Cuthbert, 2005; Krueger et al., 2005). 
Dimensions represent continua of increasing severity on different symptom-
domains (Goldberg, 2000) and an individual’s clinical state is described with 
a pattern of specific dimensional scores. Dimensions circumvent comorbidity, 
describe a patients’ clinical state specifically and cover the full spectrum of 
severity from healthy to pathological.
 Several dimensional approaches to depression and anxiety have been 
proposed. Well known is the tripartite model (Clark and Watson, 1991), which 
consists of 3 dimensions. The ‘negative affect’ (NA) dimension covers general 
psychological distress symptoms, common to both depressive- and anxiety 
disorders and could account for their observed overlap and comorbidity. The 
‘positive affect (PA)’ dimension covers the symptoms of anhedonia (e.g. lack 
of enthusiasm and excitement), specific for depression. The ‘somatic arousal 
(SA)’ dimension covers symptoms of somatic hyperarousal, specific for anxiety. 
Although the tripartite model has been found to be structurally valid, SA has 
been shown to be mainly specific for panic disorder (Mineka et al., 1998). 
Hence, several model extensions have been proposed to better account for the 
heterogeneity of anxiety (Chorpita, 2002; Joiner & Lonigan, 2000; Mineka et al., 
1998).
 Another model devised to do more justice to the internal heterogeneity of 
anxiety is the valence-arousal model (Heller, Nitschke, Etienne, & Miller, 1997). 
In this model, a distinction is made between two underlying anxiety factors: 
‘anxious apprehension’ and ‘anxious arousal’, the latter resembling the SA 
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dimension of the tripartite model. Anxious apprehension is an additional factor 
that is characterized by a concern for the future and verbal rumination about 
negative expectations and fears and is hypothesized to play an important role 
in the etiology of anxiety (Nitschke, Heller, Palmieri, & Miller, 1999).
 Although both models have contributed to the field considerably, neither 
model was fully supported across different lines of research. Concluding a 
review on the various models for depressive and anxiety disorders, Shankman 
and Klein (2003) stated that a model with two to four dimensions might not 
be sufficient to do justice to all relevant common and discrete symptoms of 
anxiety and depression. However, the validity and usability of specific aspects 
of both the tripartite model and the valence-arousal model were supported.
 Mineka and colleagues (1998) proposed a hierarchical model in which 
psychopathology was defined by a common, overarching factor of negative 
affect and specific lower-order factors describing the unique components of 
mood- and anxiety disorders. They proposed that SA could be seen as specific 
to panic disorder and that additional dimensions could account for distinct 
symptoms of other anxiety disorders. They suggested to “view individual 
disorders as representing unique combinations of different types of symptoms, 
with each type showing varying degrees of non-specificity and with no type 
being entirely unique to any single disorder” (Mineka et al., 1998). Several 
studies referring to this hierarchical model used the DSM-IV diagnoses as unit 
of research. They assumed that all lower level dimensions corresponded to 
different DSM-IV diagnoses (Krueger, 1999; Vollebergh et al., 2001; Watson, 
2005). These studies presented hierarchical models based on DSM-categories 
and were effective in presenting a partial explanation of the high rates of 
comorbidity between depression and anxiety in the DSM-IV. Another way to 
operationalize the hierarchical model is by developing a model with dimensions 
for unique symptoms of specific mood- and anxiety disorders in addition to 
common symptom scales (Mineka et al., 1998). In previous work we presented 
a proposal for such an extension of the tripartite model in which each of five 
dimensions was more or less specific for one or more disorders (Den Hollander-
Gijsman et al., 2010). Several studies have shown such an approach to work 
well (Simms, Gros, Watson, & O’Hara, 2008; Simms, Prisciandaro, Krueger, & 
Goldberg, 2012).
 Due to the above-described problems with the DSM, it is likely that dimensions 
do not follow the strict divisions of the DSM-IV. Therefore, a dimensional model 
should primarily describe the unique profiles of individuals rather than of 
DSM-disorders. Consequently, dimensions should therefore be based on more 
objective criteria such as one-dimensionality, discriminative ability (between 
individuals) and external validation, e.g., with biological markers. Almost 
all abovementioned work was conducted with factor-analyses. It is often 
overlooked that these analyses only inform about underlying structures of data 
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and do not imply that individual factors are unidimensional. To determine the 
latter, additional Rasch analyses should be conducted to check if and how the 
items are lined up along an underlying severity dimension (Wright & Masters, 
1982). Only if a factor fits to the Rasch model, it can be regarded as a dimension 
with a valid additive measurement scale. This is essential if we wish to define 
psychopathology with dimensions. 
 The current study was aimed to integrate aspects of the abovementioned 
models into one broad dimensional model, without taking DSM-IV diagnoses 
as a point of departure or specificity to particular DSM-IV diagnoses as a sign 
of validity. Instead, we aimed for a multidimensional model to characterize 
individual patients in terms of their specific symptom profile. As point of 
departure we used a large item-pool that included (1.) the items of the Mood 
and Anxiety Symptom Questionnaire (Watson & Clark, 1991) to measure NA, PA 
and SA, (2.) items of the Brief Symptom Inventory (Derogatis, 1975), to measure 
fearfulness and (3.) newly designed items to measure anxious apprehension. 
Several analyses were conducted in two large samples (n=578 and n=755) of 
psychiatric outpatients. The underlying factor-structure of the item pool was 
explored using exploratory factor analyses (EFA) and confirmatory factor 
analyses (CFA) in the first sample. In the second sample CFA was used to 
evaluate the fit of this structure and compare it with alternative models: a one 
factor model, a three factor model (the tripartite model), a higher-order model 
and a bifactor hierarchical model. Finally, Rasch analyses were performed to 
investigate and improve the unidimensionality of each factor and to evaluate 
whether they could be used as reliable additive subscales.
6.2 Methods
6.2.1 Participants and Procedure
This study was conducted on data collected through Routine Outcome 
Monitoring (De Beurs et al., 2011). ROM is a monitoring system for patient care, 
implemented in the outpatient clinics of Rivierduinen Psychiatric Hospital (a 
large organization for the provision of mental health care in the province of 
Zuid-Holland, the Netherlands) and the psychiatric department of the Leiden 
University Medical Center (LUMC). All outpatients referred to these clinics by 
their general practitioner for treatment of a mood-, anxiety- or somatoform 
disorder have an assessment session with a psychiatric research nurse at the 
start of treatment. During this session a standardized diagnostic interview, 
rating scales, and self-report rating instruments are administered. Two patient 
samples were composed of respectively 578 and 755 outpatients, who had paid 
their first visit to the clinic between March 2005 and June 2006 and had been 
assessed with Routine Outcome Monitoring.
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6.2.2 Measures
6.2.2.1 Mini International Neuropsychiatric Interview (M.I.N.I.) Plus 5.0.0.-R
The M.I.N.I. is a short structured diagnostic interview developed to explore 
the presence of 23 Axis-I disorders according to the DSM-IV diagnostic criteria 
(Sheehan et al., 1998). In this study the Dutch translation of the M.I.N.I.-Plus 
5.0.0-R (Van Vliet et al., 2000) was used to screen for the presence of current 
disorders. Psychiatric research nurses who were extensively trained and 
supervised performed the interviews.
6.2.2.2 Mood and Anxiety Symptom Questionnaire (MASQ)
The MASQ was used to assess the severity of symptoms of depression and 
anxiety over the past week (De Beurs et al., 2007 (Dutch version); Watson 
& Clark, 1991). The MASQ consists of 90 items, divided into 5 subscales 
measuring different aspects of the tripartite model: 1) anhedonic depression; 
2) anxious arousal; 3) general distress depression; 4) general distress anxiety, 
and 5) general distress mixed. All items are rated on a 5-point rating scale (1 
[not at all] to 5 [very much]). All items of the MASQ denoting positive feelings 
(anhedonic depression scale) were reversed keyed before analysis to make the 
interpretation of the results more straightforward.
6.2.2.3 Brief Symptom Inventory (BSI)
The Brief Symptom Inventory (De Beurs, 2005; Derogatis & Melisaratos, 1983) 
is a shortened version of the Symptom Checklist (SCL-90) (Derogatis et al., 
1973), and was used to measure psychological complaints or symptoms. The 
BSI consists of 53 items that are rated on a 5-point scale (0 [not at all] to 4 [very 
much]). The items measure nine subscales: somatic complaints, cognitive 
problems, interpersonal sensitivity, depression, anxiety, hostility, phobic fear, 
paranoid thinking, and psychoticism.
6.2.2.4 Anxious apprehension
We formulated four self report items (AA-01 to AA-04) to measure anxious 
apprehension (e.g., “I worried about bad things that might happen”). To 
determine the face validity of these items, they were judged by two individual 
clinical experts (psychiatrist and psychologist).
6.2.2.5 Final item-pool
A selection was made from the BSI and the MASQ items to prevent redundancy. 
The items of all five MASQ subscales were included (77 out of the 90 items: the 
remaining items were not assigned to any subscale (Watson & Clark, 1991). 
From the BSI, the items of the anxiety and phobic fear subscales were selected. 
Together with the four items measuring anxious apprehension, this resulted in 
an item-pool of 91 unique items.




Before the analyses, all items of the BSI were recoded from 0-4 to 1-5 to match 
with the scoring of the MASQ. EFA was used in sample 1 to investigate how 
many and which factors should be retained to model the underlying structure 
of the item-pool. Oblique factor rotation (oblimin) was used, because it does 
not assume that factors are uncorrelated. Factor extraction was done by use 
of a scree-plot. Items were retained for each factor if they had a high (>0.40) 
factor-loading and did not have a high (>0.40) loading on any of the other 
factors. The cut-off of 0.40 was chosen to balance between over- and under 
inclusion of items within each factor. The EFA was conducted using SPSS 17. 
Next, CFA were run to evaluate the fit of a 1-factor model on each extracted 
factor. Model-fit was evaluated with fit-indices (see below for the used methods 
and cut-off criteria). If fit was inadequate, the scale was further examined with 
EFA and items with low factor scores were deleted from the scale to improve fit. 
These steps were repeated until each factor fit well to the data. 
6.2.3.2 Model evaluation: Confirmatory Factor Analyses (CFA)
To investigate the validity of the model structure that was identified in sample 
1, CFA was conducted in sample 2. The newly identified multi-factor model was 
compared to four alternative models. In a 1-factor model, all items loaded on 
one common factor. In the tripartite model the negative affect-, positive affect- 
and somatic arousal-related items loaded on three different factors (Clark & 
Watson, 1991). In a higher order model, a higher order severity factor loaded 
on all identified (Van Kampen D., 2006) factors. In a hierarchical bifactor model 
different sets of items loaded on specific factors and, at the same time, all items 
loaded on one general severity factor (following Mineka et al., 1998). In each 
tested model the factor-loadings were set to be freely estimated; per factor one 
factor-loading was fixed to one. In the result section schematic illustrations of 
the five models are provided.
 The data were all categorical and non-normally distributed, thus maximum 
likelihood (ML) estimation of model-fit would likely result in underestimations 
of model-fit (Byrne, 2006). Therefore, we used an approach for categorical data 
(Bentler, 2006). First, a matrix of polychoric correlations between the items was 
generated. Second, model fit-statistics were estimated with ML. Third, the fit-
statistics were corrected with an appropriate weight-matrix to obtain robust fit-
statistics (Satorra & Bentler, 1988). These robust statistics have been shown to 
perform well for categorical and non-normal data (Byrne, 2006). The following 
fit-indices were used to assess model-fit: the Comparative Fit Index (CFI), the 
Root Mean Square Error of Approximation (RMSEA) and the Akaike Information 
Criterion (AIC). A CFI ≥ 0.90 and a RMSEA ≤ 0.08 indicates adequate fit (Hu & 
Bentler, 1999). The AIC can be used to compare different models, balancing 
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statistical goodness-of-fit and the number of model parameters; the model 
with the lowest AIC can be regarded as potentially most useful (Bentler, 2006). 
The EQS statistical package (Multivariate Software Inc., Encino, California, 
USA) was used to conduct the analyses.
 Spearman correlations between the raw sum scores of the different factors 
were computed to evaluate their interrelatedness with SPSS 17.
6.2.3.3 Model evaluation: Rasch analyses
To investigate the unidimensionality of the identified factors, fit to the Rasch 
model was investigated in sample 2. Calculations were done with RUMM2020 
(RUMM Laboratory, Perth, WA, Australia). The Rasch model assumes that the 
probability of a person’s response on an item is described by a logistic function 
of the distance between the location of the person and the location of the item 
on the underlying linear severity dimension. If a person is located higher on the 
underlying dimension than an item, the probability that the person responds 
with the highest response option on a Likert-item is very high. On the other hand, 
if the person is located lower on the dimension than the item, the probability 
of the lowest response option is high. If a group of items fits well to the Rasch 
model, in theory all of the items are lined up along one underlying dimension 
in order of increasing severity. An important implication of adequate fit to 
the Rasch model is that this indicates that the ordinal responses on the items 
can be added up to a linear interval-scale that is a sufficient statistic for the 
underlying severity dimension, which means that the factor is a unidimensional 
measurement scale (Wright & Masters, 1982). The latter was why we chose to 
use the 1-parameter Rasch model instead of a more-parameter item response 
model, which allows for more subtle fit assessment but does not have a simple 
sufficient statistic.
 The unrestricted partial credit model was used for fit-estimation. To estimate 
the fit to the model, the unweighted mean square standardized residual (outfit) 
was calculated for each item (formulas from: Wright & Masters, 1982, p100). 
Outfit was used because it is much less affected by large sample size because 
it is basically a χ2 statistic divided by its degrees of freedom. An outfit for an 
item that is close to 1 and within the range of 0.7 to 1.3 is considered to indicate 
adequate fit (Wright & Stone, 1979). In the current analyses, the standardized 
residuals were calculated and outputted by RUMM and the mean residual 
across all persons (the outfit) was calculated for each item using Microsoft 
Excel. Persons with a total scale score of 0 or with fit-residuals>|2.5| were 
automatically excluded from all calculations because they do not behave in line 
with the Rasch model expectations. 
 For each factor, the same analytic procedure was followed to assess fit 
of items to the Rasch model. First, for each item the polytomous category 
probability plot was screened for disordered thresholds between response 
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categories. If along the underlying dimension, a category always had a lower 
probability of endorsement than a neighboring category, the lower- probability 
category was ‘collapsed’ with the higher-probability category. If the category 
with a higher probability was one step down on the response scale, the lower-
probability category was collapsed down and if the category with a higher 
probability was one step up on the Likert scale, the lower-probability category 
was collapsed up. Second, the fit of the items within each factor was assessed 
to see if fit had improved with rescoring and extra rescoring was undertaken 
if necessary. Third, if items fit well, differential item functioning (DIF) was 
used to investigate whether item-functioning differed across gender and age-
tertiles. This method uses an ANOVA, which was likely to pick up less relevant 
DIF due to our large sample-size. Therefore, if significant DIF was found for an 
item, the item-locations were additionally compared across subgroups (e.g. 
men vs. women) to judge whether DIF was relevant and could potentially harm 
generalizability. Fourth, the person-separation index was calculated and the 
number of severity strata that could be discriminated was derived from the 
separation-ratio (G).
6.3 Results
6.3.1 Demographic and diagnostic characteristics 
The two samples contained respectively 66 % and 61 % females and the mean 
age was 37 years (range 18-78) for both samples. No significant differences 
were found between the two samples on any of the listed demographic and 
psychopathology characteristics (see Table 6.1).
6.3.2 Model selection: EFA and CFA
EFA with Oblimin rotation in sample 1 yielded various feasible solutions. Based 
on the number of unique loading items per factor and the interpretability of the 
factors, we decided on a seven-factor solution with 56% of explained variance. 
The factors were: feelings of worthlessness, positive affect, fatigue, somatic 
arousal, anxious apprehension, phobic fear, and tension (eigenvalues: 31.3, 
6.5, 3.7, 2.7, 2.3, 2.2, and 1.9). When qualitatively comparing this model with 
the tripartite model, the dimensions positive affect and anxious arousal are 
retained, a new dimension fatigue emerges, and the dimension negative affect 
is subdivided into four dimensions: feelings of worthlessness, phobic fear, 
anxious apprehension and tension (see Table 6.2).
 The positive affect factor was entirely composed of positively formulated 
feelings or emotions (reverse keyed items), which suggests that these items 
mainly load on the same factor because of their shared response-format: a 
method effect rather than a truly separate concept (Russell & Carroll, 1999; 
Spector, Van Katwyk, Brannick, & Chen, 1997). We decided to omit this factor 
from further analyses to decrease the chance on bias in the model by response 
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format. Due to this decision, all dimensions in our model are measured with 
negatively formulated items only. To do justice to the construct ‘positive affect/
positive activation’, we preserve the factor ‘fatigue’ because in theory, positive 
affect and fatigue can be interpreted as opposite poles of the same dimension 
(Clark & Watson, 1991, p. 321).
 For each remaining factor, all items with a substantial (>0.40) factor-loading 
were retained (feelings of worthlessness: 5 items, fatigue: 8 items, somatic 
arousal: 13, anxious apprehension: 5 items, phobic fear: 4 items, and tension: 
6 items). CFA with each of these factors showed that a one-factor model fit the 
factors ‘feelings of worthlessness’ (CFI=0.98), Tension (CFI=0.98), and ‘phobic 
fear’ (CFI=0.97) very well. For the other three factors, model-fit was inadequate 
(CFI ranged from 0.80 to 0.86). Therefore, an additional EFA was done on each 
of these three factors to select the items with the highest loadings on the factor. 
Subsequent CFA’s showed these fine-tuned factors to have satisfactory fit to a 
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Table 6.1 Demographic and psychopathology characteristics for sample 1 (n=578) and 
sample 2 (n=755).
Variables Sample 1 Sample 2
  March 2005 – September 2005 October 2005 - June 2006
N 578 755
Mean Age (SD) 37 (.13) 37 (.12)
Age range (18-78) (18-71)
Number of Females (%) 382 (66%) 463 (61%)
Mean BSI total (SD) 1.1 (0.71) 1.1 (0.69)
BSI-total range (0-3.3) (0-3.6)
Diagnoses (%):  
Depression/dysthymia 266 (46%) 333 (44%)
Anxiety disorder 273 (47%) 352 (47%)
Somatoform disorder 101 (18%) 102 (14%)
Diagnostic groups (%)   
No depression and anxiety 166 (29%) 210 (28%)
Only anxiety disorder 146 (25%) 212 (28%)
Only depressive disorder 139 (24%) 193 (26%)
Depressive and anxiety disorder 127 (22%) 140 (19%)
BSI = Brief Symptom Inventory
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one-factor model (CFI ranged from 0.95 to 1.00). For anxious apprehension (AA) 
and phobic fear (PF) the RMSEA was greater than 0.1 (.211 and .137 respectively) 
and we did not succeed to reduce these values with further modifications to the 
factors.
6.3.3 Model evaluation: CFA
Schematic illustrations of the five models are depicted in Figure 6.1, and the 
results of the CFA in sample 2 are shown in Table 6.4. The newly identified 
6-factor model (model 3) showed adequate fit (CFI=0.95; RMSEA=0.081). The 1 
factor model (model 1) resulted in worse model-fit (CFI=0.89; RMSEA=0.13). To 
test fit to the tripartite model, the items representing feelings of worthlessness, 
tension, anxious apprehension, and phobic fear were taken together in one NA 
factor. Together with the fatigue factor and the SA factor, these formed the 
3-factor tripartite model (model 2). This model fit worse than the 6-factor model 
(CFI=0.92; RMSEA=0.11). A 6-factor model, with a higher-order factor (model 
4) fits better than the regular 6-factor model (CFI=0.99; RMSEA=0.046) and the 
bifactor hierarchical 6-factor model (model 5) showed the best fit (CFI=0.99; 
RMSEA=0.043). In addition this model had the lowest AIC (130.8) compared 
to the other models (AIC range: 200.3 to 4177.9). This indicated that the best 
model to describe the underlying structure of our data-pool has 6 different 
factors with one additional overarching severity factor.
6.3.4 Intercorrelations
The correlations between the sum scores of each of the six factors in sample 
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Table 6.2 Comparison of the new factors with the dimensions of the tripartite model.
Tripartite model New dimensions
Somatic arousal Somatic arousal
Positive affect Fatigue
 Positive affect*
Negative affect Phobic fear
 Anxious apprehension
 Feelings of worthlessness
 Tension
* Positive affect was entirely composed of positively formulated items and we deci-
ded to continue the analyses without this dimension.
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2 are displayed in Table 6.3. The coefficients ranged from 0.30 to 0.63. The 
correlations between fatigue and phobic fear (r=0.30), between feelings of 
worthlessness and somatic arousal (r=0.33) and between somatic arousal and 
phobic fear (r=0.33) were all modest. The correlations between fatigue and 
tension (r=0.63), between feelings of worthlessness and anxious apprehension 
(r=0.59) and between tension and anxious apprehension (r=0.58) were high. 
All other correlations ranged from 0.37 to 0.56. This indicates that the identified 
structure consists of moderately to strongly related constructs. 



























5. Six-factor model 
with bifactor structure



























5. Six-factor model 
with bifactor structure
* NA = FW+AA+PF+TE
Figure 6.1 Schematic illustration of a priori structural models. The 5 pictures depict only 
a few relevant parameters; the exact number of items and error terms on symptoms and 
intermediate factors are omitted for clarity.
NA=negative affect, FW=feelings of worthlessness, FA=fatigue, SA=somatic arousal, 
AA=anxious apprehension, PF=phobic fear, TE=tension
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6.3.5 Model evaluation: Rasch analyses
Rasch analyses (Table 6.5) were performed for the complete item-set and for 
the different factors that were identified using EFA and CFA. 
6.3.5.1 All items
Because we found an overarching general severity factor we investigated the 
fit of the Rasch model on all items within the identified model. Because most 
items appeared to have disordered thresholds, they were recoded to a 4-point 
scale (0,1,1,2,3). Items BSI08 and BSI28 were recoded to (0,0,0,1,1), BSI31 and 
BSI43 to (0,0,1,1,2) and MASQ79 and MASQ81 were recoded to (0,1,1,1,2). Outfit 
ranged from 0.73 to 1.42 and only two items had an outfit that exceeded the 
criteria for good fit (BSI31: outfit=1.42; and BSI43: outfit=1.31). The person-
separation index was 0.93, which indicated that the scale could be used to 
discriminate between five severity strata (G≈4, Wright and Masters, (1982)). 
6.3.5.2 Feelings of Worthlessness
In the feelings of worthlessness factor, adequate threshold ordering was 
obtained by rescoring all items to a 3-point scale (0,0,1,1,2). Outfit ranged from 
0.72 to 0.92, indicating adequate fit to the Rasch model. No DIF was found. The 
person-separation index was 0.84, which indicated that the scale can be used 
to discriminate between 3 severity strata (G≈2).
6.3.5.3 Fatigue
In the fatigue factor, adequate threshold ordering was obtained by rescoring all 
items to a 4-point scale (0,1,1,2,3). Outfit ranged from 0.72 to 0.89, indicating 
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Table 6.3 Spearman correlations for the new scales (sumscores) in sample 2 (n=755).
 FW FA SA AA PF TE
Feelings of worthlessness (FW) 1.00 - - - - -
Fatigue (FA) 0.54 1.00 - - - -
Somatic Arousal (SA) 0.33 0.47 1.00 - - -
Anxious Apprehension (AA) 0.59 0.43 0.43 1.00 - -
Phobic Fear (PF) 0.42 0.30 0.33 0.39 1.00 -
Tension (TE) 0.56 0.63 0.55 0.58 0.37 1.00
All correlation coefficients significant at p<0.01
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Model DF S-B χ2 AIC CFI NFI RMSEA 90% CI (RMSEA)
1. One factor  351 4879.4 4177.9 0.89 0.88 0.131 0.128 -0.134 
2. Three factors  350 3572.4 2872.4 0.92 0.91 0.111 0.107 -0.114
3. Six factors  341 1244.4 562.4 0.98 0.98 0.059 0.056 -0.063
4. Six factors (higher order)  344 1069.4  200.34 0.99 0.98 0.046 0.042 -0.050
5. Six factors (bifactor) 322 774.8 130.82 0.99 0.99 0.043 0.039 -0.047
Table 6.4 Results of confirmatory factor analyses in sample 2 (n=755).
adequate fit to the Rasch model. No DIF was found. The person-separation 
index was 0.84, which indicated that the scale can be used to discriminate 
between 3 severity strata (G≈2).
6.3.5.4 Somatic Arousal
In the somatic arousal factor, adequate threshold ordering was obtained by 
rescoring all items to a 3-point scale: MASQ48 and MASQ75 to (0,0,1,1,2) and 
MASQ79 and MASQ81 to (0,1,1,1,2). Outfit ranged from 0.70 to 0.85, indicating 
adequate fit to the Rasch model. DIF was found across age on item MASQ81 
(‘Muscles were tense or sore’): item locations ranged from -0.97 (middle age) 
to -0.32 (low age), indicating that item-functioning differs slightly across 
age groups. The person-separation index was 0.65, which indicated that the 
measurement scale can be used to discriminate between roughly 2 severity 
strata (G≈1.5).
6.3.5.5 Anxious Apprehension
In the anxious apprehension factor, adequate threshold ordering was obtained 
by rescoring all items to a 3-point scale: items AA-01 and AA-02 to (0,0,1,1,2) 
and AA-03 and AA-04 to (0,0,0,1,2). Outfit ranged from 0.65 to 1.09, indicating 
adequate fit to the Rasch model for only two items (AA-01 and AA-02). Two 
other items consistently failed to adequately fit to the model (AA-03 and AA-
04), even after further rescoring. The latter items were thus dropped from the 
scale. No DIF was found. The remaining two items only had a person-separation 
index of 0.54, which indicated that the measurement scale can not be used to 
discriminate different strata of severity (G≈1). The factor is thus not very useful 
as a measurement scale.
Analyses based on polychoric correlation matrix; model-fit estimation with ML, 
Chi-square and fit indices adjusted for non-normality with Satorra-Bentler correction. 
S-B χ2 = Satorra-Bentler Chi-square; AIC = Akaike Information Criterion; 
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Model DF S-B χ2 AIC CFI NFI RMSEA 90% CI (RMSEA)
1. One factor  351 4879.4 4177.9 0.89 0.88 0.131 0.128 -0.134 
2. Three factors  350 3572.4 2872.4 0.92 0.91 0.111 0.107 -0.114
3. Six factors  341 1244.4 562.4 0.98 0.98 0.059 0.056 -0.063
4. Six factors (higher order)  344 1069.4  200.34 0.99 0.98 0.046 0.042 -0.050
5. Six factors (bifactor) 322 774.8 130.82 0.99 0.99 0.043 0.039 -0.047
6.3.5.6 Phobic Fear
In the phobic fear factor, adequate threshold ordering was obtained by rescoring 
all items to a 2-point scale: items BSI08 and BSI28 to (0,1,1,1,1) and BSI31 and 
BSI43 to (0,0,1,1,1). Outfit ranged from 0.83 to 1.07, indicating adequate fit to the 
Rasch model. No DIF was found. The person separation index was 0.61, which 
indicated that the measurement scale could be used to discriminate between 2 
severity strata (G≈1.5).
6.3.5.7 Tension
In the tension factor, adequate threshold ordering was obtained by rescoring 
all items to a 4-point scale: MASQ15, MASQ17 and MASQ77 to (0,1,1,2,3) and 
MASQ50, MASQ59 and MASQ82 to (0,1,2,2,3). Outfit ranged from 0.67 to 0.92, 
indicating adequate fit to the Rasch model for all but one item. Item MASQ79 
failed to fit the Rasch model (Outfit: 0.67), even after further rescoring and was 
therefore dropped from the scale. DIF was found across gender on item MASQ50 
(‘feeling restless’): item location was slightly higher (0.46) in females than in 
males (0.19). However the location-difference was small (<0.50), indicating only 
limited influence on the generalizability of measurement. The five remaining 
items had a separation index of 0.80, which indicated that the measurement 
scale can be used to discriminate between 3 severity strata (G≈2).
6.4 Discussion
The aim of the current study was to develop a dimensional model for depression 
and anxiety of clearly distinguishable and easily assessable dimensions, 
integrating the approaches of the tripartite model, the valence-arousal model 
and the hierarchical model. 
CFI = Comparative Fit Index; NFI = Normed Fit Index; RMSEA=Root Mean Square Error 
of Approximation; 90% CI (RMSEA) = 90% Confidence Interval of RMSEA.
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Table 6.5 Results of Rasch analyses in sample 2 (n=755).
Scale Item number Item content Threshold Item location Outfit
BSIxx = Brief Symptom inventory items; MASQxx = mood and anxiety symptom ques-
tionnaire items; AAxx = customly developed anxious apprehension items. 
Items ordered according to their location within their scale; adequate outfit coeffi-
cients printed in bold font. 
Feelings of MASQ74 Was disappointed in myself
worthlessness MASQ13 Felt worthless
 MASQ24 Blamed myself for a lot of things
 MASQ64 Felt inferior to others
 MASQ47 Felt like a failure
Fatigue MASQ90 Got tired or fatigued easily
 MASQ39 Felt like it took extra effort to get started
 MASQ56 Felt sluggish or tired
 MASQ19 Felt faint
 MASQ66 Felt really slowed down
Somatic Arousal MASQ79 Was trembling or shaking
 MASQ81 Muscles were tense or sore
 MASQ48 Had hot or cold spells
 MASQ75 Heart was racing of pounding
Anxious AA-03 I worried about bad things that could happen
apprehension  AA-04 I was concerned about things that could happen
 AA-01 I thought that things would end up badly for me
 AA-02 I had the feeling that something bad was going to happen
Phobic Fear BSI43 Feeling uneasy in crowds, such as shopping or at a movie
 BSI28 Feeling afraid to travel on buses, subways, or trains
 BSI31 Having to avoid certain things, places, or activities 
 BSI08 Feeling afraid in open spaces or on the streets
Tension MASQ77 Felt tense or “high-strung”
 MASQ59 Was unable to relax
 MASQ15 Felt nervous
 MASQ17 Felt irritable
 MASQ50 Felt very restless
 MASQ82 Felt keyed up, “on edge”
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Scale Item number Item content Threshold Item location Outfit
1 2 3
 -1.80 0.94 - -0.43 0.79
 -1.50 1.28 - -0.11 0.76
 -1.20 1.49 - 0.14 0.92
 -1.40 1.78 - 0.19 0.80
 -0.98 1.39 - 0.21 0.72
 -3.49 1.52 - -0.98 0.79
 -3.15 2.04 - -0.55 0.82
 -2.67 2.72 - 0.03 0.72
 -2.18 2.93 - 0.37 0.89
 -1.33 3.60 - 1.13 0.76
 -1.91 1.82 - -0.04 0.79
 -2.32 0.71 - -0.80 0.85
 -0.45 0.99 - 0.27 0.70
 -0.14 1.30 - 0.58 0.72
 -1.30 0.45 - -0.42 0.65
 -1.71 0.04 - -0.83 0.65
 -0.89 1.64 - 0.37 1.09
 -0.43 2.20 - 0.88 0.80
 -0.64 - - -0.64 1.07
 0.13 - - 0.13 0.87
 0.19 - - 0.19 0.88
 0.32 - - 0.32 0.83
 -3.69 1.57 - -1.06 0.67
 -2.15 0.30 1.23 -0.21 0.79
 -2.20 0.56 1.96 0.11 0.88
 -2.16 0.51 2.01 0.12 0.92
 -1.57 0.49 2.26 0.39 0.76
 -0.62 0.91 1.64 0.64 0.79
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 Model-development and evaluation were performed in independent 
samples. In the first sample a six-factor model was identified, comprising the 
following factors: feelings of worthlessness, fatigue, somatic arousal, anxious 
apprehension, phobic fear and tension. In the second sample, confirmatory 
factor analyses showed that a bifactor hierarchical model with a general 
severity factor and six specific factors fit best to the data, compared to other 
models. Additional Rasch analyses showed that five of the six factors were 
truly one-dimensional and could be used as measurement scales. Only the 
anxious apprehension factor was found not to be unidimensional, although 
this does not imply that the identified structure is invalid. Importantly, we also 
found good fit of the Rasch model for all items together, which is in line with the 
identified bifactor structure of six specific factors and a general severity factor.
 These results have some interesting implications. First, they show that a 
hierarchical 6-factor model is optimal to describe the structure of the symptom 
dimensions of mood- and anxiety disorders, when integrating important 
aspects of the tripartite model and the valence arousal model. As suggested 
by Mineka et al.(1998), the six lower order factors describe a patients’ specific 
symptom-profile, while at the same time the complete set of items reflects 
overall severity. Importantly, our findings are in line with earlier studies 
(Simms et al., 2008; Simms et al., 2012) and lend further support to the idea 
that symptomatology of depression and anxiety has a hierarchical structure.
In the current model the dimension tension was most generic and was 
correlated relatively strongly with all the other dimensions in the model and 
could be regarded as a small, more homogeneous subfactor of NA.
 Somatic arousal, anxious apprehension and phobic fear all fall into the 
anxiety realm. The present model thus distinguishes three distinct dimensions 
of symptomatology, relevant to anxiety. Both phobic fear and anxious 
apprehension are valuable additions to the single dimension of SA in the tripartite 
model, because they reflect the behavioral and the cognitive components of 
fear and anxiety. Both dimensions were only modestly intercorrelated (r=.39), 
indicating that they measure two distinct constructs. Phobic fear is a relevant 
construct because it is a defining aspect of panic disorder with agoraphobia, 
social phobia and specific phobia (Den Hollander-Gijsman et al., 2010). Anxious 
apprehension was previously found to play an important role in anxiety, as 
shown by imaging studies on the valence-arousal model (Heller et al., 1997). 
Thus, by integrating these different anxiety-related constructs the current 
model better accounts for the heterogeneity of anxiety.
 Feelings of worthlessness and fatigue are dimensions that reflect aspects of 
a depressed state. According to the tripartite model, the factor fatigue which 
reflects loss of energy can be interpreted as the negative pole of the dimension 
‘positive affect/anhedonia’ (Clark & Watson, 1991). Besides ‘fatigue’, a positive 
affect factor emerged in the factor analysis, including all positively formulated 
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items in the item-pool and was thus likely to reflect a method effect. We 
therefore decided not to include this dimension in the analyses to evaluate the 
model. For future research, it would be interesting to measure both NA and PA 
with both positively and negatively phrased items (and in both a clinical sample 
and a sample from the general population).
 The current study had several strong characteristics. First, the sample was 
large, which increases reliability, and included a broad range of outpatients 
with mood-, anxiety-, and somatoform disorders, assuring the generalizability 
of the results to the target population. Second, model-development and 
confirmation were conducted in independent samples, supporting replicability 
of the identified model. Third, in addition to investigating the factor structures, 
the usefulness of the factors as one-dimensional measurement scales was also 
evaluated with Rasch analyses (Wright & Masters, 1982). 
 The results should also be interpreted in the light of some limitations. 
First, the results only apply to outpatients with a limited range of severity and 
specific demographic characteristics and can thus not be directly generalized 
to healthy controls or inpatients. Second, model-development was based on 
a limited symptom-pool, which may have restricted the number of factors 
that was identified. In reality, even more dimensions are expected to exist, 
such as externalizing dimensions (Krueger, Markon, Patrick, & Iacono, 2005) 
comprising concepts such as ‘anger’ or ‘aggression’ (Pasquini, Picardi, Biondi, 
Gaetano, & Morosini, 2004; Picardi, Morosini, Gaetano, Pasquini, & Biondi, 
2004). Third, although the current study is based on a strong combination of 
analyses, the added value of the dimensions over DSM-IV categories should be 
further investigated.
 Dimensions should be shown to have potential added value on top of 
traditional psychopathology measures. They could be used as more specific 
phenotypes in biological etiological research to overcome the heterogeneity 
and comorbidity that has hampered research with DSM-defined research 
groups. In addition, dimensions could be used as more specific predictors 
of disease-course and treatment response. The applicability of dimensions 
for these purposes still needs to be thoroughly investigated, but they could 
be promising leads to improving diagnostics and the specificity of treatment 
indications.
 In conclusion, we present an integrated six-dimensional model to assess 
different symptoms of depression and anxiety that does justice to the 
heterogeneity of anxiety and consists of easily measurable dimensions. These 
dimensions could eventually be used as more specific phenotypes in etiological 
research and to describe patients’ symptom patterns in clinical settings.








There are two approaches to psychopathology, a categorical and a dimensional 
approach. In the categorical approach each psychiatric disorder is characterized 
by a set of criteria. Diagnoses are made by checking whether a patient meets 
the criteria for one or more disorders. This is basically a dichotomous decision 
process; a patient meets criteria and therefore has a disorder or not. At first sight, 
this approach seems pretty straightforward for research and clinical practice. 
In etiological research it enables the study of well-defined patient groups. In 
clinical practice, the psychiatrist or therapist who made a diagnosis knows which 
treatments are appropriate, based on randomized controlled trials carried out 
in patients with the same disorder. However, patients with the same disorder 
may differ very much in symptomatology. For instance, if both patients have 
a depression (i.e. both have the required 5 out of 9 symptoms) they may have 
only a single symptom in common. Besides, in clinical practice comorbidity is 
the rule rather than the exception and this contributes to the heterogeneity. For 
research into the etiology of psychopathology this heterogeneity may explain 
why the results are often inconsistent. For clinical practice this implies that the 
evidence on which treatments are based is oversimplified. This may play a role 
in the often modest treatment results.
 The dimensional view has the potential to overcome these problems as 
it allows a more comprehensive analysis of psychopathology. First of all, 
subjects are assessed not on a single, but on multiple dimensions. It is in fact 
a multidimensional approach. Each dimension is not assessed as present or 
absent, but is quantified along a continuum. And each patient is assessed along 
all the dimensions included in the investigation. The result is a much more 
refined profile of psychopathology than could be achieved with a categorical 
approach. For etiological research this may improve the chances to find a 
relationship between for instance biological factors and psychopathology. For 
clinical practice it allows (provided enough data are available) more refined 
choices for treatment and a better prediction of the prognosis.
 The aim of this thesis was to investigate diagnostic heterogeneity and to test 
the feasibility of dimensional models in a large, real-life group of psychiatric 
outpatients with mood, anxiety and / or somatoform disorders and to develop a 
dimensional model that overcomes the disadvantages of existing ones. Before 
discussing the results, the major findings will be summarized.
7.2 Summary of major findings
As the data of all patient samples in this thesis were collected with Routine 
Outcome Monitoring (ROM), we first described this method in detail in Chapter 
2. Although they initially had their reservations, most therapists considered 
ROM to be an important adjunct to diagnostics and treatment outcome 
evaluation. In addition, ROM furthers research as the data can be used to study 
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the phenomenology of psychiatric disorders and the outcome of treatments 
delivered in everyday practice. Implementation of ROM in outpatients with 
depressive, anxiety and somatoform disorders therefore seems to be feasible 
and useful.
 Next, we investigated whether in this patient sample a high rate of 
comorbidity (as discussed in 7.1) could indeed be found. We analysed the 
prevalence of axis 1 DSM-IV disorders in a group of 3798 outpatients who 
had had ROM-assessments. According to the MINI-Plus (part of ROM), 1,618 
patients (42.6%) met criteria for a single mood, anxiety, or somatoform (MAS) 
disorder, but nearly the same number, 1,556 patients (41.0%), had more than one 
concurrent MAS disorder: 967 patients (25.5%) had two comorbid disorders, 
403 patients (10.6%) had three, and 186 patients (4.9%) had four or more. This 
high prevalence of different types of comorbidity signifies heterogeneity.
 In Chapter 3 we examined whether the comorbidity discussed in Chapter 2 
is merely the coming together of two or more disorders in the same patient or 
whether the whole is more than the sum of its parts. To do so, we compared 
the scores of patient groups defined by the categorical diagnoses on several 
severity assessments, This approach is ‘semi-dimensional’ as it stays close to 
the diagnostic categories but allows quantification. We found that depression 
severity in the comorbid group was higher than in the pure depression group 
and that anxiety severity in the comorbid group was higher than in the pure 
anxiety group. This study also revealed that the mean scores on the anxiety 
measures did not differ significantly between patients with a pure depression 
and patients with a pure anxiety disorder. These results show that, with respect 
to symptom severity, comorbidity is more than simply the sum of the disorders.
 We also wanted to go beyond categorical diagnoses and explore a more fully 
dimensional model with dimensions not necessarily coupled to the diagnostic 
categories of depressive and anxiety disorders. We chose an already existing 
model as point of departure: the tripartite model of Watson and Clark. This 
model proposes that there is one nonspecific general distress factor (negative 
affect), common to both mood and anxiety disorders, and two additional 
factors specific to anxiety disorders and depression. The three dimensions 
of the tripartite model can be measured with the MASQ (Mood and Anxiety 
Symptom Questionnaire). In order to do research on the tripartite model in 
Dutch samples, a translation of the MASQ was needed. In Chapter 4 the Dutch 
adaptation of the MASQ is presented and the applicability of the tripartite model 
on our sample is tested. The psychometric properties of the translated MASQ 
were highly satisfactory. In accordance with the model, we found the MASQ 
to comprise three main scales, which discriminate well between subgroups of 
patients with mood and anxiety disorders.
 Although the tripartite model has inspired a large body of research, it has 
met some criticism as well. A major point of critique is that depression is well 
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covered with lack of positive affect and negative affect (a nonspecific aspect of 
the disorder). However, the same cannot be said for anxiety, as the dimension 
‘somatic arousal’ that is specific for anxiety does not cover all anxiety 
disorders but mainly covers panic disorder. Somatic arousal is too narrow as a 
conceptualization of anxiety, ignoring other important aspects of anxiety such 
as anxious apprehension, worry, phobic anxiety and/or avoidance.
 In Chapter 5, we present a first model that contains clearly distinguishable 
constructs, and includes main aspects of common mental disorders in 
outpatients. Our aim was to cover anxiety more adequately than the tripartite 
model does. We used items of the Mood and Anxiety Symptom Questionnaire 
(Watson & Clark, 1991) and items of the Brief Symptom Inventory (Derogatis, 
1975). A model with five dimensions was found: depressed mood, lack of 
positive affect, somatic arousal, phobic fear and hostility. The validity of the 
model was supported by the following findings: The scales appeared capable 
to differentiate between patients with either a mood or an anxiety disorder. 
Low positive affect and phobic fear were the best discriminators between 
depressed patients and patients with an anxiety disorder. Within the anxiety 
disorders, somatic arousal was specific for patients with panic disorder. Phobic 
fear was associated with panic disorder, simple phobia and social anxiety 
disorder, but not with generalized anxiety disorder. 
 Whereas the study described in Chapter 5 validated the model by comparing 
the dimensions to the categories of the DSM-IV (disorder-based approach), in 
Chapter 6 we took a step further away from the DSM-IV and closer towards a 
‘true dimensional model’ (symptom-based approach). As point of departure 
we used a large item-pool that included (1.) the items of the Mood and Anxiety 
Symptom Questionnaire (Watson & Clark, 1991) to measure NA, PA and SA, 
(2.) items of the anxiety subscales of the Brief Symptom Inventory (Derogatis, 
1975), to measure fearfulness and (3.) newly designed items to measure 
anxious apprehension. By using two different patient samples to develop 
and evaluate this second model, we arrived at a 6-factor model: feelings of 
worthlessness, fatigue, somatic arousal, anxious apprehension, phobic fear and 
tension. Somatic arousal, anxious apprehension and phobic fear are all clearly 
anxiety-like constructs. Thus, instead of only the single anxiety dimension of 
the tripartite model (somatic arousal), the present model distinguishes three 
groups of symptoms. Each individual factor and the total of factors can be 
regarded as unidimensional measurement scales, and this model can describe 




The studies presented in this thesis are explorations along the road to a fully 
dimensional model of psychopathology. Below we will discuss what we 
contributed and what our contributions mean.
 First of all, we showed in our own sample of secondary care outpatients 
with depression, anxiety and somatoform disorders that comorbidity is highly 
prevalent. This is in line with the findings of an extensive body of literature 
on comorbidity. High rates of comorbidity between anxiety disorders and 
depression have also been reported in the general population (Kessler et al., 
1996), in primary care (Roca et al., 2009) and in secondary care (Brown et al., 
2001). In fact, comorbidity of depressive and anxiety disorders is so prevalent 
that it is no coincidence (Kessler et al., 1996). These findings launched research 
into the existence of psychopathological dimensions common to anxiety and 
depression (Clark & Watson, 1991) and into genetic overlap (Kendler, 1996). The 
psychopathological dimensions common to depression and anxiety disorders 
will be discussed later, after the role of the dimensional approach in assessing 
the severity of comorbid disorders. The possible genetic overlap goes beyond 
the scope of this paper and will not be discussed further.
 We showed that in depression and anxiety disorders comorbidity is more 
than simply the sum of diagnoses. For instance, we found that some symptoms 
of comorbid occurring disorders, are more severe than if the disorders 
occur alone. This has also been reported in other studies (e.g. Dalrymple & 
Zimmerman, 2007; Fava et al., 2004; Kaufman & Charney, 2000) but has never 
been studied for comorbid depression and anxiety disorders and single 
depression and single anxiety disorders in the same clinical sample. Together 
with the symptom heterogeneity possible in patients with the same diagnosis 
(see 7.1), the results suggest that the categorical diagnoses as defined in the 
DSM-IV are too indistinct. Assessing symptom severity may make etiological 
research more fruitful and may also help to find more effective treatments. We 
will discuss this more comprehensively further on. For now, it suffices to say 
that the proposal to include the assessment of symptom severity in the DSM-5 
signifies growing support for this view.
 What is the best instrument to assess dimensions of depressive and anxiety 
symptoms? In fact, every multi-item questionnaire on depressive and / or 
anxiety symptoms yields a quantitative assessment of one or more aspects of 
psychopathology and thus may qualify for the assessment of these dimensions. 
We chose the Mood- and Anxiety Symptom Questionnaire (MASQ) of Watson 
and Clark (1991) as it is based on their tripartite model. The significance of this 
model lies in the fact that it tries to take into account the overlap as well as the 
diversity in psychopathology in subjects suffering from depressive and / or 
anxiety disorders. The overlap is assessed with a non-specific distress factor 
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(negative effect) and the diversity with a factor specific for depression and one 
for anxiety. The MASQ also was chosen because of its use in many studies, 
also with respect to etiology, not only with adult patients (Marshall et al., 2003; 
Joiner et al., 1999; Keogh & Reidy, 2000) but also in child psychiatry populations 
(Chorpita & Daleiden, 2002).
 As we made the MASQ the central assessment tool of our further 
investigations, it was important to have at our disposal a translated and 
psychometrically sound Dutch version. We carefully translated the MASQ 
and demonstrated good reliability and validity of this Dutch version in a 
large sample of 950 outpatients referred to secondary care because of mood, 
anxiety and/or somatoform (MAS-) disorders and 200 respondents from the 
general population. We did not include inpatients, primary care patients and 
patients with other disorders as our research focused on outpatients with 
MAS-disorders. However, in the future the MASQ should also be evaluated 
psychometrically in those groups of subjects. The present analysis showed that 
the factor structure of the MASQ with three factors was preserved in the Dutch 
translation. Factor-loadings of items and allocation of items to subscales was 
similar to results of Watson and Clark with US clinical samples and with patient 
samples from Great Britain (Keogh & Reidy, 2000). Recently, our group has 
developed and evaluated a shortened 30-item version, called the MASQ-D30, 
thereby increasing the feasibility of its incorporation in an assessment battery 
for ROM (Wardenaar et al., 2010).
 Translation of the MASQ was not the primary aim of our study, but rather 
a means to an end. Our main aim was to remediate the shortcomings of the 
tripartite model and the MASQ. The original authors recommended already 
in 1998 to view in future research “individual disorders as representing 
unique combinations of different types of symptoms, with each type showing 
varying degrees of nonspecificity and with no type being entirely unique to 
any single disorder” (Mineka et al., 1998, p.398). We operationalized this idea, 
by developing symptom scales that include the more unique symptoms of 
specific mood and anxiety disorders in addition to common symptom scales. 
As described in chapter 5, by adding items of the BSI to the MASQ the new 
questionnaire was able to distinguish three groups of symptoms, each one 
specific to a different kind of anxiety disorder (panic disorder, GAD, and phobic 
disorders) instead of only the single anxiety dimension of the tripartite model 
(somatic arousal).
 However, remediating the shortcomings of the MASQ in differentiating 
between the various DSM-IV categories of mood and anxiety disorders was 
not our final goal either. Rather, we set out to develop a broad dimensional 
model, not taking DSM-IV diagnoses as a point of departure nor taking 
specificity to particular DSM-IV diagnoses as the best sign of validity. We 
aimed for a multidimensional model to characterize individual patients in 
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terms of their specific symptom profile by including extra symptoms to a self-
report instrument in order to cover additional dimensions. As described in 
chapter 6, this resulted in a 6-factor model: feelings of worthlessness, fatigue, 
somatic arousal, anxious apprehension, phobic fear and tension. This model 
reveals differences in symptom profiles between patients who, according 
to the DSM-IV would all have been diagnosed with MDD. Figure 7.1 gives a 
graphic representation of the symptom profile of the two exemplary patients 
we introduced in the introduction of this thesis. Not only patients with MDD, 
but also patients with anxiety disorders and patients with comorbid depression 
and anxiety, can be characterized with the same 6 factors.
 The dimensions may be a fruitful basis for future research into prognostic 
factors of treatment response. It may well be that an optimal match exists 
between symptom profiles and treatment modality. By assessing large groups 
of patients before and after treatment with, for instance, selective serotonin 
reuptake inhibitors (SSRIs), it will become possible to determine which 
profile(s) are most sensitive for these drugs. Finding the most appropriate 
treatment (pharmacologically or psychotherapeutic) can be a lengthy trial-
and-error process. Matching of patient characteristics to treatments is the next 
step in improving evidence based medicine in psychiatry (Beutler, Forrester, 





















Patient A Patient B
Feelings of Worthlessness Fatigue
Somatic Arousal Phobic Fear
Tension Anxious Apprehension
ti t A







Figure 7.1 Fictional example of a ‘symptom profile’ for two patients, both diagnosed with 
Major Depressive Disorder according to the DSM-IV.
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will help to address the famous question first raised by Gordon Paul: “what 
treatment, by whom, is most effective for this individual with that specific 
problem, and under which set of circumstances?” (Paul, 1967, p.111).
 The model presented in Chapter 6 is a hierarchical model with a bifactor 
structure (see for a graphic representation: model 5 in Figure 6.1). Confirmatory 
factor analyses showed that this bifactor hierarchical model with a general 
severity factor and six specific factors fitted best to the data, compared to several 
other models. In a hierarchical bifactor model, different sets of items loaded on 
specific factors and, at the same time, all items loaded on one general severity 
factor. With a hierarchical common factor it is possible to determine severity 
and to differentiate between non-patients and patients. The dimensions can be 
used to form a unique symptom profile for each patient to differentiate within 
patients.
 The tripartite model is a unifactorial model with 3 factors. In a unifactorial 
model a set of items load on one factor (see for examples of unifactorial models: 
model 1, 2 and 3 in Figure 6.1). An important feature of the tripartite model 
(Clark & Watson, 1991) is the difference that is made between general and 
specific distress. The factor negative affect in the model is presented as general 
distress, whereas ‘lack of positive affect’ and ‘somatic arousal’ are presented as 
dimensions of distress specific for respectively depression and anxiety disorders. 
 This difference in general and specific distress is also an element in several 
other models which were previously suggested as reaction to the critiques on 
the tripartite model (Brown et al., 1998; Mineka et al., 1998; Zinbarg & Barlow, 
1996). There is consensus that both general and specific components are 
needed to fully represent the variation observed among mood and anxiety 
disorders (Simms et al., 2008). It is confusing, however, that the terms ‘general’ 
and ‘specific’ are not used consistently in literature. They can be used to refer 
to the content of a factor, and also to refer to their place in a higher-order or 
hierarchical model. For example, NA in the tripartite model is not a general 
factor according to the methodological structure of the model (a unifactorial 
model does not contain any general, higher order or common factor). However 
the content of NA is general (since it represents general distress and not a 
specific symptom), and in this context the term specific means specific to a 
(group of) disorder(s) or patients. We advocate to refer to NA as non-specific, 
and to avoid the term general in this context. In a hierarchical, bifactor model, 
we prefer to speak of unique and common factors.
 We concluded that a hierarchical 6-factor model is optimal to describe the 
structure of the symptom dimensions of mood- and anxiety disorders, when 
integrating important aspects of the tripartite model and the valence arousal 
model. As suggested by Mineka et al.(1998), the six unique factors in our model 
describe a patients’ symptom-profile, while at the same time the complete set 
of items reflects overall severity. Importantly, our findings are in line with earlier 
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studies (Simms et al., 2008; Simms et al., 2012) and lend further support to 
the idea that the symptomatology of depression and anxiety has a hierarchical 
structure.
7.3.2 Limitations
The results should be interpreted in the light of some limitations. First, we 
took the symptoms mentioned in the DSM definitions of mood and anxiety 
disorders as a starting point. In theory, other symptom dimensions could be 
of importance to describe the phenotype of mental disfunction which show 
different associations with etiology, the course and treatment of mental 
problems. However, depressivity and anxiety are universal notions that are 
elaborated by psychology and psychiatry. Positive and negative affect, the two 
dimensions from the circumplex model of affect (Watson & Tellegen, 1985) that 
Watson and Clark used in their tripartite model (Clark & Watson, 1991), are also 
strongly embedded and universal (Russell & Lewicka, 1989).
 Second, the described studies are limited to the common mental disorders 
depression and anxiety disorders (both internalizing disorders). Although 
the difference between internalizing and externalizing disorders is often 
confirmed in research (Kessler et al., 2005; Kotov et al., 2011; Vollebergh et al., 
2001), symptoms of externalizing disorders are also present in patients with 
internalizing disorders (and vice versa). For example, Koh and colleagues (2002) 
found a predominance of anger in depressive disorders compared with anxiety 
disorders and somatoform disorders. Therefore, it is worthwhile to extend the 
model with externalizing dimensions (Krueger et al., 2005) comprising concepts 
such as ‘anger’ or ‘aggression’ (Pasquini et al., 2004; Picardi et al., 2004). We 
made a start with the dimension ‘hostility’ in the model presented in Chapter 5.
 Third, the results only apply to outpatients before the start of their 
treatment. This implies that the findings cannot be generalized to inpatients or 
to persons with “normal” or nonpathological levels of anxiety and depression 
as a general model of affect. To make a model that can be generalized to the 
normal population it might be useful to measure all dimensions with both 
negatively and positively formulated items. After all, the measurement range 
of the dimensions will be wider when positively formulated items are included 
as well.
 Fourth, the results only apply to patients with specific demographic 
characteristics. Approximately 80 percent of the patients in our samples were 
born in The Netherlands, as were both their parents. On top of that, a condition 
to participate in ROM was to master the Dutch language well, both spoken en 
written. Therefore, no statements can be made about to what extent our results 
apply to patients with different ethnic backgrounds or literacy. Moreover, the 
results cannot be generalized to children and elderly, since we used patient 
samples of adults only.
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 Finally, this thesis focused on the reliability and the internal validity of the 
multidimensional models, not on the external validity. We did not investigate 
to what extent the dimensions correlate with biological factors like cortisol 
levels or polymorphisms and to what extent they predict treatment success 
and the course of the mental problems. This was done, but as yet with the 
original dimensions of the MASQ, by other members of the research group of 
the LUMC department of psychiatry. Van Veen et al. (2013) found that childhood 
traumas have different effects on the MASQ dimensions, whereas most adult 
life events are associated with all three. Wardenaar et al. (2012) showed that 
MASQ dimensions predicted the future 2-year course of depression and 
anxiety. Importantly, the dimensions yield predictive information on top of 
DSM-IV diagnoses. Luppino et al. (2011) demonstrated a strong association of 
most components of the metabolic syndrome with the SA dimension, but not 
the PA and NA dimension of the MASQ. Veen et al. (2011) and Wardenaar et 
al (2011) both found non-linear relations between the cortisol awakening rise 
(CAR) and dimensions of the MASQ, which could explain previous inconsistent 
findings regarding HPA-axis activity in depressed patients. And last but not 
least, Veen et al. (2012) showed that MASQ-dimensions were each associated 
with specific gene sets. It can be concluded that the external validity of the 
original MASQ dimensions is promising. It will be interesting to investigate the 
external validity of the extended dimensional model presented in this thesis.
7.3.3 Future perspectives
Before adopting a dimensional approach on a large scale, the superiority of the 
dimensional approach to the DSM-IV for the characterization of patients, the 
investigation of the etiology and the clinical utility needs to be demonstrated 
(First, 2005). Future research has to show whether a dimensional profile is 
indeed useful in deciding what the main target for treatment should be and 
what kind of treatment is indicated. For example, an overactive sympathic 
nervous system as revealed by high anxious arousal may require a different 
pharmacotherapeutic approach, while a high propensity to worry may suggest 
psychosocial therapy. With the original scales of the tripartite model, the first 
progress in using dimensions in research into etiology is already made. For 
example, Wardenaar found nonlinear associations between characteristics 
of the stress-system (cortisol awakening curve) and the dimensions of the 
tripartite model (2011) in a sample of outpatients.
 In most current research into the etiology of common mental disorders, 
patients are compared to controls regarding the presence of specific genes, or 
other biological or psychological variables. Most commonly, this is done with 
a categorical “mindset”: the presence or absence of a trait or biological marker 
is investigated in persons with or without a diagnosis (e.g., patients with a 
major depressive disorder as compared to controls). A dimensional model 
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however requires a correlational “mind set”: etiological factors (themselves 
often measured on a continuous scale) may be strongly correlated with some 
(combinations of) dimensions and less strongly with others, irrespective of the 
categorical diagnoses the patients have. Thus, in research aimed for instance 
at the endophenotypes of psychopathology we might find the “anxious 
apprehension profile” rather than “anxiety disorder”. It is quite a challenge for 
researchers to switch from a categorical to a correlational mind set. After all, all 
humans have a strong tendency toward categorization as we are more inclined 
to separate and sort things (safe - unsafe, edible - not edible) so we know 
how to navigate in the world around us. This ‘mental categorization’ is one of 
the first stages in our cognitive development, and starts at a very young age 
(Piaget, 1962). Besides our early learned custom to think in categories, another 
difficulty is that dimensions are much more complex to depict than categories, 
especially when more than 3 dimensions are involved.
 A pleasant consequence of using multi dimensional models in research is 
that statistical power is usually substantially enhanced if true variance in affect 
scores is assessed and preserved in the analysis. This is easily demonstrated by 
comparing a dimensional depression score with the dichotomous categorization 
of depressed vs. non-depressed. With the latter, much information is sacrificed 
which would have been preserved in the former.
 On the other hand, using dimensions in research means that the required 
statistical methods are more complex than when using categories. A t-test 
between two groups (e.g. not depressed vs. depressed) to test for a significant 
difference on another variable won’t do. Multiple regression analyses with 
special attention for interaction effects will be necessary. Fortunately, these 
techniques are now available in statistical software.
 It is preferable that all symptom dimensions are analysed simultaneously. 
Although the correlations between the dimensions are relatively low, they are 
correlated. If one would study or analyse them one by one, correction for this 
correlation is not possible and the wrong conclusions might be drawn. For 
example the conclusion might be drawn that a specific treatment does not have 
an effect on both dimensions A and B separately, while the interaction effect is 
missed.
 A more general point about the use of dimensions in research is that they 
break with the simple tradition of comparing etiological factors between 
healthy and diseased groups. This can lead to a disruption in research efforts; 
e.g. combined meta-analyses are not possible on studies that use DSM-
categories and studies that use a dimensional approach. This drawback can 
be prevented by a combined approach (using both the DSM and dimensional 
measures). For research, a combined approach has great benefits over using 
the categorical system solely (Brown & Barlow, 2005). It is already seen more 
and more in research that although the selection of patients for a research group 
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is still determined by the DSM-criteria, dimensional measures are added to the 
research design. An important advantage of this development is that individual 
differences between patients within one DSM-category are acknowledged (e.g. 
in analyses of experimental findings the scores on the dimensional measures 
can be taken into account as covariates). As Kaufman and Charney concluded: 
‘the use of categorical diagnostic approaches and dimensional rating scale 
in tandem will facilitate identification of meaningful phenotypes for future 
genetic, biochemical, neuroimaging, and treatment studies’ (pag.73, Kaufman 
& Charney, 2000).
 For the successor of the DSM-IV, the DSM-5 (published in May, 2013) it was 
suggested to combine categories with dimensional measures. The DSM-5 Work 
Groups were considering an additional way to help the clinician capture the 
symptoms and severity of mental illnesses, by using dimensional assessments. 
These would allow clinicians to systematically evaluate patients on the full 
range of symptoms they may be experiencing. For instance, information about 
depressed mood, anxiety level, quality of sleep, and substance use would 
be important for clinicians to know regardless of the patient’s diagnosis. 
Dimensional assessments would allow clinicians to rate both the presence and 
the severity of the symptoms, such as “very severe,” “severe,” “moderate”, 
“mild”, or “absent”. It would encourage mental health professionals to 
document all of a patient’s symptoms and not just those that were tied to their 
primary diagnosis.
 Adopting dimensions in the DSM-5 holds much promise. It is a start to 
advocate dimensions in the field. And, although clinical utility in the sense that 
assessed dimensions can be used to decide which treatment is most effective 
for a specific patient is not available yet, there is however already a benefit for 
the clinician in assessing dimensional measures next to the DSM-categories. 
When using both a diagnostic interview and several dimensional (severity) 
measures at intake, the clinician gets useful insights into the symptoms profile 
of each patient at intake and at follow-up (ROM), and therewith into the effect 
of the chosen treatment on different sorts of symptoms for the patient at hand.
 We suggest using the same dimensional measures within all DSM-categories 
of common mental disorders. For example, only when anxiety is measured 
dimensionally in both patients with a depression as well as those with an anxiety 
disorder, analyses can be done in all categories simultaneously. Only then, 
research can be done without the restrictions of the DSM. ROM as implemented 
in 2002 in Leiden, proved to be a very useful instrument to measure dimensions 
and categories, and combined with biological data enhance our insight in the 
complex relationship between depression and anxiety and their common and 
distinctive etiological factors.
 The multi-dimensional models presented in this thesis are limited to 
symptoms that were present at the time of the assessment. The questionnaires 
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used, ask the patient to report the level of presence of each symptom in the 
week prior to the assessment. A symptom profile generated with the models 
therefore does not contain any information about the history of the patient 
(duration, recurrence, familiarity etcetera). Determining what phase of the 
clinical course of the disorder a patients is in (staging) is very important. A 
clinical staging model, already widely used in oncology, could improve the 
utility of diagnostic characterisation in psychiatry as well, with emerging 
disorders (McGorry et al., 2007). Staging models are based on the fact that 
response to treatment is generally better when it is introduced early in the 
course of the illness. It assumes that earlier stages have better prognosis and 
require simpler therapeutic regimens (Vieta, Reinares, & Rosa, 2011). It would 
be ideal to include symptom-profiles (‘profiling’) in ‘staging’. Routine Outcome 
Monitoring is an important instrument for developing staging and profiling in 
psychiatry (Zitman, 2012).
 We believe that the main focus for the next years should be on research on 
profiling and staging with the aim to determine those factors that predict the 
evolution of symptoms and the effective treatment. This kind of research has 
the best chance of being successful when various research groups cooperate 
and find consensus about research designs and variables used and how to 
conceptualize them optimally. A dimensional approach to psychopathology is 
expected to be more successful than the traditional categorical approach, as it 
is a far better representation of the richness of clinical phenomena.
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Er is de laatste decennia veel onderzoek verricht naar de oorzaken en optimale 
behandeling van depressies en angststoornissen. De geboekte vooruitgang is 
echter relatief beperkt, omdat onderzoeksresultaten veelal niet consistent en 
soms zelf tegenstrijdig blijken.
 Een veel genoemde mogelijke oorzaak hiervoor is het gebruik van de DSM-IV 
om de stoornissen vast te stellen. De DSM (Diagnostic and Statistical Manual of 
Mental Disorders) is een Amerikaans handboek met diagnoses van psychische 
aandoeningen dat in de meeste landen als standaard in de psychiatrische 
diagnostiek dient en door vrijwel alle psychiaters en psychologen gebruikt 
wordt. De eerste editie is verschenen in 1952 en vanaf de derde editie (DSM III, 
1980) worden stoornissen duidelijk beschreven en wordt er gedefinieerd welke 
symptomen kunnen voorkomen bij een ziektebeeld, en hoeveel symptomen 
aanwezig dienen te zijn, voordat er gesproken kan worden van een bepaald 
syndroom of ziektebeeld bij een patiënt. Voor die tijd werden termen als 
‘depressie’ en ‘psychose’ door verschillende auteurs heel anders ingevuld. 
Door heldere standaard beschrijvingen werd de classificatie meer betrouwbaar 
en kon men er ook internationaal over communiceren. Als voorbeeld staan in 
tekstvak 1 de criteria die in de DSM-IV gehanteerd worden voor het vaststellen 
van een depressieve stoornis. In de onderzoeken in dit proefschrift is gebruik 
gemaakt van de DSM-IV-TR (2000). Zeer recent in mei 2013 is de DSM-5 
verschenen. 
 Naast de grote winst die de standaardisatie in diagnoses heeft gebracht, 
heeft deze categoriale benadering ook nadelen. Ten eerste is er veelvuldig 
sprake van comorbiditeit; DSM-diagnoses komen veel samen voor. Ten tweede 
zijn de grenzen tussen ziek en gezond (wel of geen DSM-diagnose) kunstmatig. 
Er is een afkappunt bepaald, maar in werkelijkheid is er geen afkappunt tussen 
ziek en gezond, net zoals er geen duidelijk moment aan te geven is wanneer de 
dag overgaat in de nacht: er is sprake van een continue verdeling. 
 Een derde probleem van de DSM is dat er binnen één diagnosegroep veel 
verschil kan zijn in symptomen. Om deze heterogeniteit te illustreren, staan 
in tekstvak 2 de klachten van twee fictieve patiënten beschreven, die allebei 
voldoen aan de DSM-criteria voor een depressieve stoornis. Hoewel beide 
personen dezelfde diagnose hebben, is er een groot verschil in de symptomen 
die zij ervaren. Als zij elkaar zouden spreken, zouden zij vast en zeker verbaasd 
zijn dat ze voor dezelfde ziekte behandeld (gaan) worden. Dit is mogelijk omdat 
het hebben van vijf van negen klachten voldoende is om aan de DSM diagnose 
depressie te voldoen (zie tekstvak 1). Bovendien bevatten sommige criteria 
zowel een toename als een afname van een bepaald gedrag (bijvoorbeeld 
gewichtstoename en – afname). Dit illustreert dat een groep patiënten met een 




 Een dimensionele benadering lijkt de oplossing voor alle drie de problemen. 
Je stelt daarbij geen diagnoses meer, maar karakteriseert iemand aan de 
hand van de mate waarin verschillende kenmerken voorkomen. Dat doe je 
Twee patiënten met een depressie
Patient A (vrouw, 36 jaar) voelt zich verdrietig en waardeloos, heeft moeite 
om in slaap te komen, en heeft gewicht verloren. Ze voelt zich erg schuldig 
tegenover haar gezin (man en twee jonge kinderen) en wenst vaak dat ze 
de volgende ochtend niet meer wakker wordt (“dat zou het beste zijn voor 
iedereen”).
Patient B (vrouw, 29 jaar) geniet niet meer zo van haar leven als ze voor-
heen deed. Ze slaapt erg veel en heeft weinig energie, ze is in de afgelopen 
maanden 5 kilo aangekomen. Ze krijgt weinig voor elkaar en kan zich niet 
concentreren.
DSM-IV criteria Depressie
Vijf (of meer) van de volgende symptomen zijn binnen dezelfde periode 
van twee weken bijna dagelijks aanwezig en wijzen op een verandering ten 
opzichte van het eerdere functioneren; ten minste een van de symptomen 
is ofwel depressieve stemming ofwel verlies van interesse of plezier.
1. Depressieve stemming gedurende het grootste deel van de dag
2. Duidelijke vermindering van interesse of plezier in alle of bijna alle activi-
teiten gedurende het grootste deel van de dag
3. Duidelijke gewichtsvermindering zonder diet, of gewichtstoename of af-
genomen of toegenomen eetlust
4. Insomnia of hypersomnia
5. Psychomotorische agitatie of remming
6. Moeheid of verlies van energie
7. Gevoelens van waardeloosheid of buitensporige of onterechte schuld-
gevoelens
8. Verminderd vermogen tot nadenken of concentratie of besluiteloosheid
9. Terugkerende gedachten aan de dood, terugkerende suïcidegedachten, 
of een (specifiek plan voor een) suïcidepoging
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bij iedereen op dezelfde manier, los van eventuele DSM diagnoses. Zo wordt 
bijvoorbeeld bij iedereen bepaald hoe somber hij is, hoe waardeloos hij zich 
voelt, hoe angstig enzovoort. De mate waarin die kenmerken voorkomen wordt 
bepaald aan de hand van een reeks vragen die elk gescoord moeten worden 
op de mate waarin ze van toepassing zijn, bijvoorbeeld op een schaal van 0 tot 
5. Comorbiditeit is dan geen probleem meer, want iedereen wordt op dezelfde 
kenmerken ‘gescoord’, ook het onderscheid tussen ziek en gezond speelt niet 
meer en tenslotte kan met een dimensionele benadering ook beter rekening 
worden gehouden met de heterogeniteit. 
 Het doel van dit proefschrift was om de haalbaarheid van dimensionele 
modellen te testen in een grote steekproef psychiatrische poliklinische 
patiënten met stemmingsstoornissen, angst en/of somatoforme stoornissen 
en een dimensioneel model te ontwikkelen dat de nadelen van bestaande 
modellen overwint. 
 De databestanden met gegevens van patiënten die in dit proefschrift zijn 
gebruikt, zijn verzameld met Routine Outcome Monitoring (ROM). ROM is het 
herhaald meten van de klachten en problemen van de patiënten voorafgaand 
aan, tijdens en na de behandeling. In hoofdstuk 2 wordt de methode ROM 
in detail beschreven. De studie laat zien dat implementatie van ROM 
haalbaar is en dat veel behandelaren ROM beschouwen als een belangrijke 
aanvulling voor de klinische behandeling. Ook stimuleert ROM onderzoek; de 
verzamelde gegevens kunnen immers gebruikt worden voor onderzoek naar 
de fenomenologie van psychiatrische stoornissen (zoals dit proefschrift) en de 
uitkomsten van behandeling zoals gegeven in de dagelijkse klinische praktijk. 
Opvallend is de hoge comorbiditeit in ons patiëntenbestand. Volgens het 
diagnostische interview dat bij alle patiënten is afgenomen als onderdeel van 
ROM (de MINI-Plus), voldoen 1,618 patiënten (42.6%) aan de criteria van een 
enkele stemmings-, angst- of somatoforme stoornis. Een bijna even groot aantal 
patiënten, 1,556 patiënten (41.0%) had ten tijde van de meting meer dan één van 
deze stoornissen: 967 patiënten (25.5%) met twee stoornissen, 403 patiënten 
(10.6%) met drie, en 186 patiënten (4.9%) met vier of meer stoornissen tegelijk. 
Dit veelvuldig tegelijk voorkomen van verschillende van deze stoornissen 
laat zien dat de DSM categorieën niet uitsluitend en onderscheidend zijn en 
benadrukt de behoefte aan een dimensioneel model.
 In hoofdstuk 3 hebben we de relatie onderzocht tussen ernst en comorbiditeit 
van depressie en angststoornissen in een groot patiënten bestand. Zoals 
verwacht, was de ernst van symptomen hoger in de groep met comorbiditeit 
vergeleken met de groepen met slechts één stoornis (geen comorbiditeit). De 
patiënten met meer dan één stoornis waren er dus slechter aan toe dan de 
patiënten met een enkele stoornis. De ernst van de depressieve symptomen 
in de comorbide groep was hoger dan in de groep met een ‘pure’ depressie 
en de ernst van angstsymptomen in de comorbide groep was hoger dan in de 
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groep met een ‘pure’ angststoornis. Opmerkelijk was ook dat de gemiddelde 
score op de angstschalen niet significant verschilde tussen patiënten met 
een pure depressie en patiënten met een pure angststoornis. Bevindingen 
zoals hierboven beschreven blijven verborgen als alleen categoriaal wordt 
gediagnosticeerd. Bij een dimensionele benadering komen ze wel aan het licht. 
 Een veel gebruikt dimensioneel model om de symptomen van depressie 
en angststoornissen te beschrijven is het ‘tripartite model’, ontwikkeld door 
Clark en Watson in 1991. Dit model bestaat uit drie dimensies en is ontwikkeld 
om de gemeenschappelijke en specifieke symptoom domeinen van depressie 
en angst te berschrijven. De eerste dimensie Negatief Affect (NA) bestaat uit 
symptomen van algemeen psychisch onwelbevinden, zoals boos, ontdaan, 
en verdrietig. NA is een algemene factor en is niet specifiek voor depressie of 
angst. De twee andere factoren in het model zijn respectievelijk specifiek voor 
depressie en angst. De dimensie Positief Affect (PA) bestaat uit symptomen van 
gebrek aan interesse en energie, en is specifiek voor depressie. De dimensie 
Somatic Arousal (SA) bestaat uit symptomen van somatische (lichamelijke) 
opwinding, zoals versnelde hartslag en zweten. Het is specifiek voor angst.
 De drie dimensies van het tripartite model kunnen gemeten worden met 
een vragenlijst; de MASQ (Mood and Anxiety Symptom Questionnaire). 
Om onderzoek te kunnen doen naar het tripartite model in Nederlandse 
databestanden, was een vertaling van de MASQ een vereiste. In hoofdstuk 
4 wordt de Nederlandse vertaling van de MASQ gepresenteerd en de 
toepasbaarheid en validiteit getest. De psychometrische kwaliteiten van 
de Nederlandse MASQ bleken ruim voldoende te zijn. In overeenstemming 
met het model vonden we drie schalen terug in de data, die bovendien goed 
onderscheid kunnen maken tussen subgroepen van patiënten met stemmings- 
en angststoornissen.
 Hoewel het tripartite model veel onderzoek naar dimensies heeft gestimu-
leerd, heeft het ook kritiek ontvangen. Een belangrijk punt van kritiek is dat 
de symptomen van de verschillende angststoornissen geen deel uitmaken van 
het model. De dimensie SA beslaat niet alle angststoornissen, maar vooral de 
paniek stoornis. Het is een nauwe conceptualisatie van angst. Het beperkt zich 
tot de lichamelijke uitingen van angst en negeert andere belangrijke aspecten 
zoals piekeren en vermijdings- oftewel fobische angst.
 In hoofdstuk 5 presenteren we een eerste eigen dimensioneel model dat 
een aantal belangrijke aspecten van depressie en angst omvat en bestaat 
uit duidelijk van elkaar verschillende dimensies. Ons doel was onder andere 
om meer symptomen van angst in het nieuwe model op te nemen dan was 
gebeurd in het tripartite model. We hebben in dit onderzoek vragen gebruikt 
van 2 vragenlijsten: de Mood and Anxiety Symptom Questionnaire (MASQ, 
Watson & Clark, 1991) en de Brief Symptom Inventory (BSI, Derogatis, 1975). 
Het gepresenteerde model bestaat uit vijf dimensies: sombere stemming, laag 
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positief affect, somatische arousal, fobische angst en vijandigheid (depressed 
mood, lack of positive affect, somatic arousal, phobic fear, hostility).
 De validiteit van het model werd ondersteund door de volgende bevindingen: 
de schalen bleken in staat om onderscheid te maken tussen patiënten met ofwel 
een stemmings- ofwel een angststoornis. Laag positief affect en fobische angst 
onderscheidden het best tussen depressieve patiënten en patiënten met een 
angststoornis. Ook lieten de verschillende angststoornissen een verschillend 
patroon zien qua scoring op de nieuwe dimensies. Binnen de angststoornissen 
was somatische arousal specifiek voor patiënten met een paniekstoornis. 
Fobische angst bleek geassocieerd met een paniekstoornis, een specifieke 
fobie en een sociale angststoornis, maar niet met een gegeneraliseerde 
angststoornis (GAD).
 Overwegende dat de in hoofdstuk 5 beschreven studie het model valideert 
door vergelijking van de dimensies met de categorieën van de DSM-IV 
(stoornis-gebaseerde aanpak), hebben we in hoofdstuk 6 een stap gedaan 
verder weg van de DSM-IV en meer in de richting van een ‘echt dimensioneel 
model ‘(symptoom-gebaseerde aanpak). Als uitgangspunt hebben we gebruik 
gemaakt van een groot aantal items (vragen in vragenlijst): (1) De items van 
de Mood and Anxiety Symptom Questionnaire (Watson & Clark, 1991) om NA, 
PA en SA te meten, (2) Items van de angst subschalen van de Brief Symptom 
Inventory (Derogatis, 1975), om angst te meten en (3) door onszelf geformuleerde 
vragen om ‘anxious apprehension’, piekeren over wat komen gaat, te meten. 
We legden de vragen voor aan 1333 poliklinische patiënten en analyseerden ze 
vervolgens met geavanceerde technieken om de dimensies vast te stellen. We 
gebruikten eerst de ingevulde vragenlijsten van een deel van de patiënten om 
vast te stellen om welke factoren of dimensies het gaat. Daarna keken we in de 
gegevens van de overige patiënten of het geen toevallige bevinding was, of we 
in die tweede groep hetzelfde vonden. We kwamen uit op een 6-factor model 
met de volgende dimensies: gevoelens van waardeloosheid, vermoeidheid, 
somatische arousal, angstige bezorgdheid, fobische angst en spanning 
(feelings of worthlessness, fatigue, somatic arousal, anxious apprehension, 
phobic fear, tension) . Somatische arousal, angstige bezorgdheid en fobische 
angst zijn allemaal duidelijk angstachtige klachten. In plaats van alleen de enkele 
angstdimensie van het tripartite model (somatische arousal), onderscheidt 
het in hoofdstuk 6 beschreven model drie groepen van angstsymptomen. Met 
dit dimensionele model kunnen verschillende symptomen van depressie en 
angst geregistreerd worden. Het doet recht aan de heterogeniteit van angst en 
bestaat uit eenvoudig te meten dimensies.
 Het model biedt een oplossing voor de drie problemen die aan de categoriale 
benadering kleven. Om te beginnen maakt het de heterogeniteit in klachten 
en symptomen zichtbaar bij mensen die volgens de DSM dezelfde diagnose 
hebben. Figuur 1 geeft een grafische voorstelling van het symptoomprofiel van 
Samenvatting
146
de twee hierboven besproken fictieve patiënten die volgens de DSM-IV beiden 
aan een depressie lijden (zie tekstvak 2). Het is duidelijk zichtbaar dat ondanks 
het feit dat beide patiënten de diagnose ‘depressieve stoornis’ hebben, ze, 
als we ze karakteriseren met behulp van de zes dimensies die we gevonden 
hebben, een heel verschillend symptoomprofiel hebben.
 Ook patiënten die volgens de DSM-IV een angststoornis hebben, kunnen 
worden gekarakteriseerd met dezelfde zes dimensies en zullen over het 
algemeen een ander profiel hebben. De aanwezige angstklachten die wij 
vonden bij gebruik van de DSM-IV, bij puur depressieve patiënten (zie hoofdstuk 
3) zal in deze dimensionele profielen ook zichtbaar worden. Ook de klachten 
van patiënten met comorbiditeit kunnen met deze zes dimensies worden 
gekarakteriseerd. Tenslotte speelt ook de kunstmatige scheiding tussen ziek 
en gezond bij deze dimensies geen rol meer: iedereen die de vragenlijst invult 
krijgt een profiel op basis van dezelfde zes dimensies. Dit geldt ook voor 
mensen die geen klachten hebben en voor mensen die wel psychische klachten 
hebben maar volgens de DSM-IV niet aan de criteria voor een depressie of een 
angststoornis voldoen. 
 Alvorens een dimensionele benadering op grote schaal te kunnen gaan 
gebruiken, moet de superioriteit van de dimensionele benadering ten opzichte 
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Figuur 1 Voorbeeld van een 'symptoomprofiel' voor twee patiënten, gediagnosticeerd 
met een depressie volgens de DSM-IV.
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naar de etiologie (ontstaansgeschiedenis) van psychische stoornissen maar ook 
naar de klinische bruikbaarheid. Toekomstig onderzoek moet eerst uitwijzen 
of een dimensioneel profiel inderdaad efficiënter is om te beslissen wat het 
belangrijkste doelwit voor de behandeling zou moeten zijn en wat voor soort 
behandeling wordt aanbevolen voor een patiënt. Op termijn kan het hopelijk ook 
bijdragen aan het ontwikkelen van nieuwe, meer op de specifieke kenmerken 
van de klachten van de individuele patiënt, afgestemde behandelingen en 
daarmee op wat men wel noemt ‘personalized medicine’. Wij zijn van mening 
dat de nadruk in onderzoek de komende jaren moet liggen op het bepalen van 
de factoren die kunnen voorspellen hoe symptomen zich ontwikkelen in de tijd 
en factoren die effectieve behandeling kunnen voorspellen. Een dimensionele 
benadering moet hier een onderdeel van zijn, en de verwachting is dat er 
grotere voortgang gemaakt zal worden in de kennis over depressie en angst, 
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Dankwoord
Stellingen behorend bij het proefschrift
OUT OF THE BOX
Moving from categories to dimensions 
in de phenomenology of depression and anxiety
1. Het gebruik van symptoomprofielen doet meer recht aan verschillen 
tussen individuele patiënten dan het gebruik van een categoriale indeling 
(dit proefschrift).
2. De bevinding dat patiënten met een depressie (zonder comorbide 
angststoornis) even hoog scoren op angstschalen, als patiënten met  
een angststoornis, bewijst hoe complex de relatie tussen depressie   
en angststoornissen is (dit proefschrift).
3. Een gegeneraliseerde angststoornis lijkt meer op een depressie dan   
op de andere angststoornissen in de DSM-IV (dit proefschrift).
4. Ondanks de hoge comorbiditeit tussen depressie en angststoornissen,   
is het mogelijk unidimensionele constructen aan te wijzen die specifiek 
zijn voor de verschillende stoornissen (dit proefschrift).
5. Longitudinale data die in de dagelijkse praktijk routinematig worden 
verzameld zijn meer geschikt voor hypothese vormend onderzoek   
dan voor hypothese toetsend onderzoek.
6. Voor het succesvol implementeren van Routine Outcome Monitoring is 
inzicht in het zorgproces binnen de organisatie de eerste voorwaarde.
7. Wij begrijpen mensen en gebeurtenissen vaak door hen in categorieën 
te plaatsen. Op die manier vereenvoudigt het categoriseren ons dagelijks 
leven. Maar categoriseren leidt ook vaak tot fouten doordat er details 
weggelaten worden, of doordat er misinformatie wordt toegevoegd   
(L. Berkowitz, sociaal psycholoog, 1926).
8. Classificatie is de dood van de fenomenologie (K. Jaspers, Duits filosoof 
1883-1969).
9. Ten gevolge van zijn persoonlijkheid en zijn omstandigheden, leeft  
ieder, zonder uitzondering, in een zekere beperktheid van begrippen en 
opvattingen. (A. Schopenhauer, Duits filosoof 1788-1860).
10. De productiviteit op een kantoortuin met onderzoekers is gerelateerd  
aan het aantal bezette bureaus; Het verband heeft de vorm van een 
omkeerde U.
11. “Strakjes” duurt soms heel lang (Pancras jr. en Dorien den Hollander, 
2004).

